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ABSTRACT
Many of the molecules that are thought to be involved in nervous
system development have the property of binding to proteoglycans
(PGs). Furthermore, PGs have been shown to modulate the biological
activity of many of these molecules in vitro. Taken together, these
observations suggest that PGs play roles in nervous system
development. Characterization of proteoglycan function and
expression in the nervous system is still in the early stages. A recent
report revealed that as many as 25 different PG core proteins are
found in the rat brain, many with distinct patterns of developmental
expression (Herndon and Lander, 1990). The surprising diversity of
PG core proteins revealed by this study supports the hypothesis that
individual proteoglycans have been adapted to fufill distinct functions
in the developing nervous system. To test this hypothesis and to begin
to identify potential functions of PGs in the nervous system, we
developed a purification strategy to identify the major cell surface
heparan sulfate proteoglycans (HSPGs) of the developing rat brain. We
report here on studies identifying one of these molecules as a novel
cell surface HSPG related to the previously identified cell surface
HSPG, glypican. This molecule, which we have named cerebroglycan,
is restricted in expression to the developing nervous system. In situ
hybridization experiments demonstrated that cerebroglycan is
transiently expressed by immature post-mitotic neurons during the
period encompassing axon outgrowth and cell body migration,
suggesting a possible role for cerebroglycan in these processes.
Immunolocalization experiments revealed that cerebroglycan core
protein is strongly localized to the fibre tracts of the developing brain,
consistent with a role for cerebroglycan in the growth of axons.
Biochemical and structural characterization of cerebroglycan
demonstrated that cerebroglycan binds strongly to laminin-1, a
molecule thought to be involved in axon guidance. The strong binding
may be due, in part, to an interaction of the cerebroglycan core
protein with laminin-1. The data described here support the
[hypothesis that individual PGs fufill distinct functions in the
developing nervous system, and are consistent with the possibility that
cerebroglycan participates in the growth or guidance of axons.
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CHAPTER 1
PROTEOGLYCAN STRUCTURES AND POTENTIAL ROLES IN
NERVOUS SYSTEM DEVELOPMENT
I. Introduction
Proteoglycans (PGs) are simply proteins that have been substituted
with one or more glycosaminoglycan (GAG) carbohydrate chains. As
will be discussed in the section II below, a GAG is a linear polymer of
repeating disaccharides. Several types of GAG exist, each defined by
the type of disaccharide of which they are composed. For the familiar
GAG heparin (and the related GAG heparan sulfate), the disaccharide
subunit is a glucuronic or iduronic acid linked (1-4) to N-acetyl or N-
sulfoglucosamine. For chondroitin sulfate (another commonly
encountered GAG) the subunit consists of a glucuronate linked (1-3) to
N-acetylgalactosamine. Most types of GAG chains undergo a series of
modifications in the Golgi apparatus that encompass (1) N and 0-
sulfations, and (2) epimerizations, resulting in a heterogenous, highly
negatively charged structure.
PGs have traditionally been categorized on the basis of the type of
GAG chains they bear: a PG core protein that is substituted with a
heparan sulfate (HeS) chain is a heparan sulfate proteoglycan (HSPG),
and a core protein substituted with chondroitin sulfate (CS) is a CSPG,
etc. In recent years, a number cDNA clones for PG core proteins have
been isolated, and it has become apparent that there are distinct
families of PGs. Table 1 summarizes the families of PGs expressed in
the nervous system; many of the PGs in the table will be discussed in
section IV of this chapter with regard to their potential ligands and
roles in development.
PGs have attracted the interest of developmental biologists as a
result of the very large repertoire of molecules with which they can
interact. These interactions are typically mediated by the GAG chains,
and, have often been found to involve the binding of sulfated residues
on the GAG chain to clusters of basic amino acids in the GAG-binding
ligand [reviewed in (Cardin and Weintraub, 1989; Jackson et al.,
1991)]. The molecules that PGs bind include growth factors such as
members of the FGF family; extracellular matrix glycoproteins such as
laminin, fibronectin, and thrombospondin; proteases such as
thrombin, urokinase, and tissue plasminogen activator; and protease
inhibitors such as anti-thrombin III, and protease nexin-1 [reviewed in
(Lander, 1989; Lander, 1990; Lander and Calof, 1993)]. Many of these
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molecules have been implicated in developmental processes and cell
behaviors such as cell proliferation and differentiation, cell adhesion
and migration, axon outgrowth and synapse formation, and metastasis
and tumor formation. PGs, by the virtue of being able to bind to so
many ligands of interest, have become suspected of being "guilty by
association" of participating in these same biological processes.
Section III of this chapter will discuss the binding of PGs to their
ligands. Section IV will review data on PG expression and evidence
that PGs actually do play functional roles in development, with special
reference to the nervous system.
II. Glycosaminoglycan Structure: Heterogeneity Resulting from a
Complex Biosynthesis
Figure 1 is a schematic comparison of syndecan family and glypican
family PGs, and serves to illustrate several features of PG and GAG
structure. The biosynthetic steps that lead to these structures are
outlined below.
As reviewed in Gallagher et al. (1992), GAG biosynthesis begins in
the ER with the synthesis of a PG core protein. Possibly while still in
the ER, the hydroxyl group of one or more serine residues on the core
protein is substituted with xylose; these serines will ultimately be
linked to GAG chains. For glypican family HSPGs, the ER is also the
site of lipid attachment. Immediately after translation, a C-terminal
cleavage and addition signal is recognized and a glycosyl-
phosphatidylinositol (GPI) lipid anchor is attached (Low, 1989). The
rules governing GPI attachment have not been completely worked out,
but the attachment signal includes a hinge region, rich in prolines and
basic amino acids, followed by a hydrophobic region (Kodukula et al.,
1 993).
The protein sequence requirements for GAG attachment have also
riot been fully elucidated; however, serines that serve as GAG
acceptors are always found adjacent to glycine, and these ser-gly
attachment sites are usually preceded and often flanked by acidic
amino acid residues. Several more specific motifs have been
suggested such as (SG)n-(X)2 -5 -D/E and D/E-XSG-(X)n-D/E (Bemfield
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et al., 1992); however no single rule has been found to hold true for all
sites.
Two galactose residues and a glucuronate (GlcA) are added to the
serine-linked xylose, completing the tetrasaccharide link that will join
the GAG chain to the core protein. The GAG is polymerized in the
Golgi upon this tetrasaccharide by the successive addition of
hexuronate and hexosamine residues which occur as UDP-linked
precursors. Heparin and heparan sulfate are polymerized by the
alternate addition of GlcA and N-acetylglucosamine (GlcNAc);
chondroitin sulfate is polymerized by successive addition of GlcA and
N-acetylgalactosamine (GalNAc). Both CS and HeS undergo further
modifications in the Golgi. These modifications include N-
deacetylation followed by N-sulfation (for HeS), and the epimerization
of GlcA to iduronate (IdoA) as well as O-sulfations (for both HeS and
CS). Unfortunately, when CS is modified by epimerization of GlcA to
IdoA it is identified as a new class of GAG, dermatan sulfate (DS). This
designation was in place before it became apparent that CS regions
and DS regions often occur on a single GAG chain. Figure 1 shows the
structures of some representative disaccharides from an HeS and a
CS/DS chain. For HeS, in addition to N-sulfation, O-sulfation occurs at
position C2 of IdoA residues, C6 of glucosamine residues, C3 of N-
sulfoglucosamine residues (GlcNSO3) and C2 of GlcA residues
(although these latter two sulfations are rare compared to the others).
CS/DS can be sulfated at C4 or C6 of the GalNAc residue or at C2 of
IdoA and GlcA residues. In HeS saccharides are linked (1-4)
throughout, while in CS/DS, uronic acid is linked (1-3) to a
galactosamine that is linked (1-4) to the next uronic acid, and so on.
Not illustrated in Figure 1 are the structures of two other GAGs,
keratan sulfate (KS), and hyaluronic acid (HA). KS is composed of
repeating [galactose-GlcNAc] subunits, and has the unusual property of
being polymerized on both N-linked and O-linked carbohydrate
templates (Hounsell, 1989; Stuhlsatz et al., 1989). HA is composed of
[GlcA-GlcNAc] disaccharide subunits, and is found unattached to
protein. HA is the only GAG that does not contain sulfate groups
[reviewed in (Jackson et al., 1991)].
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An interesting feature of HeS structure, illustrated in Figure 1, is
the striking domain structure of the HeS chain. HeS chains, which
range in the size from 30 to 200 disaccharides (14-100 kDa), are
characterized by regions of sparsely modified residues punctuated by
islands of highly modified residues (Gallagher et al., 1992). In PGs
isolated from human skin fibroblasts, the highly modified regions were
on average about 5 disaccharides in length, and these regions were
separated by spans of ~ 18 disaccharides that were very sparsely
modified (Gallagher et al., 1992). The sparsely modified regions
consisted mostly of disaccharides containing GlcNAc residues, while
the GlcNSO3 residues were typically restricted to the highly modified
zones. In addition, O-sulfations were found to be restricted to a subset
of residues within the N-sulfated regions.
In heparin, such a domain structure is not so apparent. Instead,
most disaccharides are found to be highly modified. The domain
structure of HeS, and the extensive but incomplete modifications
found within the highly modified domains, give HeS a more complex
structure than the other GAGs, arguably more complex even than
heparin, which, although more extensively modified, does not contain
such a striking domain structure.
The domain structue of HeS can be explained by the nature of HeS
biosynthesis. The guiding principles of HeS synthesis were first
elucidated by studying the synthesis of heparin in a cell-free system
derived from a mouse mastocytoma cell line [for review see (Lindahl et
al., 1986)]. In this system, sulfation can be controlled by whether or
not the sulfate donor 3'-phosphoadenylylsulfate (PAPS) is added, and
the products can be labelled to facilitate later analysis by including
UDP-[1 4 C]-monosaccharide precursors in the reaction [cf (Lindahl et
al., 1973; Kusche et al., 1988)].
Using this system, it was found that heparin biosynthesis occurs in
a distinctly stepwise fashion in which the product of each step forms
the substrate for the next step. The sequence of the biosynthetic
steps has been established: (1) heparin is polymerized as an
unmodified polymer of [GlcA-GlcNAc] residues, as described above; (2)
the polymer is modified by N-deacetylation, and (3) N-sulfation; (4)
disaccharides containing GlcNSO3 are modified by epimerization of
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GlcA at C5 to produce IdoA; (5) IdoA is O-sulfated at C2; and (6)
GlcNSO3 is O-sulfated at C6. The rare O-sulfations at the C3 position
of GlcNS03 appear to be the final modification for those residues. This
rare modification has been shown to be crucial for the formation on
heparin and HeS chains of a binding site for antithrombin III (ATIII).
The binding of ATIII to HeS and heparin will be discussed further in
section III of this chapter. It should be noted that even in heparin,
the above modifications do not occur completely along the length of
the GAG chain. At each step of the pathway, a fraction of the available
substrates are further modified by the next biosynthetic enzyme(s).
The result is that complexity is multiplied as biosynthesis proceeds.
The biosynthesis of heparin, as described above, provides a
compelling explanation for the domain structure observed for HeS.
Since each biosynthetic step requires the modification of the previous
step to form its substrate, early modifications control the locations of
subsequent modifications along the length of the HeS chain. In
heparin, the early steps of N-deacetylation and N-sulfation are
extensive, resulting in extensive subsequent modifications. In HeS,
the commonly encountered form outside of mast cells, these early
modification steps appear to be restricted, resulting in the localization
of subsequent modifications to discrete domains. The fact that, as
described above, O-sulfations appear to be restricted to regions of N-
sulfated residues is also consistent with stepwise HeS synthesis.
Another interesting consequence of this scheme of biosynthesis is that
the highly modified regions are rich in IdoA whereas poorly modified
regions contain mostly GlcA. NMR studies of IdoA groups has
demonstrated that IdoA is actually an equilibrium mixture of three
different conformations (Casu et al., 1988). This apparent
conformational flexibility has important implications in the binding of
GAGs to their ligands. Potentially, the added flexibility of these
domains could facilitate GAG-protein binding by giving functional
groups on the GAG chain freedom to search out binding partners in
the protein's GAG binding site.
A qualification of HeS synthesis as described above is that it
represents an extrapolation of data for heparin synthesis in a cell free
system in vitro. The question of the extent to which the rules worked
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out for heparin in vitro will apply to HeS synthesized in vivo has
recently been addressed (Bame et al., 1991). In this study the
structure of HeS in a Chinese hamster ovary (CHO) cell line deficient
in N-sulfotransferase was examined. The mutant CHO cells produced
HeS that was 3-5 fold undersulfated at the N-groups of glucosamines,
compared to wild type (wt) cells. Although the mutant cells expressed
even more O-sulfotransferase activity than wt cells, the HeS of the
mutant cells was also significantly undersulfated at all the O-sulfation
sites, and the amount of IdoA was also substantially reduced. Thus, as
had been observed for heparin, these later modifications appear to
depend on the earlier steps of N-deacetylation and N-sulfation,
supporting the view that HeS synthesis also proceeds in a stepwise
fashion. An important implication of these studies is that regulation of
the sites of N-sulfation is likely to be a major mechanism of regulating
the overall structure of HeS. The factors responsible for the spacing of
N-sulfation in HeS chains are currently unknown.
In addition to the regulation of HeS structure arising from stepwise
biosynthesis, there appear to be higher order mechanisms in
operation. A variety of studies have reported changes in HeS structure
that correlate with developmental stages or the growth state of cells.
For example, the size of HeS chains attached to the cell surface HSPG
syndecan appears to vary dramatically with developmental age in the
mouse lung epithelium, decreasing in size as development proceeds
(Brauker et al., 1991). Tissue specific variations have also been noted:
syndecan HeS chains in simple epithelia appear to be significantly
larger than the HeS chains of syndecan isolated from stratified
epithelium (Sanderson and Bernfield, 1988). Monoclonal antibodies
that recognize specific HeS-associated epitopes gave distinct staining
patterns in developing hamster embryos that varied with
developmental age and tissue type, and that only partially overlapped
(David et al., 1992). The non-overlapping aspect of the staining could
be the result of a core-restricted expression of the GAG epitopes, or a
cell type specific expression of the epitopes on multiple cores, but, in
any case, it is suggestive of a higher order regulation of HeS structure.
Additional strong evidence for such regulation comes from structural
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analysis of HeS from transformed cells, which has consistently
revealed aberrant patterns of sulfation (Gallagher and Lyon, 1989).
The basis of the developmental, tissue, and growth state specific
alterations in HeS structure described above is unknown, but in one
recent study, indirect evidence for the existence of a regulatory factor
that is probably not one of the biosynthetic enzymes has been obtained
(Shworak et al., 1994b). In this study, the effect of PG overexpression
on the synthesis of the ATIII binding site on HeS chains was
examined. The ATIII binding site, as will be discussed in section III
below, is a specific pentasaccharide sequence that contains multiple
specific O-sulfations that are absolutely required for high affinity ATIII
binding, including a rare 3-0 sulfation [reviewed in (Bjork and Lindahl,
11982)]. The binding of heparin or HeS to ATIII greatly potentiates the
ability of ATIII to inactivate serine proteases, such as thrombin, in the
coagulation cascade. Overexpression of the cell surface HSPG
ryudocan (also called syndecan-4) in endothelial cells and in L cells
resulted in an overall increase in total HeS synthesized, but a decrease
in the absolute amount of ATIII binding HeS (HSact). This result
suggests that a factor required for the synthesis of HSact is limiting,
and further suggests that the factor contains multiple components
since HSact levels actually decline rather than simply plateauing. The
additional observation that in all other respects, including the total
synthesis of 3-O-sulfated residues, HeS synthesis appears normal in
these cells suggests that the limiting factor may be a regulatory
element rather than a biosynthetic enzyme (Shworak et al., 1994b).
Intriguingly, overexpression of a ryudocan core protein with GAG
attachment sites eliminated had a similar effect on the levels of HSact
produced in these cells, suggesting that the ryudocan core protein
may interact with the putative regulatory control element.
Interactions mediated by PG core proteins have been noted before [eg
binding of collagen fibrils by the core protein of the CSPG decorin
(Vogel et al., 1984), and the binding of TGF-[ by the core protein of
the HSPG betaglycan (Cheifetz and Massague, 1989)], and data will be
presented in Chapters 4 and 5 of this thesis that suggests that PG core
interactions with PG ligands may be more widespread than previously
appreciated.
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As discussed below, subsequent to the discovery of a specific ATIII
binding site in heparin and HeS, evidence for specific recognition of
particular HeS sequences by other GAG binding molecules has begun
to accumulate. Much effort has been focussed on the ligand binding
properties of particular PG core proteins on the cell surface and in the
extracellular matrix. It is refreshing to note that, in the end, a deeper
understanding of the biological processes in which PGs are involved
will also require us to learn more about what's going on inside the cell,
in the Golgi apparatus, where PG structure is determined.
III. Interactions of PGs with their Ligands
In the discussion below, considerable weight is given to the
interactions of HeS and HSPGs with their ligands at the expense of CS
and CSPGs. The binding of HeS to GAG binding sites on target
molecules typically occurs with higher affinity than the binding of CS,
and so is more easily detected and more readily studied. Some
notable exceptions include the binding of thrombospondin-1 (TSP-1)
and tenascin (TN) to CS, which will be discussed below. Since HeS
interactions with proteins have been more intensively studied, they
will be considered first, to illustrate some of the underlying principles
in GAG-protein interactions.
Table 2 gives a partial list of molecules known to bind GAGs. Many
of these molecules were identified as containing heparin-binding
regions. In vivo, the more likely ligand for these molecules is heparan
sulfate (HeS), which is expressed by virtually all adherent cell types.
Heparin in vivo is largely restricted to mast cells. In the discussion
below, these sites will often be referred to as HeS binding sites. HeS
typically binds to these molecules with a somewhat lower affinity, but
affinities can approach those observed for heparin (Binding of brain
HeS relative to heparin for a number of molecules has been
characterized by Mary Herndon; manuscripts in preparation).
General Features of GAG-Protein Interactions
No one feature of protein structure has been identified that is
common to all HeS-binding domains. HeS-binding regions have been
identified in a number of protein folding motifs [reviewed in (Lander,
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1994)] including fibronectin type III repeats, immunoglobulin
domains, and collagen triple helices. In addition, a large number of
proteins with unique or uncharacterized protein structures also
contain HeS-binding regions. Given that HeS and CS are highly
sulfated, polyanionic molecules, it is not surprising that many studies
have revealed HeS-binding motifs that are rich in basic amino acids.
Early proposals for heparin-binding consensus sequences included
BBXB and BBBXXB where B represents a basic amino acid residue
(Cardin and Weintraub, 1989). More recently it has become
appreciated that HeS-binding domains can be more complex than a
contiguous stretch of a few basic residues (Cardin and Weintraub,
1989). HeS-binding elements at distant locations on a polypeptide
chain can be brought together to form the complete HeS-binding
domain. [cf platelet factor 4 binding to heparin (Stuckey et al., 1992),
In addition, some heparin-binding molecules appear to contain
heparin-binding sites that are not composed of basic amino acids [e.g.
collagen types I, II, and III (San Antonio et al., 1994); and
thrombospondin (Adams and Lawler, 1993)].
In addition to the GAG-binding sites on proteins, a complete
picture of GAG-protein interactions requires a description of protein-
binding sites on GAGs. It has long been appreciated that specific
saccharide sequences within GAG chains can form binding sites for
particular proteins. The classic example is the ATIII binding site in
heparin (see below for more details of ATIII-heparin interactions).
This site was elucidated by depolymerization of heparin with nitrous
acid and fractionation of the resulting oligosaccharides on an ATIII
affinity column [for review see (Bjork and Lindahl, 1982)]. A small
fraction of the total oligosaccharides was found to bind to ATIII with
high affinity. The surprising result was that, despite the heterogeneity
of heparin as a whole, the composition of the oligosaccharides with
high affinity for ATIII was remarkably constant. Subsequently, the
structure of these oliogosaccharides was analyzed using an arsenal of
chemical and enzymatic techniques, with the end result being that a
specific pentasaccharide sequence was identified that comprised a
binding site for ATIII [reviewed in (Marcum and Rosenberg, 1989)].
The structure of the ATIII binding site is shown in Figure 2 [after
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(Jackson et al., 1991)]. A striking feature of the structure is the
presence of a rare 3-O-sulfate on the central GlcNSO3 residue. In fact
the majority of the 3-O-sulfates present in heparin are now known to
be within ATIII binding sites. Removal of this group by a 3-O-sulfatase
results in a dramatic decrease in affinity for ATIII.
Recently, the emerging story of HSPG involvement in FGF binding
to FGF receptors (see below for details) has sparked interest in
determining the structural requirments for HeS binding to FGF. Using
techniques similar to those described for ATIII, the HeS binding sites
for FGF-1 and FGF-2 have been elucidated. As shown in Figure 2,
these sites appear to have less stringent structural requirements than
the ATIII binding site. Nevertheless, they are not identical. The
preferred binding site for FGF-1 includes a 6-O-sulfate on GlcNSO3
(Mach et al., 1993) whereas the binding site of FGF-2 does not
(Turnbull et al., 1992).
Another recent study suggests that specific interactions between
GAGs and proteins may be commonplace (San Antonio et al., 1993). In
this study, 1 2 5 1-labelled, low molecular weight heparin (Mr - 6000)
was fractionated by electrophoresis through agarose gel lanes
containing the extracellular matrix molecules laminin-1 (LN-1),
fibronectin (FN-1), type I collagen (CI), and thrombospondin (TSP-1).
(This technique, called affinity coelectrophoresis or ACE, has been
described previously (Lee and Lander, 1991); see also Chapter 4 of
this thesis for a description). LN-1, FN-1, and CI were all found to
fractionate low molecular weight heparin into high and low affinity
fractions. Fractions with high affinity for any one of these molecules
were also found to bind with high affinity to the others. However, high
affinity binding could not be explained on the basis of net charge, or
the presence of ATIII binding sites. Thus there appear to be distinct
sequences within heparin that are bound preferentially by extracellular
matrix proteins.
To illustrate the complexity and the functional consequences of
GAG-protein interactions, two well-characterized examples will be
considered next. Additional examples of GAG/PG binding will be
discussed in section IV below.
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Antithrombin III, a Prototypical Heparin/HeS Binding Molecule
One of the most extensively characterized HeS-binding proteins is
ATIII. The studies of ATIII binding to heparin [as reviewed in
(Jackson et al., 1991)] provide an excellent example of both the
potential complexity of GAG-protein interactions, and the types of
techniques that can be brought to bear the problem. One potential
heparin binding region in ATIII was identified by studies in which
proteolytic fragments of ATIII were isolated that retained some
heparin binding capacity. These fragments encompassed a region
from residues 124-145 that contains several basic amino acid residues
(Rosenfeld and Danishefsky, 1986; Smith and Knauer, 1987).
Antibodies raised against peptides based on this region were found to
block heparin binding to ATIII, and, interestingly, were also shown to
be partially able to substitute for heparin in accelerating the
inactivation of thrombin by ATIII (Smith et al., 1990). When the
region is modeled as an a-helix, helical wheel presentation reveals
that the basic amino acids in this region fall on one face of the helix,
and hydrophobic amino acids on the opposite side. Chemical
modification of the lysines in this region results in a loss of heparin
binding and thrombin inactivation ability (Liu and Chang, 1987;
Peterson et al., 1987). Interestingly, pre-binding of heparin protects
some of the lysines in the 124-145 region from modification, but
results in exposure of other lysines outside this region that had been
previously resistant to modification, suggesting a conformation change
in ATIII upon heparin binding (Chang, 1989).
Another region of ATIII apparently important for heparin binding
was identified on the basis of mutations resulting in disfunction. Thus
several hereditary forms of ATIII have been isolated in which Arg-47
has been substituted with another amino acid. These forms exhibit
decreased heparin binding and decreased thrombin inactivation
(Jackson et al., 1991).
The above findings have led to a view in which the initial binding of
heparin to ATIII induces a conformational change that results in the
formation of the complete heparin binding domain required for high
affinity heparin binding (Jackson et al., 1991). Studies that
demonstrate that reduction of disulfide linkages reduces heparin
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binding by ATIII, and conversely that heparin binding renders
disulfide bonds resistant to reduction, support this view (Sun and
Chang, 1989), as do spectroscopic studies that demonstrate an
apparent conformational change upon heparin binding [cf (Bjork and
Lindahl, 1982; Evans et al., 1992)].
Heparin accelerates the inactivation of thrombin by ATIII by as
much as 2000-fold. The contribution of the heparin-induced
conformational change to ATIII's activity towards thrombin has been
the subject of some debate. Two opposing models were advanced
early on, the conformation model and the template model. In the
conformation model, the enhancement of ATIII inactivation of
thrombin is attributed to the conformational change induced by
heparin binding, a change that exposes the active site for more
efficient interaction with thrombin (Rosenberg and Damus, 1973).
The template model emphasized the fact that heparin also binds to
thrombin [cf (Holmer et al., 1979)]. In this model the effect of
heparin is to provide a template to which both ATIII and thrombin
bind, bringing the molecules into close apposition and thereby
accelerating the rate of the reaction. As is often the case for the
dichotomies created by scientific debate, evidence has accumulated
suggesting that both models are correct. In one recent study using
heparin oligosaccharides of defined size, a sharp threshhold for the
enhancement of thrombin inactivation by ATIII was observed at the
size range of 14-16 disaccharide units. This size requirement favors
the template model. However, a similar size requirement was not
observed for accleration of ATIII inhibition of the protease, factor Xa,
nor for the acceleration of heparin cofactor II inhibition of thrombin,
or the potentiation of protein C inhibitor's interaction with several
serine proteases (Pratt et al., 1992). The findings emphasize that
although patterns may recur, heparin's effect (and that of HeS) on
interactions of proteases and their inhibitors will vary from case to
case. In the case of the ATIII-thrombin interaction, both a
conformational change and the "template effect" appear to be
important. In another recent report, the pentasaccharide sequence of
heparin that binds ATIII with high affinity caused by itself a
conformational change and a partial acceleration of ATIII inactivation
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of thrombin. The further addition of low-affinity heparin chains of
higher molecular weight potentiated the rate of inactivation to an
extent nearly equal to that of intact high affinity heparin chains (Evans
et al., 1992).
Binding of PGs to Members of the FGF family: The Coreceptor
Hypothesis
A recent incarnation of the debate described above involves the
coreceptor hypothesis. In this model, the HeS chains of an HSPG
participate in the binding of a ligand to another high affinity, non-PG
re:ceptor (Bernfield et al., 1992). Recently, strong evidence in support
of the coreceptor hypothesis has come from studies of the binding of
FGF-2 (bFGF) to its high affinity receptor. FGF-2 fails to bind to
'Chinese hamster ovary (CHO) cells deficient in HeS production, even
though these cells were transfected to overexpress FGFR-1, a high
affinity receptor for FGF-2. The addition of soluble heparin or HeS
re:constitutes an FGF-2/FGFR-1 interaction on the surface of these
cells (Yayon et al., 1991). In a similar set of experiments treatment of
cells with heparitinase (which cleaves HeS chains) or growth of cells
in chlorate (which inhibits sulfation of GAG chains) resulted in a loss of
FGF-2 binding to the cell surface, blocked the ability of added FGF-2 to
;stimulate the growth of fibroblasts, and resulted in the terminal
differentiation of mouse myoblasts (which is normally suppressed by
FGF-2) (Rapraeger et al., 1991).
Several of the experiments aimed at elucidating the molecular basis
of the apparent requirement for HeS in the binding of FGFs to tyrosine
Ikinase receptors are reminiscent of experiments done with ATIII and
thrombin. Experimental approaches have included mutagenizing basic
amino residues thought to be involved in heparin/HeS binding (Heath
et al., 1991), and, as described below, examining the effects of using
variously sized oligosaccharides in binding assays. Two models that
are not mutually exclusive have emerged, a template model, similar to
that described for ATIII above, and the "dimerization model." In the
dimerization model, the function of HeS is to facilitate the
dimerization of FGF molecules that then bind and help to dimerize
their high affinity receptors. Dimerization is believed to be a common
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step in signalling through tyrosine kinase receptors. The dimerized
receptors are thought to reciprocally auto-phosphorylate each other,
an initial step that results in a signalling cascade (Ullrich and
Schlessinger, 1990).
Evidence in support of the template model has come from a study
of the kinetics of the FGF binding to its receptor. The binding of FGF-
1 to HeS and FGFR-1 on the cell surface occurred with apparently
similar "on" rates, but the "off' rate was higher for FGF bound to HeS
than for FGF bound to FGFR-1. However, in solution, FGF-1 bound to
FGFR- 1 exhibited on off rate similar to that of FGF-1 bound to HeS.
This was interpreted to suggest that a cell surface molecule, possibly
anl HSPG, stabilizes the interaction of FGF-1 with cell surface FGFR-1
by participating in the formation of a ternary complex (Nugent and
Edelman, 1992). Additional support for a template effect has come
from the identification of an apparently essential heparin binding
domain in the FGFR-1 tyrosine kinase receptor (Kan et al., 1993).
Antibodies raised to a synthetic peptide from this region as well as
point mutations of lysine residues led to a loss of heparin binding and
heparin-mediated FGF-1 binding to FGFR-1. In addition, there have
been reports of a minimum size of heparin-derived saccharides that
will potentiate FGF interactions with FGFR-1 [cf (Ornitz et al., 1992;
Guimond et al., 1993)], although the minimum size designated varies
from report to report, possibly reflecting differences in the way the
saccharides were prepared. Guimond et al. (1993) also demonstrated
that heparin has similar effects on the binding of FGFs 1 and 4 to
binding to cell surface tyrosine kinase receptors, and that different
heparin-derived oligosaccharides have different effects on binding.
This indicates there is specificity in the interaction of heparin with
the different FGFs and their receptors. Specificity of GAG-protein
interactions will be discussed further below.
Ornitz et al. (1992), in a set of experiments designed to
demonstrate a requirement for heparin in FGF binding to its receptor
in solution, also demonstrated that FGF molecules can be crosslinked
into dimers in the presence of added heparin but not in its absence.
In a subsequent report, a synthetic heparin analog that binds
monovalently to FGF-1 was found to inhibit FGF receptor dimerization
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and tyrosine kinase activation (Spivak-Kroizman et al., 1994). Even
small di or tri-saccharides, used in relatively high concentrations, can
apparently serve to dimerize FGF molecules (presumably by binding to
multiple sites on each molecule) and activate the FGF signalling
pathway (Ornitz et al., 1995).
None of the above observations rule out a model in which both the
template effect and dimerization play a role in FGF binding to FGF
receptors. Indeed there has already been one report in which a model
was advanced that incorporated elements of both template and
dimerization hypotheses (Pantoliano et al., 1994). Most of the studies
done to characterize the effects of heparin on the binding of FGFs to
their receptors have used heparin as a model for the HeS that is likely
to be contributed by HSPGs in vivo. The question of which HSPGs
actually serve as the coreceptors for FGFs has only begun to be
addressed. A cell surface localization for such HSPGs may seem a
priori to be the most likely situation; however it is conceivable that an
HSPG in the extracellular matrix (ECM) could serve a similar function.
It has long been proposed that ECM HSPGs could act as a reservoir for
growth factors such as the FGFs, protecting them from proteolytic
degradation [c.f. (Saksela et al., 1988)]. In fact, in a series of recent
reports in which distinct PG core proteins were immunopurified from
human fetal lung fibroblasts, the ECM HSPG perlecan, and not the cell
surface HSPGs glypican (GPN), syndecan-1 (SYN-1), and fibroglycan
(syndecan-2, SYN-2), was found to be able to potentiate the binding
FGF to CHO cells deficient in HeS. Perlecan also potentiated FGF-2
binding to soluble or immobilized FGFR-1 (Aviezer et al., 1994a;
Aviezer et al., 1994b). GPN, SYN-1, and SYN-2 were found to actually
decrease binding of FGF-2 to immobilized FGFR-1 or to the HeS
deficient CHO cells. Whether perlecan will generally be found to serve
as an FGF coreceptor remains to be determined, but the above data
suggest that it may be an FGF coreceptor for human fetal lung
fibroblasts. One caveat in these studies is that the effects of the
various HSPGs were measured by adding immunopurified HSPGs to
the binding reactions. It is not clear that identical behavior would be
observed if the HSPG were in their natural settings (i.e. in the matrix
or intercalated in the plasma membrane).
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Although FGF binding to FGF receptors is probably the most
extensively characterized example of a system implicating HSPGs as
coreceptors, support for the coreceptor hypothesis has also come
from studies of cell adhesion on fibronectin (FN) and NCAM-NCAM
adhesive interactions. CHO cells deficient in HeS synthesis were
found to be unable to attach and spread on a heparin-binding
fibronectin peptide, and, although they did adhere to intact FN, they
did not form focal adhesions as wild type CHO cells did (LeBaron et al.,
1988). These results suggest that both cell surface HSPGs and
integrins, the classical FN receptors, are required for full adhesive
response to FN. The extent to which HSPGs and integrins interact, if
at all, during adhesion to FN remains to be determined. NCAM-NCAM
interactions have been shown to be sensitive to added heparin, an
antibody to the NCAM heparin binding region, or added NCAM
proteolytic fragment encompassing the heparin binding region (Cole
et al., 1986a; Cole and Glaser, 1986b). Further, a genetic deletion of
the heparin ibinding region results in the loss of NCAM binding to
heparin, and a loss of retinal cell adhesion to NCAM coated dishes
(Reyes et al., 1990). Taken together, the data suggest that a cell
surface HSPG participates in at least some NCAM-NCAM adhesive
interactions.
Interactions of CSPGs with their ligands
Comparitively little is known about CS/CSPG interactions with CS-
binding proteins. Perhaps because CS affinity for heparin/HeS-binding
proteins is typically lower than the affinities of heparin and HeS, less
work has been done to characterize CS-protein interactions at the
molecular level. However, examples of proteins that bind to CS with
affinities comparable to that of HeS exist. Thrombospondin-1 (TSP-1)
binds to neonatal rat brain CS with a Kd of 235 nM, very similar to the
Kd of 180 nM measured for HeS isolated from the same source (Mary
Herndon, unpublished data). This is interesting in light of the
observation, mentioned above, that TSP-1 failed to fractionate low
molecular weight heparin into low and high affinity fractions (San
Antonio et al., 1993). It is possible that TSP-1 contains GAG binding
sites that are promiscuous enough to be satisfied by either HeS or CS.
27
It is also possible that TSP-1 has separate CS and HeS binding sites
that each bind to their respective GAGs with similar affinities.
The binding of CS by TSP-1 appears to have functional
consequences. In one study, attachment of myoblasts to TSP-1 was
not inhibited by heparin or the GRGDS peptide, which interferes with
inany integrin-mediated interactions, but was inhibited by the addition
of chondroitin sulfate (Adams and Lawler, 1994). This suggests that
for some cell types, a cell surface CSPG may be important for TSP-1
binding. In another study Chinese hamster ovary cells that were
pretreated with chondrotinase showed a decreased ability to bind and
internalize TSP-1 (Murphy-Ullrich et al., 1988), supporting the view
that cell surface CSPGs contribute to cell interactions with TSP-1.
Another molecule for which CS binding has been noted is tenascin
(TN). TN is a large extracellular matrix glycoprotein with six subunits
each in the size range of 190,000 - 225,000. TN binds to the CSPGs
phosphacan and neurocan in solid phase binding assays. Phosphacan
was further shown to inhibit the binding of C6 glioma cells to a TN
substrate (Grumet et al., 1994).
IV•. Expression and Function of Proteoglycans during Development
with Special Reference to the Nervous System
Many of the putative biological roles for PGs have been suggested on
the basis of PG expression and the expression of PG-binding molecules
during development. This section will review the evidence for PG
expression and function in the developing nervous system. The
information is organized by developmental process, and the PG-
binding molecules that have been implicated in that process. The
individual PGs involved (where identified) are discussed.
Regulation of Cell Proliferation
Many molecules that are thought to be involved in the control of cell
proliferation bind to heparin and HSPGs. These include heparin
binding growth factors and extracellular matrix molecules. Evidence
that PGs play a functional role in interacting with these molecules is
reviewed below.
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Acidic FGF (FGF-1), and basic FGF (FGF-2) are two small (Mr- 16
kDa) polypeptides that were first purified from bovine brain on the
basis of their ability to stimulate the proliferation of 3T3 fibroblasts
(Lobb and Fett, 1984; Thomas et al., 1984). The sequences of these
two proteins were subsequently determined directly by protein
sequencing and shown to be 55% identical (Gimenez-Gallego et al.,
1985). Currently there are seven known members of the FGF family
expressed in a wide variety of tissues and developmental stages.
FGF-1 and FGF-2 are expressed at several locations in the
developing nervous system, including the ventricular zone and cortical
plate of the developing rat cerebral cortex (Gonzalez et al., 1990; Fu et
al., 1991; Wilcox and Unnerstall, 1991). In addition, these molecules,
have been shown to stimulate proliferation and survival of neural cells
in vitro (Walicke et al., 1986; Unsicker et al., 1987; Walicke, 1988;
Murphy et al., 1990; Hughes et al., 1993).
As discussed in section III above, HSPGs have been implicated as
coreceptors for members of the FGF family, since binding of FGFs to
their high affinity tyrosine kinase receptors appears to require HeS.
Several studies have reported on findings that support the view that
HSPGs can influence FGF activity. As reviewed in Gallagher (1989),
these studies have shown that HeS chains and FGFs can form
biologically active complexes that have potent mitogenic activity for a
variety of cell types. In one of these studies purified HSPGs secreted
from bovine capillary endothelial cells were found to bind to FGF-2 and
protect it from degradation by the proteinase plasmin, leading to the
suggestion that one role of HSPG binding to FGF could be to protect
FGF from degradation at sites where proteolytic activity is high, such
as zones of neovascularization (Saksela et al., 1988). The view of the
extracellular matrix as a reservoir of FGF-2 is supported by a study that
showed that FGF-2 can be released from the matrix by treatment with
heparitinase or by the addition of soluble heparin (Bashkin et al.,
1989). Evidence of the presence of endogenous FGF-2 in an
extracellular matrix derived from an in vivo source comes from a study
that showed that incubation of Descemet's membranes of bovine
corneas with platelets, neutrophils or lymphoma cells resulted in the
release of FGF-2 (Ishai-Michaeli et al., 1990). These cells were found
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to express a heparanase activity that could be inhibited by carrageenan
lambda, a GAG analogue, and carrageenan lambda also inhibited the
release of FGF-2. Taken together, the results suggest that some cell
types can mobilize matrix-bound FGF-2 by degrading the HeS chains of
an extracellular matrix HSPG to which FGF-2 is bound.
To date, the identities of the core proteins that actually interact
with members of the FGF family in vivo have not been defined. It has
been proposed that syndecan-1 (SYN-1) could act as a coreceptor for
FGF-2 (Bernfield et al., 1992). SYN-1 has been shown to bind to FGF-2
via its HeS chains (Bernfield and Hooper, 1991), and expression of
SYN-1 in lymphoblastoid cells confers low affinity FGF-2 binding sites
on these cells (Kiefer et al., 1990). Furthermore, SYN-1 is transiently
expressed on rapidly proliferating, condensing mesenchymal cells in a
variety of locations during development, suggesting that one function
of SYN-1 could be to bind a growth factor that stimulates mesenchymal
cells to divide [reviewed in (Bernfield et al., 1992)]. This possibility is
supported by a report that demonstrated a highly similar expression
pattern of SYN-1 and epidermal growth factor in developing tooth
mesenchyme (Partanen and Thesleff, 1987).
Some authors have reported that a biologically active FGF-2/HSPG
complex is released from cell surfaces by the bacterial enzyme
phosphoinositol-specific phospholipase C (PIPLC), which cleaves
glycosylphosphatidylinositol (GPI) anchors. These studies point to the
possibility that members of the glypican (GPN) family of GPI-anchored
HSPGs could also serve as coreceptors for members of the FGF family.
However, as described in section III above, an experiment using PG
core proteins immunopurified from human fetal lung fibroblasts
demonstrated that the large secreted HSPG perlecan, and not GPN or
SYN-1, was able to potentiate the binding of FGF-2 to HeS-deficient
CHO cells, or to FGFR-1, a tyrosine kinase receptor for FGF (Aviezer et
al., 1994a; Aviezer et al., 1994b). In fact, although GPN and SYN-1
bound FGF-2, they were actually found to inhibit the subsequent
binding FGF-2 to FGFR-1.
Recently, additional evidence that perlecan family HSPGs may serve
as FGF coreceptors has come to light (Nurcombe et al., 1993). In this
study, the timing of expression of FGF-1 and FGF-2 mRNAs in the
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developing mouse mesencephalic and telencephalic neuroepithelium
was examined. FGF-2 mRNA was found on embryonic day 9 (E9) and
thereafter, but FGF-1 mRNA was only detected beginning on E11.
Interestingly an HSPG [subsequently shown to be a novel member of
the perlecan family of HSPGs (Joseph et al., 1995)] isolated from the
same tissue on E9 was found to bind with preferentially to FGF-2,
whereas the same HSPG isolated from E11 tissue bound preferentially
to FGF-1. Thus the switch in the binding preferences of the HSPG
coincided with the appearance of FGF-1 in the neuroeptihelium
suggesting that this HSPG may be regulated to preferentially interact
with FGF-1 when it appears. As discussed above, FGF-1 and FGF-2
have similar but distint binding sites on HeS chains, suggesting one
way cells could discriminate between these two growth factors.
The results described above suggest that different HSPGs may exert
different effects on FGF interactions with FGF receptors. In particular,
the results raise the possibility that cells could regulate their response
to FGF-2 by regulating which types of HSPGs they produce. For
example, SYN-1 and GPN could act as competitive inhibitors of
perlecan potentiation of FGF-2 binding to FGFR-1.
Nevertheless, it appears likely that the individual HSPGs involved in
potentiating growth factor action are likely to vary from tissue to
tissue. Ratner et al, (1988) have reported on a molecule mitogenic for
Schwann cells that was found to be peripherally associated with the
surface of dorsal root ganglion neurons (which are themselves
mitogenic for Schwann cells). This factor could be extracted from the
cell surface with heparin, suggesting it could be held at the cell
surface by an HSPG. If this is the case, it suggests that a cell surface
HSPG on the neuronal cell surface presents the growth factor to a
receptor on the Schwann cell surface.
The P-type transforming growth factor (TGF-P) family of
polypeptide growth factors consists of at least five related species,
three of which are found in mammals. The structures of TGFP1, P2,
and [3 are similar; each is synthesized as a pre-pro monomeric
polypeptide. The pre-pro form is cleaved, but the pro-peptide
remains associated, maintaining the latent state until cleaved
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monomers dimerize, causing the pro-peptides to dissociate [reviewed
in (Lyons and Moses, 1990)]. In in vitro assays, TGF[ family members
are mitogenic for some cell types such as cells derived from bone, and
growth inhibitory for many other cell types. Members of the TGFP
family are expressed in the developing nervous system. TFG[2 and 03
are found associated with glia and astrocytes in the embryonic
midbrain and ventral spinal cord (Pelton et al., 1991).
The receptor system for the TGF3s is complex. TGFP receptors
type I and II are transmembrane molecules that form a signalling
complex when TGFP is bound (Wrana et al., 1992). The type II
receptor contains a serine/threonine kinase in its cytoplasmic domain.
The type III receptor for the TGF[s is betaglycan, a heteroglycan with
a 100 kDa core protein that can be substituted with CS or HeS chains,
and is widely expressed in the developing embryo (L6pez-Casillas et
al., 1991). Interestingly, TGFfs bind to betaglycan via the core
protein. The functional role of betaglycan's GAG chains remains
unknown (Cheifetz and Massague, 1989).
In one recent study, betaglycan expressed in a rat skeletal muscle
myoblast cell line (a cell type that does not normally express
betaglycan) was found to enhance the growth inhibition response to
exogenous TGF 1, apparently by participating in the formation a
ternary complex involving the signalling TGFP type II receptor (L6pez-
Casillas et al., 1993). Thus betaglycan appears to be able to act as a
coreceptor, at least for TGF 1.
The CS/DSPG decorin also binds to TGF3, and, like betaglycan, the
binding is mediated by the core protein. Decorin expression has been
detected in the floor plate of the developing mouse spinal cord, a
structure believed to be important for the guidance of commisural
axons (see below). Decorin expressed in Chinese hamster ovary cells
was found to bind endogenous and exogenous TGF 1 and suppress the
growth promoting activity of TGF 1 for those cells. The mechanism of
TGFP inactivation by decorin remains to be determined (Yamaguchi et
al., 1990). Thus betaglycan and decorin both bind to TGFP via their
core proteins but appear to exert opposite effects on TGFP activity:
betaglycan enhances TGF3 activity and decorin neutralizes it.
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The large extracellular matrix (ECM) glycoproteins laminin-1 (LN-
1), fibronectin (FN), and thrombospondin-1 (TSP-1) have also been
shown to exert effects on cell proliferation and differentiation. The
structures of these molecules and their tissue distribution will be
discussed in greater detail in the next section with regard to their
effects on cell migration and axon outgrowth.
LN-1 causes cell proliferation and an increase in 3 H-thymidine
uptake for several cell types in vitro [reviewed in (Lander and Calof,
1993)]. Interestingly, different LN-1 fragments are active for different
cell types. This is possibly a reflection of the large number of cellular
receptors for LN-1, including as many as six different combinations of
a and 3 integrin subunits, the cell surface enzyme galactosyl
transferase, and, potentially, HSPGs (Lander and Calof, 1993).
In contrast to LN-1, FN has often been found to exert growth
inhibitory effects on cells. For example, mitogen-stimulated Schwann
cells, in what appears to be an autrocine mechanism of growth
control, secrete a metalloprotease that cleaves FN, liberating a 29 kDa,
N-terminal, heparin binding fragment that inhibits proliferation (Muir
and Manthorpe, 1992). Transformed Schwann cells do not secrete
the protease, suggesting that this mechanism may be a primary mode
of growth control for Schwann cells.
In the developing rodent cerebral cortex, FN expression, initially
found throughout the ventricular zone (a layer where neuronal
precursor cells are rapidly dividing), becomes restricted to the
preplate overlying the ventricular zone as soon as the preplate
appears. (Stewart and Pearlman, 1987). The preplate is formed by
the earliest cells to exit the cell cycle and begin differentiation (on
E11-E12 in the mouse). Given the activity of FN noted above for
Schwann cells it is interesting to speculate that one function of FN in
the early cortex could be to act as a brake on proliferation, facilitating
the transition from precursor to immature neuron.
The ECM glycoprotein TSP-1 is observed associated with the cell
surfaces of neuroepithelial cells throughout developing mouse nervous
system at early times (El 1 and E13) when cell proliferation is
proceeding at a high rate (O'Shea and Dixit, 1988). Outside of the
nervous system, TSP expression in the skeletal muscle also correlates
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with cell proliferation. In the early embryo, TSP is found on the
surface of undifferentiated myoblasts (O'Shea and Dixit, 1988). At
adult stages, TSP is upregulated in response to crush injury (Watkins
et al., 1990) or in response to amyotrophic lateral sclerosis (Rao et al.,
1992), conditions that correspond to renewed myoblast proliferation
and migration.
In addition to the binding of intact PGs to ligands that exert an
effect of cell proliferation, many authors have reported that free HeS
can exert an effect on cell growth by binding to ligands in the nucleus
[reviewed in (Hart et al., 1989)] Many of these reports have been met
with natural skepticism since HeS chains are synthesized in the Golgi
and attached to core proteins destined to be secreted or intercalated
in the plasma membrane. Despite the attempts made to demonstrate
HeS and CS observed in the nucleus was not a biochemical
contaminant or the result of non-specific binding by an immunological
probe, a conclusive demonstration of a nuclear localized GAG remained
elusive.
A series of more recent reports has provided additional evidence
that HeS can be localized to nucleii [reviewed in (Gallagher, 1989)]. In
these reports, a GPI-linked HSPG on confluent hepatoma cells was
found to express a fraction of HeS chains enriched in 2-O-sulfated-Glc-
A, a rare modification. This same modification was found to be
enriched on chains isolated from the nuclei of these cells.
HeS/HSPGs derived from confluent cells, and containing a mixture of
HeS structures, were added to logarithmically growing cells resulting
in a selective enrichment of the 2-O-sulfated-GlcA forms in the
nucleii, and causing growth arrest at the G 1/S boundary of the cell
cycle. The fact that the forms isolated in the nuclear pool contained a
high percentage of HeS chains with a unique structure uncommon in
the other cellular pools argues against non-specific contamination in
these experiments (Fedarko and Conrad, 1986; Ishihara et al., 1986;
Fedarko et al., 1989).
These reports raise the possibility that a cell surface GPI-anchored
HSPG (possibly a member of the glypican family of HSPGs) may be
involved in a growth control mechanism at least in these cells. This is
34
intriguing in light of the recent discovery of a Drosophila homolog of
the mammalian glypican family. This molecule, the dally protein, was
identified on the basis of a mutant phenotype in which the G2/M
transition is blocked at a number of locations in the developing
nervous system, such as the lamina furrow of the outer proliferative
center, and the morphogenetic furrow of the eye disc (Nakato et al.,
1995). The dally protein will be discussed in greater detail in Chapter
6 of this thesis with regard to functions of glypican family members in
the developing nervous system.
Cell Migration and Axon Outgrowth
Many of the molecules that that are thought to play roles in cell
migration and axon outgrowth are potential ligands for PGs. The
section below summarizes the structures of some of these molecules,
their expression patterns in the developing nervous system, their
biological activities, and their potential interactions with PGs.
The extracellular matrix molecule laminin (LN) is composed of
three separate polypeptide chains, the a chain, the [ chain, and the y
chain (formerly, the A, B 1, and B2 chains), each encoded by a separate
gene. The -440 kDa a chain associates with the P and y chains, ~ 220
and ~210 kDa respectively, forming a distinctive cross shaped
structure, with three short arms and one long arm, that can be
visualized by electron microscopy [reviewed in (Beck et al., 1990)]. So
far, 4 a chain isoforms, 3 0 chain isoforms, and 2 y chain isoforms have
been identified. Of the 24 possible forms of intact LN that could be
assembled from these chains, seven have been identified in vivo and
are designated LN-1 through LN-7. Classic LN (alplyl), of the kind
derived from EHS sarcoma, is LN-1. Other well characterized forms
are LN-2 (a2[lyl; formerly merosin), and LN-3 (al 012yl; formerly S-
laminin).
LN-1 was originally purified from the conditioned medium of a
variety of cell types on the basis of its potent neurite outgrowth
promoting activity [cf (Lander et al., 1985)]. Subsequently it has also
been demonstrated that LN-1 is actually able to guide neurites in vitro
[cf (Gundersen, 1987)]; which is to say, neurites will accurately follow
a patterned LN-1 substratum. Axon guidance in vivo by one of the LNs
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has yet to be formally demonstrated, but LN expression patterns in the
developing nervous system are provocative.
LN-1 is expressed in the avian optic tract during the time when
retinal ganglion cells (RGCs) are extending axons through the tract to
targets in the optic tectum. Furthermore, responsiveness of purified
RGCs to LN-1 in vitro corresponds to the window of axon outgrowth in
vivo. RGCs isolated from retina on embryonic day 11, after axon
outgrowth is complete, no longer extend neurites on LN-1 in vitro,
whereas RGCs from earlier time points do (Cohen et al., 1986; Cohen
et al., 1987). Interestingly, the loss of RGC responsiveness to LN-1
correlates with the downregulation of a6 integrin subunit by these
cells (deCurtis et al., 1991). LN isoforms are also found associated
with the pathways through which spinal cord motoneurons and dorsal
root ganglion neurons grow, as well as in the subplate of the
developing rat cortex, a region through which cortical and thalamic
axons grow (Rogers et al., 1986; Hunter et al., 1992).
LN-1 and LN-2 support the migration of olfactory epithelial (OE)
neurons in vitro, whereas fibronectin (FN) and type I collagen type do
not. A subset of these neurons is known to migrate from the OE to the
hypothalamus during development. The specificity in the preference
of OE neurons for LN over other ECM molecules tested suggests that a
LN isoform may be part of the migratory substrate for these cells in
vivo [reviewed in (Hynes and Lander, 1992).
The PG ligands for LN isoforms in vivo are not well characterized.
The HSPG perlecan copurifies with LN-1 [cf (Lander et al., 1985), and
perlecan HeS chains bind to LN-1 in in vitro assays. This has led to
the suggestion that perlecan may be involved in the proper assembly of
LN isoforms in the ECM (Yurchenco and O'Rear, 1993; Colognato-Pyke
et al., 1995) In addition, the cell surface HSPGs glypican (GPN) and
syndecan-3 (SYN-3) are known to be expressed in the developing rat
nervous system (Carey et al., 1992; Gould et al., 1992; Litwack et al.,
1994; Gould et al., 1995). The subject of the main part of this thesis
is the identification, cloning, and characterization of a novel member
of the GPN family of HSPGs. This molecule was named cerebroglycan
(CBG), and is also expressed in the developing rat nervous system.
Evidence will be presented in Chapters 4 and 5 of this thesis
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supporting the possibility that CBG, GPN, and SYN-3 could function as
receptors or coreceptors for LN isoforms.
Fibronectin (FN) is another large glycoprotein of the ECM found in
the developing nervous system. FN consists of two chains, each -220
kDa, that are disulfide linked near their C-termini. Although both
chains are encoded by the same gene, they are known to be alternately
spliced, creating the opportunity for several FN isoforms to be
assembled [reviewed in (Hynes, 1990; Reichardt and Tomaselli,
1991)]. FN is a composite of several structural motifs, including FN
repeats types I, II, and III. FN type III repeats are also found in other
molecules such as tenascin. So far, six different ap combinations of
integrin subunits have been identified as FN receptors (Hynes, 1992).
FN also contains heparin binding domains, one near the N-terminus
and one near the C-terminus of each subunit.
In the peripheral nervous system FN is found on associated with
the nerve fibres of sensory and sympathetic ganglia, as well as in the
matrix through which neural crest cells migrate (Rogers et al., 1989;
Hynes and Lander, 1992). In the central nervous system, FN is
transiently expressed in the developing cortex. FN is expressed in the
early ventricular zone, but becomes restricted to the preplate, a
structure comprised of some of the earliest cortical neurons to be
born. When the forming cortical plate splits the preplate into the
marginal zone (MZ), laterally, and the subplate (SB), medially, FN
expression remains associated with both the MZ and the SP. FN
expression is also associated with radial glial fibres in the developing
cortex; these fibres constitute possible pathways of migration for
cortical neurons (Stewart and Pearlman, 1987; Sheppard et al., 1991).
At later time points, when axon outgrowth into and out of the cortex
has been essentially completed, FN expression disappears from that
structure.
Evidence that FN is involved in the migration and axon outgrowth
of neuronal cells comes from studies involving a variety of cell types
[reviewed in (Rogers et al., 1989; Hynes and Lander, 1992)]. FN
supports the migration of neural crest cells in vitro, and, as discussed
above, FN is richly expressed in vivo in the extracellular matrix
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through which neural crest cells migrate. The RGD peptide, which
blocks many of the integrin-FN binding interactions (as well as some
integrin interactions with other ECM proteins), inhibits neural crest
cell migration when injected into embryos.
PNS neurons respond to a FN substrate in vitro by extending stable
neurites. Interestingly, although some CNS neurons extend neurites
in vitro on FN, these neurites are not stable and retract within a few
dlays (Rogers et al., 1989). Studies comparing CNS and PNS
interactions with FN fragments suggest that CNS neurons may use a
cell surface HSPG to interact with FN (Rogers et al., 1983; Rogers et
al., 1989). PNS neurons attach and extend neurites on both a 75 kDa
fragment of FN containing integrin binding sites alone and a 33 kDa
fragment containing the C-terminal heparin binding domain and
another integrin binding site. In contrast, CNS neurons (spinal cord
motoneurons) attach and extend neurites only on the 33 kDa
fragment. Interestingly, the neurites extended by the spinal cord
motoneurons in these experiments were stable, persisting for several
days in culture, unlike neurites extended on intact FN by a variety of
CNS neuronal cell types. One interpretation of these studies is that FN
is capable of sending multiple, and sometimes conflicting signals to
CNS neurons. The multiple integrin binding sites on the intact FN
molecule provide a possible mechanism for such complex interactions.
The fact that spinal cord motoneurons responded to the 33 kDa
fragment, heparin binding fragment of FN raises the possibility that an
HSPG on the cell surface of these cells could be involved in the
interaction, although, as noted above, this fragment also contains an
integrin binding site adjacent to the heparin binding domain.
A recent study has demonstrated that neuronal cells can utilize a
cell surface HSPG to attach and spread on synthetic FN fragments,
derived from the 33 kDa fragment, that contain the heparin binding
domain without the integrin binding site (Haugen et al., 1992). The
adhesion and spreading can be inhibited by heparitinase, or by
antibodies raised to a GPI-anchored HSPG in melanoma cells. These
same antibodies recognize a core protein of Mr 51 kDa, that shifts
upward dramatically upon reduction, on western blots of neuronal PG
preparations. The glypican family of cell surface HSPGs, unlike the
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syndecan family HSPGs, contains several cysteine residues, and
changes in the Mr of the glypican core have been noted before upon
reduction (David et al., 1990; Herndon and Lander, 1990). Taken
together, the biochemical data suggest that the cell surface PG in
these studies is a member of the glypican family, and that it may play a
role in the interactions of neuronal cells with FN.
Thrombospondin (TSP) is a large extracellular matrix glycoprotein
consisting of 3 chains of chains of Mr- 140 kDa, that are linked by
disulfide bonds. Each subunit of TSP contains two heparin binding
domains and multiple integrin binding sites. TSP also binds to
sulphatides (sulfated glycolipids) and to proteases such as
plasminogen. There are currently five known isoforms of TSP, TSP-1
through TSP-4, and COMP (cartilage oligomeric matrix protein).
COMP differs from the other members of the TSP family in that it is
isolated as a pentameric molecule. So far, TSP hybrids that
incorporate subunits from different TSP genes into the same molecule
have not been identified (Adams and Lawler, 1993).
Vitronectin (VN), in contrast to most other ECM glycoproteins, is a
relatively small molecule consisting of a single 78 kDa chain. Its
presence in the nervous system is just beginning to be characterized.
TSP-1 and VN are both present in the developing retina
(Neugebauer et al., 1991), and both TSP-1 and VN promote
attachment and neurite outgrowth by retinal neurons in vitro.
Attachment to TSP-1 is inhibited by the addition of soluble heparin
(Neugebauer et al., 1991), indicating a possible role for cell surface
HSPGs in the interaction of retinal neurons with this molecule.
TSP-1 is also expressed widely throughout other areas of the
developing nervous system, including the cerebellum, where it is
found associated with granule cell neurons in the premigratory zone of
external granule layer and in the molecular layer (O'Shea et al., 1990).
Interestingly, an antibody to TSP-1 was found to block granule cell
migration from the external granule layer to the molecular layer,
suggesting TSP-1 may directly participate in this process (O'Shea et
al., 1990). As described in Chapter 3 of this thesis, cerebroglycan
(CBG) mRNA in the developing rat cerebellum is also specifically
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associated with neurons of the premigratory zone raising the
possibility that CBG and TSP-1 interact on the cell surfaces of these
neurons. One report has also described extensive colocalization of the
cell surface HSPG syndecan-1 with TSP in developing embryos,
including in the very early neuroepithelium (embryonic day 8.5 of the
mouse) (Corless et al., 1992).
Tenascin (TN) is a multidomain extracellular matrix molecule
comprised of six separate chains of -190-220 kDa each. The chains
are linked to each other through a disulfide-rich region near their
amino termini. As with FN, the subunits of TN are encoded by a single
gene, but can be alternately spliced. TN manifests several different
biological activities for neuronal cells in vitro including cell
attachment and neurite outgrowth promoting activity for some
neuronal cell types, as well as anti-adhesive and neurite repulsive
activities for others. The locations of some of these activities have
been mapped using TN fragments (Chiquet, 1989; Erickson and
Bourdon, 1989; Lander and Calof, 1993).
TN is expressed in the pathways traversed by migrating neural
crest cells. In particular, TN is enriched in the rostral portion of
somitic sclerotome. This is the same portion that neural crest cells
preferentially enter, suggesting that TN may provide a favorable
substrate for neural crest cell migration. Attempts to support this
notion with in vitro experiments have met with mixed results. TN
isolated from chick brain (also called cytotactin) does not support
chick neural crest cell migration, and slows down neural crest cell
migration on FN when mixed with FN in the substrate. In contrast,
TN isolated from chick fibroblasts does support the migration of
neural crest cells [reviewed in (Chiquet, 1989)]. The fact that TN can
be alternatively spliced provides one possible explanation for this
discrepancy.
TN has also been found in the central nervous system, where it
appears later and is more widespread than either FN or LN-1. In the
developing mouse cortex, TN appears in the subplate and marginal
zones as FN is disappearing (see above) and subsequently becomes
expressed throughout the maturing cortical plate (Sheppard et al.,
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1991). In the somatosensory cortex, TN is expressed at the
boundaries of the whisker barrel fields, but not in the center. The
barrel fields represent separate functional units within the cortex, and
the significance of TN expression at their boundaries is not yet
understood. By adulthood TN expression in the cortex has
dramatically declined.
TN is also found in the developing mouse cerebellum (Chuong et al.,
1987). In this structure, TN expression is associated with the
cerebellar granule cell neurons and with the surfaces of the Bergmann
glia, along which the granule cells migrate. Antibodies to TN block
cerebellar granule cell migration in cerebellar slice cultures. The
granule cells migrate into the molecular layer where the Bergmann
glia are found, but progress no further.
Although TN can bind to heparin, its interactions with heparin and
HSPGs have not been well characterized. However, several
experiments have demonstrated interactions of CSPGs with TN. TN
isolated from chick brain was found to copurify with a large CSPG
termed "cytotactin binding PG" (Hoffman and Edlman, 1987; Hoffman
et al., 1988). When this PG was purified away from TN, it was shown
to bind purified TN in solid phase assays. More recently, the CSPGs
phosphacan, an extracellular variant of RPTP-1, a protein tyrosine
phosphatase, and neurocan, a large CSPG related to the aggrecan
family, were shown to bind to TN in solid phase assays (Grumet et al.,
1994). The TN-binding of these CSPGs was found to be largely
mediated by the core proteins. Interestingly, neurocan is also
expressed at the boundaries of barrel fields in the somatosensory
cortex (Oohira et al., 1994). This, together with the apparent binding
of the neurocan core protein to TN in in vitro assays suggest that
neurocan may be a ligand for TN in vivo.
Recently, a new class of molecules important for axon guidance was
discovered. These molecules, called the netrins, are expressed in the
developing spinal cord, and were isolated on the basis of their ability
to promote the axon outgrowth of commisural spinal cord axons in
vitro (Kennedy et al., 1994; Serafini et al., 1994). Subsequently,
netrin-1 was found to be expressed in the floor plate of the spinal
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cord, a important structure for commisural axon navigation, and
netrin-2 was found to be expressed in the ventral spinal cord above
the floor plate. The netrins have homology to the C. elegans protein
UNC-6, a laminin-related molecule involved in the circumferential
migration of cells and axons in the worm.
The netrins are heparin-binding molecules, and are isolated as
peripheral membrane proteins from homogenized brain. This raises
the possibility that a cell surface or matrix associated HSPG could
serve as a ligand for the netrins. The GPI-anchored cell surface
HSPGs glypican (Litwack, 1995), and cerebroglycan [(Litwack, 1995)
and Chapter 3, this thesis] have expression associated with the
commisural axons of the developing spinal cord, raising the possibility
that they could serve as netrin receptors or coreceptors.
Additionally, a recent study has demonstrated that the CS/DSPG
decorin is also expressed in the floor plate (Litwack, 1995). Decorin
was shown to bind to netrin-1 with an affinity of - 90 nM, whereas
decorin GAG chains have an affinity for decorin > 1 4M, suggesting
that the decorin core protein binds to netrin-1 (Litwack, 1995).
Decorin has previously been shown to bind to collagen fibrils and TGFP
via its core protein (Vogel et al., 1984; Cheifetz and Massague, 1989).
In addition to the extracellular matrix molecules discussed above,
another class of heparin binding molecules that has been implicated in
cell migration is the class of cell adhesion molecules. This family of
molecules, typified by neural cell adhesion molecule (NCAM) and L1
features extracellular domains that contain immunoglobin constant
region repeats. These molecules mediate cell-cell adhesion via
homophilic binding of cell adhesion molecules on the surfaces of the
adhering cells. NCAM is widely expressed in the developing brain,
and potential functions in cell migration and axon outgrowth were
suggested by antibody perterbation experiments in which NCAM
antibodies were injected into embryos. In these experiments, the
anti-NCAM antibodies caused effects such as perturbation of optic
nerve fiber projection to the optic tectum, and changes in the growth
patterns of nerves in the developing limb, or nerves undergoing
regeneration [reviewed in (Goridis and Brunet, 1992)]. However, the
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phenotype of mice in which NCAM is knocked out is rather subtle:
the gross morphology of the brain remains intact, there is a modest
but notable decrease in the size of the olfactory bulb, and the animals
performed below average in the Morris water maze, a test thought to
be a measure of spatial learning ability (Cremer et al., 1994)
The related molecule L1 is expressed in migratory and
premigratory granule cells in the developing cerebellum and is also
found associated with the parallel fibres, axons extended by granule
cells as they migrate (Chuong et al., 1987). On the cellular level,
electron microscopy shows that L1 is present at the sites of neuron-
neuron contact in the developing cerebellum, but not at sites of
neuron-glia contact (Persohn and Schachner, 1987), suggesting that
L1 may function via neuron-neuron interactions rather than by binding
to L1 on the surface Bergmann glia, along which granule cells migrate.
Antibodies directed against L1 cause granule cells to cease migrating
and pile up at the border of the molecular layer (Chuong et al., 1987),
suggestive of a role for L1 in granule cell migration. No PG ligands for
L1 have yet been identified, but the large transmembrane CSPG NG2
has been found to inhibit neurite outgrowth of cerebellar granule cells
in vitro, and to possess a neurite-repulsive activity for these neurites
(Dou and Levine, 1994). Interestingly, NG2 expression is observed in
the deep portion of the molecular layer in a region just underlying the
parallel fibres of the granule cell neurons. This observation, together
with the neurite repulsive activity of NG2 for granule cell neurons has
led to the suggestion that NG2 may form a barrier for these axons,
constraining them to the axon tracts in the more superficial part of
the molecular layer (Dou and Levine, 1994).
Evidence that cell surface HSPGs may be involved in NCAM-NCAM
adhesive interactions has been obtained from a series of experiments
that demonstrated that heparin, antibodies against cell surface HSPGs,
antibodies against the NCAM heparin binding domain, peptides
derived from the heparin binding domain, and a genetic deletion of
the heparin binding domain all block NCAM-NCAM binding (Lander,
1990). The HSPG(s) involved have not yet been characterized
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V. Conclusion
Perhaps the strongest theme emerging from the data reviewed
above is that we have a lot to learn about the expression and function
of proteolgycans in the nervous system. There are many potential
ligands for PGs in the nervous system, but the PGs that bind to them
have, in many cases, not been identified, or only tentatively identified.
Functional consequences of PG's interactions with their ligands have
been inferred from preliminary experiments in vitro, but the task of
testing them in vivo is still in the early stages. Some exciting stories
have begun to emerge (the apparent requirement of heparan sulfate
for FGF function comes to mind), but many more wait to be
discovered.
A recent report has demonstrated that as many as 25 distinct core
proteins are expressed in the developing and adult rat brain (Herndon
and Lander, 1990). At the time of this writing, only three of the core
proteins in this study have been positively identified, two as a result of
the experiments reported in Chapter 2 below. It is likely that PGs
characterized elsewhere will account for several of the remaining 25
cores, but the molecular identity of some probably awaits cloning and
characterization of new PG cores. To begin to make sense of which
PGs bind to which ligands exerting which effects, a more complete
understanding of the PGs involved and the details of their interactions
with potential ligands, will be required.
In Chapter 2, we report the cloning and preliminary
characterization of a novel HSPG core protein that we have named
cerebroglycan. In Chapter 3, cerebroglycan expression in the
developing embryo was examined by in situ hybridization and found to
be restricted to the developing nervous system, making cerebroglycan
the first tissue-specific PG to be reported, and supporting an earlier
hypothesis (Herndon and Lander, 1990) that individual PG core
proteins are adapted to fulfill specific functional roles during
development. Examination of cerebroglycan mRNA expression in
several structures strongly supports the view that cerebroglycan is
specifically expressed by immature neurons in the process of axon
outgrowth and/or cell body migration. Immunohistochemical
localization of cerebroglycan core protein further revealed that
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cerebroglycan is most strongly associated with axon tracts in the
developing nervous system, further supporting the idea that
cerebroglycan expression correlates with the motile phases of
neuronal development. In Chapter 4, evidence is presented that is
consistent with the possibility that cerebroglycan could serve as a
receptor or coreceptor for the neurite outgrowth promoting molecule
LN-1. Chapter 5 describes experiments in which the molecular
weight of intact cerebroglycan is determined and describes additional
experiments, that, taken together, suggest a role for the cerebroglycan
core protein in the binding of intact CBG to LN-1.
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Figure 1. Proteoglycan and glycosaminoglycan structure
To illustrate several features of proteoglycan and glycosaminoglycan
structure, the structures of the two major families of cell surface
HSPGs are compared. (A) A representative structure of the syndecan
family of HSPGs. The syndecan family is characterized by a conserved
intracellular domain that contains potential tyrosine phosphorylation
sites and that is also thought to interact with cytoskeletal components.
The syndecan family members syndecan-1 and ryudocan (syndecan-4)
have been shown to substituted with both heparan sulfate and
chondroitin sulfate chains. (B) A representative structure of the
glypican family of HSPGs. The glypicans are characterized by a lipid
anchorage to the outer leaflet of the plasma membrane, and a
conserved pattern of cysteine residues that is likely to result in a
highly folded tertiary structure, stabilized by disulfide bonds. The
heparan sulfate chains on both PGs contains regions of highly modified
structure separated by spans of sparsely modified disaccharides. (C)
Representative structures of sparsely modified heparan sulfate, highly
modified heparan sulfate, and chondroitin/dermatan sulfate are
shown, as well as the basic structure of the glycosyl-
phosphatidylinositol lipid anchor of the glypican family PGs. GlcNAc =
N-acetylglucosamine; GlcUA = glucuronic acid; GlcNSO3-= N-
sulfoglucosamine; IdoUA = iduronic acid; GalNAc = N-acetyl-
galactosamine; 4S, 2S, etc. indicate sites of O-sulfation.
'This figure courtesy of Mary Herndon
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Figure 2. Protein binding sites within heparan sulfate chains
(A) The structure of the antithrombin III binding site. Functional
groups required for binding with high affinity to antithrombin III are
indicated with asterisks. The dagger indicates the location of a rare
3-O-sulfate that is also required for binding to antithrombin III. The
majority of 3-O-sulfates found on heparan sulfate chains are found
within antithrombin III binding sites. (B) The structure of a
disaccharide required for binding to FGF-2. (C) The structure of a
disaccharide required for binding to FGF-1. The structures in B and C
occur in the context of longer oligosaccharides with variable
structures. Abbreviations: GlcNSO 3 - , N-sulfoglucosamine; GlcUA,
glucuronate; IdoUA, iduronate; 2S, 3S, 6S, indicate sites of O-
sulfations; R, -H or -S0 3 - substituent.
This figure courtesy of Mary Herndon
A. Antithrombin III
CHO-R
NH-S03*
GlcNSO3 , 6S GlcUA GlcNS3 ,3,6S IdoUA+2S GlcNSO" , 3S,±6S
B. FGF-2
CHoOH
IdoUA,2S GlcNSO3
C. FGF-1
0-SO3 NH-SO3
GlcNSO 6S3.IdoUA,2S
Table 2. Proteins to which Glycosaminoglycans Bind
Extracellular Matrix Molecules
Laminin Fibronectin
tenascin many Collagens
Thrombospondins
Vitronectin
Cell Adhesion Molecules
NCAM
Myelin-associated
glycoprotein
Cytokines
FGFs 1 thru 7
HB-EGF
Neural Schwann Cell
Mitogen
L1/NgCAM
PDGF
TGF-0
chemokines (e.g.,
11-8, MIP-1p)
PECAM- 1
VEGF
IL3
Proteases and Anti-proteases
Antithrombin III Protease Nexin-1 Heparin Cofactor II
Amyloid P-protein Urokinase plasminogen Tissue plasminogen
precursor activator activator
Thrombin
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CHAPTER 2
IDENTIFICATION, MOLECULAR CLONING AND PARTIAL GENOMIC
CHARACTERIZATION OF CEREBROGLYCAN, A NOVEL GLYPICAN-
RELATED HEPARAN SULFATE PROTEOGLYCAN
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INTRODUCTION
The development of the nervous system is believed to be guided by
an abundant and diverse set of extracellular cues. Growth factors such
as FGF-1,2 and 5 can stimulate neural precursor cells to proliferate or
differentiate (Walicke et al., 1986; Unsicker et al., 1987; Walicke,
1988; Murphy et al., 1990; Hughes et al., 1993). Migrating neurons
and growing axons receive guidance information from large
extracellular matrix glycoproteins such as laminin (Gundersen, 1987;
Sanes, 1989; Reichardt and Tomaselli, 1991), or fibronectin (Rogers
et al., 1989), diffusible factors such as the netrins (Kennedy et al.,
1994; Serafini et al., 1994), and adhesion molecules such as NCAM
(Neugebauer et al., 1988) and L1 (Lindner et al., 1983; Chuong et al.,
1987) on the surfaces of other cells. Even after axons reach their
targets, proper synapse formation is still dependent upon extracellular
cues from molecules such as S-laminin (laminin-3) (Noakes et al.,
1995; Porter et al., 1995) and agrin (Bowe and Fallon, 1995). As
divergent as these cues are, many share a common feature: the ability
to bind the glycosaminoglycan (GAG) heparan sulfate (HeS), of heparan
sulfate proteoglycans (HSPGs).
In most cases, alternative, non-HSPG receptors have been
identified for the ligands described above, leaving open the question of
what the functional consequence of binding to HeS might be. It has
been proposed that cell-surface HSPGs act as "co-receptors" for their
ligands, functioning to bring them together with more conventional
molecules (e.g. signal-transducing receptors) on the cell surface
(Bernfield et al., 1992). Strong evidence for this model comes from
studies of the interaction of basic fibroblast growth factor with one of
its tyrosine kinase receptors, an interaction that fails to occur in the
absence of HeS (Rapraeger et al., 1991; Yayon et al., 1991; Kan et al.,
1993). Additional evidence has also come from studies of cell-surface
protease inhibition by heparin-binding anti-proteases (Marcum et al.,
1987; Cunningham et al., 1992), homophilic cell adhesion mediated
by the neural cell adhesion molecule NCAM (Cole et al., 1986a; Reyes
et al., 1990), and integrin-mediated cell-matrix interaction (LeBaron
et al., 1988; Woods and Couchman, 1992).
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The co-receptor model provides a useful framework within which
to understand the general functions of HSPGs, but does not address
the issue of whether specific functions are associated with individual
molecular species of HSPG. Prior to the work described below, five
distinct polypeptides had been identified as major carriers of HeS on
mammalian cells. Four of these are transmembrane proteins, and
form a gene family, the syndecans, on the basis of strong evolutionary
conservation in their cytoplasmic and transmembrane domains
(Bernfield et al., 1992). The fifth is a glycosylphosphatidylinositol
(GPI)-anchored protein known as glypican (David et al., 1990). The
expression of these PG core proteins varies dramatically from tissue to
tissue, especially during the course of development (Bernfield et al.,
1992). Tissue-specific and developmental variation also occurs in the
structure of the HeS that is found on HSPG core proteins, and such
variation can give rise to substantial differences in the binding
properties of intact PGs (Marcum et al., 1987; Sanderson and
Bernfield, 1988; Salmivirta et al., 1991; Sanderson et al., 1992a;
Nurcombe et al., 1993). Taken together, the data suggest that
individual HSPGs may indeed be specialized to carry out particular
functions.
Consistent with the hypothesis that distinct HSPG cores have
distinct functions in nervous system development, earlier work has
shown that as many as nine individual HSPG core proteins are
expressed in the developing rat central nervous system (Herndon and
Lander, 1990). Furthermore, the expression of many of these HSPGs
is developmentally regulated.
Only three of these HSPGs, previously identified as ("M7"), ("M12"),
and ("M13"), exhibit detergent partitioning properties indicative of
integral membrane proteins (Herndon and Lander, 1990). These
three molecules, are thus likely to represent the major cell surface
HSPGs of the central nervous system. To begin to assess whether
these HSPGs participate in distinct developmental events in the
nervous system, we developed a strategy to establish their molecular
identities by protein purification and sequencing. We report here on
studies that identify HSPG M12 as the rat homologue of glypican, and
M13 as a novel, glypican-related HSPG that we have named
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cerebroglycan (CBG). The cloning of murine and human CBG cDNA
fragments, the partial characterization of mouse CBG genomic
structure, and the mapping of CBG in the mouse genome are also
described.
Glypican, cerebroglycan, the previously identified molecule OCI-5
(Filmus et al., 1988), and the subsequently indentified HSPGs, K-
glypican (Watanabe et al., 1995), and dally, a Drosophila protein
(Nakato et al., 1995), define a new family of GPI-anchored cell surface
HSPGs. The core proteins in this family exhibit an unexpectedly high
degree of structural homology, raising the possibility that these
molecules have evolved for more specialized functions than simply to
be the passive bearers of GAG chains.
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MATERIAL AND METHODS
Materials
Heparitinase was purified from Flavobacterium heparinum by
hydroxyapatite and phosphocellulose chromatography (Linker and
Hovingh, 1972). The GAPDH cDNA clone was the generous gift of Dr.
Timothy Hayes, NIH, Bethesda MD. All restriction enzymes were from
New England Biolabs (Beverly, MA). Chondroitinase ABC, TritonX-100,
NEM (N-ethylmaleimide), pepstatin A, and PMSF
(phenylmethylsulfonyl fluoride), and PVP-40 (polyvinyl pyrrolidone)
were obtained from Sigma (St. Louis, MO). Trypsin, CHAPS (3-[(3
Cholamidopropyl) dimethyl-ammonio]-l-propanesulfonate), and yeast
RNA were from Boehringer Mannheim (Indianapolis, IN). RNA and
DNA ladders, and M-MLV reverse transcriptase were from Gibco BRL
(Gaithersburg, MD). RNasin was from Promega. (Nitrocellulose was
from Schleicher and Schuell (Keene, NH). DEAE-Sephacel, salmon
sperm DNA, and Taq DNA polymerase were from Pharmacia
(Piscataway, NJ). Formamide was from Fluka (Buchs, Switzerland).
a 3 2 P-labelled dCTP and a 3 5 S-labelled UTP were from DuPont NEN
(Boston, MA). Week 16 human fetal brain was obtained from Dr. Gene
Major, NINDS, NIH. Custom primers for PCR and sequencing were
synthesized at the MIT Biopolymers Lab. All other reagents were from
Mallinckrodt (Paris, KY), except as noted.
Purification and Microsequencing of PO rat brain HSPGs
Detergent extracts of a crude membrane fraction of neonatal (P0)
Sprague-Dawley rat brains were prepared essentially as described
previously (Herndon and Lander, 1990). Briefly, whole brains were
removed PO rats and meninges were removed under ice cold saline.
Brains were resuspended in 9 volumes of ice cold buffer A (0.3 M
sucrose, 4 mM HEPES [pH 7.5], 1mM EDTA, 1ig/ml pepstatin A, 0.25
mg/ml NEM, and 0.4 mM PMSF), and homogenized using a teflon on
glass homogenizer. Homogenates were centrifuged at 12,.000 g for 30
minutes at 40C. The pellet was rehomogenized in buffer A, and
centrifuged again. The supernatants from the two 12,000 g spins
were pooled and centrifuged at 378,000 g for 30 minutes at 40 C. The
membrane containing pellet was recovered and homogenized in buffer
75
B (50 mM Tris-HCI [pH 8], 0.15 M NaCl, 1% CHAPS, 1 mM EDTA, and
1 tg/ml pepstatin A). After centrifugation at 378,000 g for 60
minutes at 40C, the supernatant was recovered, and the pellet was
rehomongenized and recentrifuged for 40 minutes at 432,000g, 4 0C.
This supernatant was pooled with the previous buffer B supernatant
and stored at -80oC.
Detergent extracts from a total of 34.35 g (wet weight) of brain
were thawed, pooled and filtered through a 0.2 gi filter. Total PGs
were isolated by anion exchange chromatography on DEAE-Sephacel
as described previously (Herndon and Lander, 1990). The detergent
extract was loaded at 21 cm/hour to a 254 ml DEAE-Sephacel column
pre-equilibrated in buffer C (50 mM Tris-HCI [pH 81, 0.15 M NaC1,
0.1% TritonX-100). After loading was complete, the column was
eluted with 4 column volumes of buffer C; 2 column volumes of buffer
D (50 mM Tris-HCI [pH 8], 0.25 M NaCl, 0.1% TritonX-100); 2 column
volumes of buffer E (50 mM Tris-HCI [pH 8], 0.25 M NaCl, 0.1%
TritonX-100, 6 M urea); 5 column volumes of buffer F (50 mM sodium
formate [pH 3.5], 0.25 M NaCI, 0.1% TritonX-100, 6 M urea); 2.5
column volumes of 100 mM Tris-HCI [pH 8], 0.1% TritonX-100; and 1
column volume of 50 mM Tris-HC1, 0.1% TritonX-100. PGs were
eluted with 3 column volumes of buffer G (50 mM Tris-HCI [pH 8],
0.75 M NaCl, 0.1% TritonX-100, and collected in -6 ml fractions.
Fractions were analyzed by passing through an aliquot of each through
a nitrocellulose filter pre-wet with 6% trichloroacetic acid, staining
with amido black (0.25% in 45% methanol, 5% acetic acid), and
destaining with 2% acetic acid in 90% methanol. On the basis of the
staining, 27 fractions containing a total of 165 ml were pooled. At this
point, PGs previously isolated from the membrane fraction of an
additional 12.0 grams (wet weight) of PO rat brains were added to the
pool along with 0.3 prCi of 12 5 I-labelled, membrane associated PGs,
purified and radiolabelled as previously described (Herndon and
Lander, 1990). The addition of the radiolabelled PGs allowed
subsequent purification steps to be followed.
Centriprep-10 tubes (Amicon; Beverly, MA) were used to
concentrate the PG pool and exchange the elution buffer for 50 mM
Tris-HCI (pH 8.0), 0.15 M NaCl, 0.1% Triton X-100. The sample was
76
then treated with Chondroitinase ABC (0.09 units/ml) in the presence
of 1mM EDTA, 1ig/ml pepstatin, and 0.4 mM PMSF for 2 hr at 37oC,
and loaded immediately onto a DEAE-Sephacel column (0.2 ml packed
volume), equilibrated in buffer C. The column was washed successively
with 4 ml 0.2 M NaCI, 100 mM sodium acetate (pH 3.5), 0.1%
TritonX-100; 2 ml 0.1 M Tris-HC1 (pH 8.0), 0.1% TritonX-100; 3 ml
50 mM Tris-HCI (pH 8.0), 0.1% TritonX-100; and 0.8 ml 25 mM
ammonium acetate (pH 7.0), 0.1% TritonX-100. An HSPG-enriched
fraction was eluted with a 20 ml gradient of NaCl from 0.15 M to 0.75
M, in 25 mM ammonium acetate (pH 7.0) and 0.1% TritonX-100. All
significantly radioactive fractions eluted by 2 0.3 M NaCI were pooled.
In this manner, approximately 100 gg of HSPG were recovered (as
determined by amino acid analysis).
A Centricon-10 (Amicon) tube was used to concentrate the pooled
sample and exchange the buffer to 50 mM NaCl, 25 mM ammonium
acetate, 0.1% Triton X-100. The sample was made 25 mM in Tris-HC1
(pH 7.1 at 370C), and protease inhibitors (as with the chondroitnase
digest above) added along with heparitinase to a final concentration of
9 gg/ml. The HSPG sample was digested for 3 h at 370C,
concentrated in a Centricon-10 tube and loaded to a 6% SDS-PAGE
gel, polymerized over a strip of 9% acrylamide (see Figure 2). A
control digest of identical composition but with no HSPGs was loaded
in an adjacent lane of the gel. After electrophoresis to resolve HSPG
M7, HSPGs M12 and M13, captured in the strip of 9% acrylamide,
were excised (along with the enzyme blank) and recast in a second 9%
acrylamide gel. After further electrophoresis to resolve M12 and M13,
both the 6% gel (containing M7) and the 9% gel were electroblotted
overnight at 25 V and 40C to nitrocellulose in 25mM Tris-HCl (pH
8.3), 20% (v/v) ethanol, 0.005% SDS. Bands were visualized by
staining with amido black (Schaffner and Weissman, 1973), and the
bands corresponding to HSPGs M7, M12, and M13 were excised, as
were corresponding regions from the enzyme blank lanes.
The nitrocellulose-bound HSPGs and their blanks were blocked
with PVP-40 (0.5% in 100 mM acetic acid at 370C for 30 min) and
then digested with trypsin for 18 h at 370C in 100 mM ammonium
carbonate/acetonitrile (95:5 by volume) (Tempst et al., 1990).
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Released digestion products were analyzed by reverse phase HPLC on a
Hewlett Packard model 1090L HPLC equipped with a Vydac 218TP52
C18 column (Vydac, Hesperia, CA), and multiple peaks of absorbance
at 210 nm were collected and subjected to microsequencing by
automated Edman degradation.
Calculation of Yields
The inclusion of radioiodinated PGs in the purification allowed
yields for some purification steps to be estimated. For the first
concentration step (prior to chondroitinase digestion), the yield was
calculated by (cpm, ret.)/[(cpm, tot.) - (cpm, filt.)], where "cpm, ret."
was the cpm retained and recovered from the Centricon concentrator,
"cpm, tot." was the total number of cpm in the pool prior to
concentration, and "cpm, filt." was the cpm that passed through the
Centricon filter. This latter value represents primarily unincorporated
1251, and so needs to be subtracted from total cpm to get an accurate
indication of protein yield.
In the second DEAE step (after chondroitinase treatment), CSPG
core proteins either flowed through, or were removed with a stringent
wash. Earlier experiments showed that the PGs remaining bound to
DEAE were essentially depleted of CSPG cores (not shown). To
estimate the yield of HSPGs eluted from the second DEAE column, the
following expression was used:
yield = (cpm, gradient)/[(cpm, tot.)-(cpm, f.t.)-(cpm, s.w.)];
"cpm, gradient" is the total number of counts eluted by the salt
gradient (primarily HSPGs), "cpm, tot." is the total number of counts
applied to the column, "cpm, f.t." is the number of counts that flowed
through the column, and "cpm, s.w." is the number of counts that were
eluted by the stringent wash.
The yield for the second concentration step, after the second DEAE
column was estimated simply by (cpm, recovered)/(cpm, applied)
since there was little if any unincorporated 12 5 I remaining by this
step.
PCR Protocols
Amplification of an HSPG-M13 cDNA
78
Degenerate PCR primers were based on the sequence of peptide
M 13-22 (see Results and Table 1). The sequences of the primers
were 22L: 5 '-GGCCTCTAGA(T/C)ATGCA(T/C)GA(T/C)GCNGA-3' and
22R: 5'-GCGCGGGCCCCT(G/A)TCNGC(G/A)TA(C/T)TG(C/T)TG-3'.
PCR reactions were performed using 25 pmol of each PCR primer, 2
Itg of PO rat brain cDNA as template, 80 4iM of each dNTP, and 2 U of
Taq polymerase. The reaction profile was denature at 95 0C for 60
sec., anneal at 50 0C for 90 sec., and extend for 90 sec. at 720C. The
resulting 80 bp product was gel purified and subcloned into pCR1000
(Invitrogen; San Diego, CA) for sequencing.
Amplification of a murine cerebroglycan homolog
Total RNA was isolated from 1.2 grams (wet weight) of embryonic
day 17 mouse brain by guanidinium isothiocyanate extraction
(Chomczynski and Sacchi, 1987). Reverse transcriptase reactions
were set up in IX Taq polymerase buffer with (1) 0.4-3.8 ýig RNA
(heated to 90o0C for 5 minutes and placed on ice), (2) 100 pmol of
random hexamers or 100 pmol of the primer OM13-165 (see below),
based on the sequence of rat cerebroglycan, (3)1 mM dNTPs, (4) 40
units of RNasin, and (5) 200 units of M-MLV reverse transcriptase.
Reactions were incubated at room temperature for 10 minutes and at
42 0C for 60 minutes. Reactions were terminated by boiling for 8
minutes and stored at -20oC until PCR.
PCR reactions were performed by adding 80 p1 of LX Taq
polymerase buffer containing 2.5 units of Taq polymerase, 50 pmol of
primer OCBG-137, and 50 pmol or 20 pmol of primer OM13-165 (20
pmol was used for reactions were OM13-165 had been used in the
reverse transcription step). The reaction profile was 95 0C for 30
seconds, 48 0 C for 1 minute, and 72oC for 1 minute for a total of 30
cycles. The major -400 bp band visible in all reactions after gel
purification was subcloned directly into the pCR1000 vector
(Invitrogen; San Diego, CA) for sequencing. The sequence of the
primer OM13-165 was 5'-GAGAGACTCGAGTGAGGCGTCCCACAT'CC-3'.
'The underlined residues are a XhoI site and clamp sequences. The
remaining are complementary to nucleotides 1284-1265 of the CBG
cDNA sense strand. The sequence of the primer OCBG-137 was
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5'-CACTGGTGGCAGCCCGG-3'. This primer is identical to nucleotides
894-910 in the CBG cDNA sense strand.
Amplification of a human cerebroglycan homolog
Total RNA was isolated by guanidinium isothiocyanate extraction
(Chomczynski and Sacchi, 1987) from week 16 human fetal brain.
cDNA was synthesized in a reaction containing 13 jig of total RNA, 2.8
jig of primer 22R (see above), 1 mM dNTPs, 1 unit/pl of RNasin, and
20 units/!l of M-MLV reverse transcriptase for 10 minutes at room
temperature and 60 minutes at 420C. A nested set of degenerate
primers was used. The outer set was gdoL1 (5'-CCICA[A/G]G[A/G]-
ITA[T/C]ACITG[T/C]TG-3') and gdoR2 (5'-CC[A/G]CAI[T/C]C[T/C]TG-
IA[T/A]IAC[T/C]TT-3'). The inner set was gdoL2 (5'-Tr[T/C]TGG-
GCI[C/A][A/G]I[T/C]TI[T/C]TIGA-3') and gdoR3 (5'-IGCIGCIACIA[G/A]-
IGCIC[G/T]IG-3'). See Figure 10 for the relationship of these primers
to sequences of cerebroglycan, glypican, and K-glypican.
The first round of PCR used 100 pmol of primers gdoL1 and gdoR2,
100pM of dNTPs, 2.5 units of Taq polymerase, and 0.4pg of cDNA,
prepared as described above, in a 100 p1 reaction. The reaction
profile was 95oC for 1 minute, 53oC for 1 minute, and 720C for 1.5
minutes for a total of 24 cycles. A diffuse band of 800-1000 bp was gel
purified and used in a second round of reactions. The second round of
PCR was performed essentially as above, yielding a products of -~ 180
bp and -168 bp. The 168 bp product was gel purified and subcloned
into pCR1000 (Invitrogen; San Diego, CA) for sequencing.
Alternatively, a second round of PCR using modified gdoL2 and
gdoR3 primers was performed. These primers had restriction sites
added to their 5' ends (extra sequence in italics, restriction sites
underlined):
BamHIL2 (5'-CGGGATCCCGIT[T/C]TGGGCI[C/A][A/G]I[T/CITI[T/C]-
TIGA-3') and EcoRIR3 (5'-GGAATTCC IGCIGCIACIA[G/A]IGCIC[G/T]-
IG3'). PCR with these primers was performed with a different profile:
(1) 95oC for 1 minute, (2) 37oC for 1 minute, (3) slope= +0.70 C/3sec.,
(4) 720C for 1 minute, (5) repeat (1)-(4) 2 more times, (6) 950C for 1
minute, (7) 53oC for 1 minute, (8) 720C for 45 seconds, (9) repeat
(6)-(8) 19 times.
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This reaction profile also resulted in two major products at -168
and 180 bp. The 180 bp product was subcloned into the
BamHI/EcoRI restriction sites in pBluescript (Stratagene) for
sequencing.
Amplification of a mouse genomic fragment for SSCP analysis
PCR reactions were performed with 25 ng of genomic DNA in a 40
gl reaction that was 250 giM dNTPs, 0.05 units/~l Taq polymerase,
and 25 nM for each primer. The primers were muCBG-L (5'-GGTCC-
AGGGTCTGGAGAC-3'), and muCBG-R (5'-GCCTGTCTGCAGCCTTCC-3')
(see Figure 9). The reaction profile was 1 minute at 94oC, 1 minute at
550C, and 1 minute 10 seconds at 720C, for a total of 35 cycles. For
SSCP analysis, 10iCi of 3000 Ci/mmol a32P-dCTP was included in
each reaction. To verify authenticity, the major product just above 615
bp was gel purified and subcloned into pCR1000 (Invitrogen; San
Diego, CA) for sequencing.
Library Construction and Screening
PO rat brain polyA-enriched RNA was prepared by fractionation on
oligo dT cellulose using a Fast Track mRNA isolation kit (Invitrogen;
San Diego, CA). cDNA was synthesized from 5 gg of polyA+ RNA using
an oligo dT primer with the ZAP cDNA synthesis kit (Stratagene; La
Jolla CA). The resulting cDNA was ligated into EcoRI/XhoI digested
and dephosporylated Uni-ZAP XR vector arms (Stratagene) and
packaged for plating (Giga Pack Gold II, Stratagene). The library was
amplified once before plating on XL1-Blue host cells. The library was
screened with a probe generated by a PCR reaction (as described
above), that included a 3 2 P-dATP.
A primer-extended PO rat brain cDNA library was synthesized from
5gg of polyA-enriched RNA (prepared as described above) and 120
pmol of primer OM13-165 (based on the sequence of cDNA M13-A,
see Results, and above) using a Timesaver cDNA synthesis kit
(Pharmacia). The resulting cDNA, ligated to EcoRI adaptors, was
cloned into EcoRI-digested, dephosphorylated Xgtl0 arms
(Stratagene), packaged (Giga Pack Gold II, Stratagene), and plated on
NM514 host cells for screening with a probe generated from the 100
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bp Bgl II fragment of M13-A (see Results) by random-primer labelling
(70200 Random Primed DNA Labelling Kit, United States Biochemical;
Cleveland, OH).
A mouse genomic library (129/Sv) (gift of the lab of Susumu
Tonegawa, MIT) was plated on LE392 host cells for screening with a
probe generated by random-primer labelling (70200 Random Primed
DNA Labelling Kit, United States Biochemical; Cleveland, OH) of the
215 bp Aat II/Sma I restriction fragment of the rat CBG cDNA. This
fragment begins 95 bp upstream from the start ATG. Two CBG
genomic clones were identified, plaque purified, and subcloned into
pBluescript (Stratagene) for sequencing and restriction mapping. The
library was rescreened with a probe made by random-primer labelling
of the 818 bp Aha II/Afil restriction fragment of the rat CBG cDNA.
Five overlapping clones were isolated, and subcloned for further
characterization.
DNA Sequencing
Gel purified fragments were subcloned into pBluescript SK-
(Stratagene), pSL301 (Invitrogen), or pCR1000 (Invitrogen). cDNA
inserts were sequenced by the dideoxy chain termination method
using a modified T7 DNA polymerase (Sequenase kit 2.0, United
States Biochemical). T3, T7, and M13 (-40) primers, as well as custom
made primers, were used in reactions with denatured, supercoiled
plasmids. All rat cerebroglycan cDNA sequences were determined
with both dGTP and dITP; some of the remaining sequencing
reactions were performed with dGTP only.
Southern Blot Analysis
Rat genomic DNA was prepared from Sprague-Dawley rat
thymocytes according to established methods (Sambrook et al., 1989),
and stored at 4oC under ethanol. 10ig of DNA, digested to
completion with HindIII, KpnI, or Xhol, was electrophoresed and
blotted to nitrocellulose (Sambrook et al., 1989). Prehybridization,
'hybridization, and washing, were done as previously described (Church
and Gilbert, 1984). The hybridization step and the subsequent washes
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were performed at 680C (high stringency). The filter was
autoradiographed with XAR-5 film (Kodak; Rochester, NY).
Northern Blot Analysis
Total RNA was isolated by guanidinium isothiocyanate extraction
(Chomczynski and Sacchi, 1987). 20pg of total RNA from embryonic
day 18 (E18), PO, and adult rat brain was used for the Northern
analysis, performed according to Sambrook et al. (Sambrook et al.,
1989), except that yeast RNA (200 gg/ml) and salmon sperm DNA
(100 gg/ml) were included in the hybridization buffer. Filters were
exposed to Kodak XAR-5 film or imaged with a phosphorimager
(Molecular Dynamics; Sunnyvale, CA). The blot was re-probed for
glyceraldehyde-phosphate dehydrogenase (GAPDH) mRNA to
normalize for different loading and transfer efficiencies between the
lanes.
Analysis of single stranded conformational polymorphisms (SSCP)
PCR reactions were performed as described above with genomic
DNA samples from the test cross NCI-Frederick #77-122 (B6 X
spretus) X B6. B6 refers to C57B 16 (Mus musculus) and spretus refers
to Mus spretus. 9 volumes of 95% formamide, 10 mM NaOH, 0.02%
bromphenol blue and 0.02% xylene cyanole was added to an aliquot of
each reaction. After heating at 950C for 5 minutes, samples were
placed on ice, spun briefly and loaded to a 0.4 mm thick, 20 cm long
gel of 0.5X MDE acrylamide gel (AT Biochem Inc., Malvern, PA). Gels
were run at 220 volts for 18 h with circulating water to cool. After
electrophoresis, gels were dried down and autoradiographed or
exposed in a phosphorimaging cassette (Molecular Dynamics). The
SSCP was scored for each sample as heterozygous (the B6 X Spretus
pattern) or homozygous (the B6 pattern). The tabulated results were
analyzed by Dr. Mark Daly at the Whitehead Institute for Biomedical
Research, MIT, using the program Mapmaker.
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RESULTS
Preparation of a partially purified HSPG fraction
from neonatal rat brain
As a first step toward establishing the molecular identity of the
HSPGs M7, M12, and M13, a neonatal rat brain fraction enriched for
HSPGs and depleted of CSPGs was prepared. PGs were prepared by
DEAE-chromatography of a detergent extract of neonatal rat brain
membranes as previously described (Herndon and Lander, 1990). A
trace quantity (0.3 pCi) of previously isolated, radioiodinated neonatal
membrane PGs was added to the PG pool to allow the subsequent
purification steps to be followed.
CSPGs were removed by treatment with chondroitinase ABC and re-
fractionation on DEAE-Sephacel. Figure 1 shows the elution profile for
the second DEAE purification. After chondroitinase digestion, a
substantial fraction of the CSPG core proteins flow through a DEAE
column when applied in 0.15 M NaCl (peak I in Figure 1). In
preliminary experiments, SDS-PAGE analysis of the material in peak I
demonstrated that it is comprised primarily of the CSPG core proteins
identified previously (Herndon and Lander, 1990) as M1, M6, and M8
(not shown). A small but significant amount of the M1 protein core
does bind DEAE in 0.15 M NaCI even after chondroitinase digestion.
This material can be largely removed by a stringent wash (0.2 M NaC1,
0.1 M sodium acetate pH 3.5)(peak II in Figure 1). After pH was
restored, HSPGs were eluted with a salt gradient (peak III). The bulk
of the HSPG material eluted at -0.45 M NaC1.
To obtain an indication of the amount of material in the HSPG pool,
an aliquot was subjected to amino acid analysis. The results of the
analysis indicated that approximately 100 ýig of total protein had been
recovered from 46.4 g (wet weight) of brain.
Electrophoretic separation and protein sequencing of neonatal rat
brain HSPG core proteins.
To obtain amino acid sequence from individual HSPG cores, the
HSPG pool was digested with heparitinase, concentrated, and
separated on an SDS-PAGE minigel to resolve the core proteins. The
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proteins were electroblotted to nitrocellulose, visualized by amido
black staining, and excised. After digestion in situ with trypsin,
liberated peptides were separated by HPLC and subjected to Edman
degradative sequencing.
One obstacle, identified in preliminary experiments, was the
incompatibility of M7 with M12 and M13 in electrophoresis and
electroblotting. Control experiments demonstrated that an acrylamide
gel of at least 9% total acrylamide was required to adequately resolve
M12 from M13. However, M7 did not transfer efficiently from gels
higher than 7% acrylamide. To overcome this obstacle, a two stage
electrophoresis step was used. As Figure 2 illustrates, M7 was
separated on a 6% acrylamide gel polymerized over a strip of 9%
acrylamide. M12 and M13, captured in the strip, were excised and
recast into a second acrylamide gel of 9% total acrylamide, where they
were resolved by further electroporesis.
A second obstacle stemmed from the requisite use of heparitinase
in the preparation of the HSPG cores for electrophoresis. To
minimize the possibility of heparitinase contamination in the final
sequencing step, an enzyme blank was processed in parallel to the
HSPGs. As an example, Figure 3 shows the HPLC chromatograms of
HSPG M12 and its enyzme blank. Peaks present in the blanks were
disqualified from further analysis.
As shown in Table 1, sequence data were obtained for several M12
and M13 peptides. No peptides were obtained for HSPG M7 (see
Discussion). Peptides derived from HSPG M12 were 74-100%
identical to regions of the GPI-linked HSPG glypican (not shown),
cloned from human lung fibroblasts (David et al., 1990). This
suggested that HSPG M12 is the rat homologue of glypican and
subsequent cloning of rat glypican cDNA verified this [see (Karthikeyan
et al., 1994; Litwack et al., 1994)]. Peptides derived from HSPG M13
could also be aligned with human glypican, but had an overall identity
of only 58%, suggesting that HSPG M13 might be a novel glypican-
related HSPG. Because of its unique pattern of expression in the
developing rat nervous system (see Chapter 3, this thesis), HSPG M13
was subsequently named cerebroglycan (CBG), and will be referred to
as CBG hereafter.
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cDNA cloning and sequencing of cerebroglycan
To facilitate further characterization of CBG, a cDNA was obtained
from neonatal rat brain by PCR. Using primers 22L and 22R, which
were based on unambiguous sequence at either end of peptide M13-22
(Table 1), a major PCR product of -80 bp was obtained. This product
was subcloned and two independent clones were isolated and
sequenced. Both contained the sequences of primers 22L and 22R,
and the intervening sequences of both gave a deduced protein
sequence that was an exact match for peptide M13-22 (data not
shown), verifying that a genuine CBG cDNA had been amplified.
To obtain a complete cDNA, a neonatal rat brain cDNA library
was screened with a probe generated by PCR using a 3 2 P-labelled
dATP and primers 22L and 22R, with the gel-purified 80 bp CBG
cDNA fragment as the template. Three positive plaques were
identified out of 900,000 screened in the amplified library. All three
were plaque purified, and all contained inserts of -1600 bp.
Preliminary sequence data supported the conclusion that all three
inserts were identical products of a single cloning event. Additional
sequencing of this cDNA, referred to hereafter as M13-A, showed that
it contained an 862 bp open reading frame followed by 659 bp of 3'
untranslated sequence, and was unlikely to encode full length CBG.
Therefore, a primer extended library was constructed using neonatal
rat brain RNA and primer OM13-165 based on sequence 165 bp from
the 5' end of M13-A. The library was screened with a random-primer
labelled probe generated from the 100 bp Bgl II fragment of M13-A
(see Figure 4), and 52 positives were identified out of 9 X 104
plaques. Two of these, M13PX-1 and M13PX-2, were plaque purified
and found to contain inserts of -1200 and -1100 bp respectively. The
combined length of M13-A and the overlapping M13PX-1 is an
excellent match for the size of the CBG mRNA observed in Northern
analyses (see below), indicating that together, M13-A and M13PX-1
constitute an essentially full length CBG cDNA. Figure 4 illustrates
how the complete CBG cDNA sequence was obtained from M13-A,
M13PX-2, and M13PX-1 by a combination of subcloning and the use of
custom sequencing primers.
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Sequence Analysis
The combined sequences of M13-A, M13PX-2, and M13PX-1
comprise a cDNA of 2631 bp, shown in Figure 5. The first ATG codon
(at position 70), occurs in a poor context for initiation of translation
(Kozak, 1991), and the open reading frame that follows terminates
after 240 bp. The second ATG codon (at position 236) occurs in a
favorable context, with a G in the -3 position. Beginning with this
codon, an open reading frame extends 1740 bases before terminating
at position 1975. An AATAAA cleavage and polyadenylation signal is
found at position 2582, followed 13 bases later by a poly-A tract. The
deduced amino acid sequence of the long open reading frame
correctly predicts the sequences of all four CBG tryptic peptides
(underlined in Figure 5), including the three that were not used in
screening the cDNA library.
The deduced amino acid sequence features a stretch of
hydrophobic amino acids at both the amino and carboxy termini, that
could serve as a signal sequence and a GPI-attachment signal
respectively. CBG was previously shown to be GPI-linked on the basis
of its ability to be released from Triton X-114 micelles by
phosphatidylinositol specific-phospholipase C (Herndon and Lander,
1990). With the removal of these signal sequences, the mature
protein would have a predicted molecular weight of 58.6 kDa, in good
agreement with the size of the CBG core protein, as observed on
reducing SDS-PAGE gels [57 kDa; (Herndon and Lander, 1990)]. The
protein contains seven "ser-gly" sequences, five of which (boxed in
Figure 5) are potential GAG attachment sites (see Discussion). No "N-
X-S" or "N-X-T" N-linked glycosylation consensus sequences are
present.
As Figure 6 (panel A) illustrates, the CBG protein sequence shows
significant homology to four other molecules, rat glypican (Karthikeyan
et al., 1994; Litwack et al., 1994), the deduced protein sequence of
OCI-5, a developmentally regulated transcript cloned from a primitive
intestinal epithelial rat cell line (Filmus et al., 1988), K-glypican,
cloned from mouse kidney cDNA (Watanabe et al., 1995), and the
Drosophila protein, dally (Nakato et al., 1995). The homology is
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moderate but extensive, with islands of highly conserved sequence
surrounded by divergent sequences. Most striking is the conservation
of cysteine residues (black and underlined in Figure 6A): Of the 14
cysteines in the predicted sequence of the mature CBG protein, all are
conserved in the other molecules. Glypican, K-glypican, and OCI-5
have and additional pair of cysteines near the carboxy terminus that is
absent from the other molecules. In addition, all of the proteins have
at least one putative ser-gly GAG attachment site (Figure 6A, on the
left hand side of the second set from the bottom), in a cluster near the
carboxy terminus. Figure 6, panel B shows the percent identity of
each of the five molecules to the other four. Among the mammalian
proteins CBG, glypican, and K-glypican are more closely related to
each other than to OCI-5. The dally protein has a similar level of
identity to each of the mammalian proteins.
Southern hybridization
To assess whether CBG is present as a single copy in the genome,
10 gg of rat thymus DNA was digested to completion with HindIII,
KpnI, or Xhol, separated by agarose gel electrophoresis, and
transferred to nitrocellulose. The filter was probed with a random
primer-labelled probe made from the 100 bp BglII frament of the
M13-A cDNA. The resulting autoradiogram is shown in Figure 7. In
each lane a single band appears indicating that the gene encoding CBG
is present as a single copy in the rat genome. The high level of
stringency at which the hybridization was performed would not have
detected the presence of CBG-related proteins such as glypican, OCI-
5, K-glypican, or other as yet unidentified molecules.
Northern hybridization
The CBG core protein is observed in the membrane fraction of
embryonic day 18 (E18) and newborn (PO) rat brain, but not in the
adult (Herndon and Lander, 1990). To examine the expression of CBG
mRNA, Northern blot analysis was performed using 20 gg of rat brain
total RNA from each of these three developmental stages, and a
random-primer labelled probe generated using cDNA M13-A as the
template (Figure 8). A single transcript of about 2.7 kb was seen that
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is relatively abundant at E18, less so at PO, and undetectable in the
adult sample. The filter was re-probed with a glyceraldehyde-
phosphate dehydrogenase (GAPDH) probe (Figure 8, lower),
demonstrating that there was not an appreciable difference in the
amount of RNA loaded in each lane. Thus, the developmental
expression of CBG mRNA agrees with that previously observed for CBG
protein.
Isolation of homologous CBG cDNAs from mouse and human
To assess the evolutionary conservation of CBG cDNA and protein
sequence, and to generate probes for future experiments, murine and
human homologues of CBG were isolated by PCR. To obtain a murine
cDNA, primers 0M13-165 and OCBG-137 (see Materials and Methods)
were used in an RT-PCR reaction with embryonic day 17 mouse brain
total RNA. A major product of the predicted 400 bp size was obtained
and subcloned. Two independent subclones muCBG-1 and muCBG-2
were isolated, and preliminary sequencing indicated that they were
identical. The complete sequence of muCBG-1 was obtained by a
second round of sequencing; however, the complete sequence of both
strands has not been determined. Comparison of muCBG-1 with rat
CBG (Figure 9) revealed 94% identity at the nucleic acid level, and
99% identity at the protein level. The one substitution that was
observed was conservative -- valine for alanine.
A cDNA likel;y to be human CBG was obtained using a nested set of
degenerate primers, based on conserved sequences in rat glypican,
mouse K-glypican, and rat CBG (see Figure 10, top). The outer set of
primers was used in a PCR reaction with week 16 human human fetal
brain cDNA. To enrich for CBG-like sequences, the cDNA was
sythesized from total RNA using the degenerate primer 22R, based on
rat CBG protein sequence (Table 1). The products of this round of
PCR, separated on an agarose gel and stained with ethidium bromide,
contained, in addition to several non-specific products, a diffuse band
just below 1 kb, close to the predicted size of 954 bp. This material
was purified and used in a second round of PCR with the inner set of
primers. Two major products near the predicted size of 180 bp were
obtained. Subcloning and sequencing revealed that the larger of these
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two products is likely to be a human CBG cDNA fragment. The second
product, about 12 bp smaller, is likely to be a human K-glypican cDNA
fragment.
Figure 10 (bottom) shows the alignment of these cDNAs with rat
CBG and mouse K-glypican respectively. The putative human CBG
fragment is 81% identical with rat sequence at the nucleic acid level
with 87% identy at the protein level. The putative human K-glypican
fragment is 81% identical to mouse K-glypican nucleic acid, and 78%
identical at the protein level.
CBG genomic structure and mapping
To begin to characterize CBG genomic structure a mouse genomic
library was screened with a probe based on the rat CBG cDNA
sequence. To bias toward isolating clones containing sequence from
the first translated exon, a 215 bp Aat II/Sma I restriction fragment,
beginning 94 bp ustream of the start ATG, was used as a template to
generate a 3 2 P-dCTP labelled probe. Hybridization of the probe to the
mouse genomic library identified two positive plaques out of a total of
760,000 screened. Overlapping clones were isolated by re-screening
the library with the 818 bp Aha II/Afl I restriction fragment of the rat
CBG cDNA. Figure 11 shows a partial restriction map of the CBG
genomic locus.
Sequencing of the CBG genomic clones has revealed the
intron/exon boundaries of the first two translated exons. Additionally,
two CBG cDNA clones containing a partially unspliced cDNA were
fortuitously isolated. Sequencing of these clones (Figure 12) revealed
the locations of additional intron/exon boundaries. The locations of all
intron/exon boundaries identified so far are summarized in Figure 13.
In Figure 13, the assumption is made that mouse and rat CBG have the
same genomic structure, an assumption that has been validated for two
intron/exon boundaries so far (see below).
To map CBG in the mouse genome, it was necessary to find a
polymorphism linked to the CBG locus. This was accomplished by
identifying a single stranded conformational polymorphism (SSCP) in
the CBG loci of C57B16 (Mus musculus) and Mus spretus mice. To
identify the SSCP, two primers (muCBG-L and muCBG-R) were
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designed based on the sequence of the muCBG-1 PCR fragment (see
Figure 9). These primers were chosen to flank the site of an intron
identified in the same region of two partially unspliced rat CBG cDNAs
(Figure 12). Because intron sequences can be highly divergent, they
are the best candidates when searching for a SSCP. PCR with the
primers muCBG-L and muCBG-R and Mus spretus or Mus musculus
genomic DNA yielded a major product of about 615 bp, very close to
the 613 bp predicted by the size of the intron in the rat clones.
Subcloning and partial sequencing of the Mus musculus product
demonstrated that it contained the sequences of the primers, and
coding sequence identical to muCBG-1, interrupted by sequence
highly similar to the sequence of the rat intron (not shown). This
demonstrated that an authentic mouse genomic CBG fragment had
been amplified.
To test the genomic fragment for a SSCP, a3 2 P-dCTP was included
in PCR reactions to generate labelled genomic CBG fragments from
Mus musculus and Mus spretus genomic DNA. The gel purified
fragments were re-run on a strand separating gel (see Materials and
Methods), revealing the presence of a SSCP (Figure 14). This SSCP
was then scored by PCR with genomic DNAs from the test cross [NCI-
Frederick #77-122 (Mus musculus X Mus spretus) X Mus musculus].
The results, summarized in Table 2, indicated that the CBG locus in
the mouse genome maps to the distal end of the long arm of
chromosome 5 (distal to Epo, a marker -6 cM from the telomere). No
previously identified mouse mutants (e.g. reeler) correspond to this
location in the mouse genome (see Discussion).
91
DISCUSSION
Purification of the major HSPGs of neonatal rat brain.
Amino acid analysis of the HSPG pool obtained after chondroitinase
treatment and re-purification on DEAE-Sephacel indicated that 100
pýg of protein had been isolated.
The table at right gives the PurificationStep Estimated Yield
calculated or predicted yields 1st DEAE column 40%
for the steps prior to amino acid 1st concentration 89%
analysis. The yield for the first 2nd DEAE column 54%
DEAE step is predicted to be 2nd concentration 63%
-40% based on the results of total yield 12%
add back experiments in an earlier
study (Herndon and Lander, 1990) in which radioiodinated PGs were
added back to a crude homogenate and followed through a subsequent
DEAE purification step. Calculated yields for the second DEAE step
and the concentration steps were made possible by the inclusion of
trace amounts of radioiodinated membrane PGs in the present
purification. Although the true yield of the first DEAE step is
unknown, the apparently slightly higher yield in the second DEAE
purification step may be a result of gradient elution rather than step
elution. An earlier study has shown that as much as 9% of the
recoverable PG material is lost in the "tail" of a single step elution
(Herndon and Lander, 1990). Acceleration of the tail's elution by a
gradient would be expected to improve yield. Of the apparent 46% of
the HSPGs not recovered in the second DEAE step, a substantial
fraction was probably lost due to irreversible binding to DEAE.
Previous studies showed that as much as 44% of bound PGs may
remain associated with DEAE, even after elution with high salt
(Herndon and Lander, 1990).
The total yield implies that roughly 0.83 mg of HSPG core protein
was present in the crude membrane starting material derived from
46.35 grams (wet weight) of neonatal rat brain. This results in a value
of 0.02 mg HSPG/gram of neonatal rat brain (or 2.7 mg HSPG per
gram of brain membrane protein). This value is somewhat higher than
previously reported values (Herndon and Lander, 1990), which may be
a reflection of the fact that these earlier estimates were based on
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binding of the anionic dye amido black, which binds less as efficiently
to anionic PGs than to the protein standard (bovine serum albumin)
used in the assay. In the present study, the amount of HSPG was
measured by amino acid analysis, a more reliable method. If CBG
accounts for -20% of the total HSPG at this age, it would constitute
-0.05% of the total brain membrane protein.
Preliminary experiments with radioiodinated neonatal membrane
PGs indicated that the material in the HSPG pool eluted from the
second DEAE column is virtually depleted of CSPG core proteins. The
amount of labelled PG that flowed through or was eluted by the
stringent wash in the second DEAE step, taken as a fraction of the
labelled PG applied, indicates that CSPGs account for -50% of the
material in the neonatal membrane PG fraction. Assuming HSPG cores
and CSPG cores are radioiodinated to a similar specific activity, this
implies that as much as 0.04 mg total PG/gram brain (wet weight) may
be present in crude membrane fraction of neonatal rat brain.
Molecular identities of HSPGs M7, M12, and M13
The protein sequence of peptides derived from HSPG M12
suggested that M12 is the rat homolog of glypican. The sequences of
all four M12-derived peptides have subsequently been identified
within predicted amino acid sequence of two independently isolated
rat glypican cDNAs (Karthikeyan et al., 1994; Litwack et al., 1994).
Rat brain M12, like human glypican cloned from lung fibroblasts, is a
glycosylphosphatidylinositol (GPI)-anchored HSPG with a core protein
of Mr 65 kDa (David et al., 1990; Herndon and Lander, 1990).
Antibodies raised against a rat glypican fusion protein specifically
precipitate M12 from a crude mixture of brain PGs and recognize a
band that comigrates with the M12 core protein in Western blots
(Litwack et al., 1994).
No microsequence was obtained for HSPG M7. Possible reasons for
the failure to obtain sequence include poor transfer of M7 to
nitrocellulose after electrophoresis, and poor recovery of M7 tryptic
peptides after in situ digestion. Autoradiography of the minigel from
which M7 was transferred revealed that a significant portion of the M7
band remained in the gel. M7 aggregates with other species in PG
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fractions as demonstrated by gel filtration (Herndon and Lander,
1990). This behavior may have caused M7 to partially precipitate in
the gel and become resistant to electroblotting. The M7 core protein
size and pattern of developmental expression in the rat brain are
indistiguishable from those of the HSPG syndecan-3 (Carey et al.,
1992; Gould et al., 1992), and an antibody to syndecan-3 has recently
been shown to immunoprecipitate M7 from growth cone particle
preparations (Ivins et al., 1995) The predicted protein sequence of
syndecan-3 contains an extensive serine-threonine-proline rich region
similar to the highly glycosylated regions of several mucin-like
proteins (Gould et al., 1992). If M7 -- which is known to be highly
sialylated (Herndon and Lander, 1990)-- is rat syndecan-3, the
presence of this domain may have rendered it protease-resistant,
decreasing the yield of tryptic peptides.
The sequences of the four M13-derived peptides suggested that
M13 is a novel glypican related HSPG. To further characterize M13,
an M13 cDNA clone was isolated from a newborn rat brain cDNA
library on the basis of the sequence of one of the M13 peptides.
Several lines of evidence confirm that the cDNA obtained in this study
encodes the GPI-anchored HSPG core protein previously designated as
M13 (Herndon and Lander, 1990): The cDNA encodes all four of the
peptides that were obtained from the tryptic digest of M13; it
encodes a protein of the correct size, that contains likely GPI-
anchorage and GAG-attachment sequences (see below); and it
hybridizes to an mRNA that is present in embryonic and neonatal rat
brain, but not in adult brain [matching the pattern previously observed
for M13 protein (Herndon and Lander, 1990)]. As described in
Chapter 3 of this thesis, expression of HSPG M13 is limited to the
nervous system. This result is surprising because no other
proteoglycan is known to be restricted in expression to a single tissue.
To reflect the nervous system-specific expression of this proteoglycan,
we have chosen to name PG M13 "cerebroglycan."
Cerebroglycan Sequence Analysis
The deduced amino acid sequence of cerebroglycan (CBG) contains
seven serine-glycine pairs, representing possible glycosaminoglycan
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(GAG) attachment sites. Of these, ser 1 5 5 , ser 4 9 8 and ser 5 0 0 all
match the sequence SGXG, and all occur within regions of protein
sequence that are rich in acidic residues. Both features have been
proposed to define a consensus for GAG attachment (Bourdon et al.,
1987; Bernfield et al., 1992). In addition, two other serine-glycine
pairs (ser5 5 and ser 9 2 ) occur either just before or just after an acidic
residue, and might also represent GAG attachment sites (Bernfield et
al., 1992). Interestingly, ser4 9 8 and ser 5 0 0 were sequenceable
residues of peptide M13-22. Since substitution with GAG would be
expected to result in a blank round in Edman degradative sequencing,
it would appear the majority of the CBG population is substituted at
only one or perhaps neither of these sites. Amino acid yields of these
serines in the Edman degradation reaction were about 30% of the
yields obtained for the neighboring glycines. This is the typical yield
ratio observed for a labile amino acid such as serine compared to a
non-labile one such as glycine (Richard Cook, MIT Biopolymer Lab,
personal communication). Thus amino acid sequencing provided no
evidence of substitution at either of these sites. See Chapter Five of
this thesis for further discussion of CBG GAG attachment.
The cerebroglycan protein sequence has a stretch of hydrophobic
amino acids at both the amino and carboxy termini, as indicated in
Figure 5. These sequences could serve as the signal sequence and a
GPI-attachment signal respectively, being cleaved off in the mature
protein. The precise cleavage sites are unknown, and those indicated
in Figure 5 are predictions based upon the -1,-3 rule (von Heijne,
1990), for the signal sequence, and the o, o + 2 rule (Kodukula et al.,
1993), for the GPI-attachment signal. Of the two potential GPI-
attachment sites indicated, ser 5 5 7 has a slightly higher probability
than asn 5 5 3 , based on amino acid preferences at the o and c+2 sites
of other GPI-anchored proteins. Following the candidate GPI-
attachment sites are a potential "hinge" region (rich in proline and
charged amino acids), and a stretch of hydrophobic amino acids; both
the hinge and hydrophobic stretch are features of GPI attachment
signals (Kodukula et al., 1993).
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Cerebroglycan Belongs to a Family of GPI-Anchored PGs
The deduced amino acid sequence of cerebroglycan shares
significant homology with four other molecules: (1) the HSPG glypican
(David et al., 1990); (2) OCI-5, originally identified as a
developmentally regulated transcript cloned from a rat intestinal
epithelial cell line, and recently shown to be expressed as an HSPG
(Filmus et al., 1988; Filmus et al., 1995); (3) K-glypican, cloned from a
mouse kidney cDNA library (Watanabe et al., 1995); and (4) the
product of the Drosophila gene dally (Nakato et al., 1995) (see Figure
6). Thus it is now apparent that in addition to the syndecan family of
transmembrane cell surface HSPGs, there is also an entire family of
molecules related to glypican. All members of the glypican family are
intercalated in the membrane by a GPI lipid anchor. Glypican family
members also all have at least one putative GAG attachment site in a
conserved cluster near the carboxy terminus.
The homology between glypican family members is moderate but
extensive, being characterized by blocks of identity or conservative
substitutions separated by stretches of divergent sequence. A pattern
of 14 cysteine residues is found in all family members so far identified.
The presence of these cysteines in the Drosophila dally protein, which
appears to be related to the ancestor of the mammalian glypicans,
indicates that this well conserved structural pattern is of an ancient
origin.
The conserved pattern of cysteines also suggests that these PGs
may have similar, compact tertiary structures, stabilized by disulfide
bonds. This view is supported by the fact that both glypican and
cerebroglycan show a dramatic increase in apparent molecular weight
in SDS-PAGE gels upon reduction (Herndon and Lander, 1990). In
addition, a proteolytic fragment obtained in some preparations of K-
glypican can be only be observed in SDS-PAGE gels upon reduction
(Watanabe et al., 1995).
It is also of interest to note the high level of conservation among
orthologues of the mammalian glypican family members. The mature
polypeptides of human glypican and rat glypican are 91% identical at
the amino acid level, and the predictied protein sequences of the
human cDNA fragments of cerebroglycan and K-glypican obtained in
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this study are 87% and 78% identical to their respective rat and
mouse counterparts. The ectodomains of the human and mouse
syndecan-1 and human and rat syndecan-4 are only 70% and 76%
identical respectively. In the syndecan family ectodomains, only a
protease susceptible domain near the plasma membrane and the
regions surrounding the GAG attachment sites are strongly conserved
(Bernfield et al., 1992)., suggesting the primary function of the
syndecan family ectodomains may be to present GAG chains at the cell
surface. In contrast, the protein cores of the glypican family members
may serve a more complex function that has constrained their
evolution. For example, these core proteins might bind as yet
unknown ligands. Examples of ligand-binding PG core proteins
include the core proteins of betaglycan [which binds TGF-D3 (Cheifetz
and Massague, 1989)] and decorin [which binds to collagen fibrils
(Vogel et al., 1984; Krusius and Ruoslahti, 1986)].
Alternatively, the conserved protein structure of the glypican family
HSPGs may play a regulatory role in post-translational processing. For
example, the protein might interact with components of the Golgi
apparatus in order to influence the type of GAG that it receives (e.g.
HeS versus chondrotin sulfate), or even the sequence of GAG
modifications (e.g. sulfation) that is subsequently generated. Recent
studies underscore the importance of differences in GAG modification
on the biological properties of HSPGs (Sanderson et al., 1992a;
Nurcombe et al., 1993; San Antonio et al., 1993).
Finally, among the mammalian glypican family members, glypican,
K-glypican, and cerebroglycan are all more closely related to each
other than to OCI-5. This suggests that there may be a subfamilies
within the glypican family. It will be interesting to see if, in the
future, additional glypican family members are identified.
Genomic structure of Cerebroglycan
As a result of the partial characterization of CBG genomic structure,
three CBG exons have been identified (Figure 13). The first exon
(exon I, Figure 13) codes for the first 55 amino acids, including the
signal sequence, and contains one of the fourteen conserved cysteine
residues. Interestingly, this exon ends with the serine of the first ser-
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gly putative GAG attachment site. Given the tendency for individual
exons to contain intact functional domains (Darnell et al., 1986), the
fact that the serine and glycine of this ser-gly pair are on different
exons seems to disfavor the possibility that GAG is attached at this site.
In syndecan-1 and syndecan-4, none of the serine-glycine pairs that
are thought to attach GAG are split to separate exons (Vihinen et al.,
1993; Baciu et al., 1994).
The second exon (exon II, Figure 13) encodes the next 53 amino
acids, including three of the conserved cysteine residues and one
putative GAG attachment site. This ser-gly (ser92) fits the minimal
description of one type of GAG attachment site observed in the
syndecan family, namely, a single ser-gly that is preceded and often
flanked by acidic amino acids (Bernfield et al., 1992) -- D/E-X-S-G-
(X)n-D/E -- although it has no flanking acidic amino acid residue.
Although the 3' boundary of the third exon has not been defined,
another downstream exon (exon Q, Figure 13) was defined by the
fortuitous cloning of a partially spliced cDNA (Figure 12). This small
exon, which begins at Ile 2 1 7 in CBG, encodes only 27 amino acids and
contains no putative GAG attachment sites or conserved cysteine
residues. However, the level of homology among glypican, K-glypican,
and cerebroglycan is unusually high in this region. Glypican and K-
glypican, with an overall identity of 41%, are 70% identical in the
region of the exon. CBG and K-glypican, 36% identical overall, are
52% identical here, and CBG and glypican, which share a 37% identity
overall, are 48% identical in the region of the exon. In addition, many
of the non-identical residues represent conservative substitutions.
The high level of conservation in the region of this exon suggests that
it fulfills some important structural or functional role, at least in the
most closely related mammalian family members, glypican, K-glypican,
and CBG.
The 3' splice acceptor sequence of one intron in Figure 13 shows
substantial deviation from the typical consensus sequence for splice
acceptors (Mount, 1982). Typically, the invariant AG at the 3' intron:
exon boundary is preceded by a distinctive polypyrimidine tract. In
this case of this intron, many of the pyrimidines in the tract have been
substituted with purines. This raises the possibility that CBG mRNA
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expression is regulated at the level of splicing. It has been established
that the efficient expression of many mammalian genes requires the
presence of at least one intron. One recent study has shown that the
level of increased expression conferred on an intronless minigene by
the inclusion of an intron varies dramatically with the efficiency with
which the intron is spliced out (Korb et al., 1993). Another study
demonstrated that muscle-specific expression of a Ca++/ATPase splice
variant is likely the result of trans-acting factors that activate an
otherwise inefficient splicing process (Van den Bosch et al., 1994).
Given the exquisite pattern of spatial and temporal CBG mRNA
expression (as will be described in Chapter 3), the possibility of
regulation at the level of splicing is intriguing. However, preliminary
experiments have shown that the -4 kb Xba fragment, upstream from
exon I in the CBG genomic clone, is sufficient to confer restricted,
CBG-like expression to a lacZ reporter construct in transgenic mice
(John Fesenko, unpublished observations).
Localization of the CBG gene in the mouse genome
The segregation of a CBG-specific single stranded conformational
polymorphism (SSCP) in a test cross of a B6/Spretus mouse with a B6
mouse resulted in the assignment of the CBG gene to the distal end of
the long arm of chromsome 5. The known markers in this region are
shown below:
FLK2
GNB-2 ACT-1 FLT1
ZP3 EPO PDGFA GSH-2
END OF
(1.3) (4.1) (1.1) (0.5) CHROMOSOME 5
4 CBG
Cerebroglycan maps somewhere between EPO and the end of the
chromosome. The numbers refer to distances in centimorgans
between the arrows. The markers shown above and their location in
the human genome are:
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Marker Name hum. locat.
ZP3 zonapellucida protein 3 ND
GNB-2 guanine nucleotide binding
protein B-2 7q21
EPO erythropoetin 7q21
PDGFA platelet derived growth
factor, alpha 7pter-q21
ACT-1 actin-1 7pter-q22
GSH-2 genomic screening
homeobox-2 ND
FLT- 1 FMS-like tyrosine kinase-1 13p12
FLK-2 fetal liver tyrosine kinase-2 ND
Because of the nervous system-specific expression of CBG mRNA
and protein (see Chapter 3), it was of interest to determine whether
any known behavioral or neurological mutants colocalized with CBG in
the mouse genome. No such markers are known to be present in the
distal portion of chromosome 5 (Wayne Frankel, Jackson Labs,
personal communication). The markers that map close to CBG are
found on chromosomes 7 and 13 in the human genome, making these
two chromosomes possible candidates for the location of the human
CBG gene.
In summary, two of the three major cell surface HSPGs of the
developing rat brain have been identified. These molecules are rat
glypican, and a novel glypican-related protein that we have named
cerebroglycan (CBG), and for which we have obtained a full length
cDNA. Glypican and cerebroglycan belong to a family of HSPGs
characterized by GPI-lipid anchorage to the cell surface, and
conserved protein structure, including a pattern of 14 cysteine
residues that is absolutely conserved. The developmental expression
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of CBG mRNA and protein is restricted: no CBG is detected in adult
brain. The genomic structure of CBG has been partially elucidated and
its location in the mouse genome has been determined. In addition,
mouse and human CBG cDNA fragments have been obtained. The
reagents obtained in this study lay the foundation for further
characterization of CBG function and expression in the developing rat
nervous system.
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Figure 1. Purification of neonatal rat brain membrane HSPGs
Total PGs, isolated from a neonatal (PO) rat brain membrane fraction
by DEAE chromatography, were digested with chondroitnase ABC and
fractionated again on DEAE-Sephacel. The addition of a trace amount
of previously isolated, radioiodinated PO membrane PGs, prior to
chondroitinase digestion, allowed the purification to be monitored.
The cpm of 1251 in each fraction was measured in a y-counter. Most
of the CSPG core proteins [e.g. CSPGs "Ml," "M6," and "M8" as
identified in Herndon and Lander (1990)] flowed through when
applied in 0.15 M NaCl (Peak I). A small but significant amount of the
M1 protein core was retained, but could be eluted with a stringent
wash: 0.1 M sodium acetate [pH 3.5], 0.2 M NaCl (peak II). The
HSPGs were subsequently eluted with a gradient of 0.15-0.75 M NaCl
(peak III). Earlier experiments demonstrated that peak III is
centered around 0.45 M NaCl (not shown). See Materials and
Methods for details.
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Figure 2. Electrophoretic separation of HSPGs M7, M12, and M13
To resolve the HSPG core proteins M7, M12, and M13, a two stage
electrophoresis step was used. (I) The heparitinase-digested,
concentrated HSPG pool was loaded onto a 6% T acrylamide, SDS
minigel, polymerized over a strip of 9% T acrylamide (lane 1 of the
gel). An enzyme blank and pre-stained molecular weight markers
were loaded in lanes 2 and 3. (II) After electrophoresis to resolve the
M7 core protein, the M12 and M13 cores (in the 9% T acrylamide
strip) were excised and re-cast in a second 9% T acrylamide gel. (III)
Further electrophoresis resolved the M12 and M13 cores. The
locations of the molecular weight markers are indicated as are the
rough locations of the HSPG core proteins as revealed by subsequent
electoblotting and amido black staining. See Materials and Methods
for details.
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Figure 3. HPLC chromatography of M12-derived peptides
The HSPG M12 core protein was digested in situ with trypsin after
electroblotting to nitrocellulose. The peptides liberated by digestion
were separated by HPLC as described in Materials and Methods. The
chromatograms show milli-absorbance units (mAU) versus elution time
in minutes. Purple line is absorbance at 210 nm; green line is
absorbance at 277 nm. (A) The chromatogram of the M12-derived
tryptic peptides. The numbered peaks contained peptides whose
sequences were determined (see Table 1 below). (B) The
chromatogram of the enzyme blank. The blank was obtained by
trypsin digestion performed on a congruent section of the
nitrocellulose excised from the same level of the blot as the M12 band
in an adjacent lane. The blank was composed of heparitinase at
identical concentration in an identical buffer to the M12 sample.
Peaks in (A) that eluted at identical times to peaks in (B) were
disqualified from further analysis.
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Peptide
M13-9
M13-10
M13-21
M13-22
M12-15a
M12 -15
M12-18
M12-26
M12-29
Sequence
C A TN
RSSAEERPPTTGAYGTNLXRK WS R GKyL H
KSVAAR
A
RSCE? LGMHLQENSVK
W
KA LG" D L D M H D A D E DA S G S G G G Q Q Y A D D
22L 22R
KMELETALHDSSR
KXAEALRPFGDAPR
KTPLTRALPGLSEQEGQK
KALQATLATQLHGIDDHFQ
RXL FAITNN~G NQGXNPEVD
Table 1. Peptide Sequence from HSPGs M12 and M13
Selected M12 and M13 tryptic peptides were subjected to automated Edman degradation
after separation by reverse-phase HPLC. Multiple letters indicate ambiguities in the
sequence, bold letters indicate the sequence which was later verified by from the deduced
amino acid sequence of M 12 and M13 cDNAs. 22L and 22R: bars indicate the
unambiguous amino acid sequence upon which the PCR primers 22L and 22R werebased.
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Figure 4. Cerebroglycan cDNA sequencing strategy
The restriction sites used in subcloning and sequencing are indicated
by letters: A= ApaI, B= BglII, E= EagI, K= KpnI, M= Mspl, P= PstI,
R= EcoRV, S= SmaI, Sa= Sau3AI, Sc= Sacd, Sp= SphI, and T= TaqI.
Arrows indicate individual sequencing reactions. The custom
oligonucleotides used in sequencing are numbered. Oligonucleotide
three was OM13-165, the primer used in the construction of the
primer extended library. The three CBG cDNAs are indicated by the
heavy lines below the restriction map.
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Figure 5. Nucleotide sequence of cerebroglycan cDNA and translation
The merged sequences of cDNAs M13-A, M13PX-1, and M13PX-2 are
given along with the deduced amino acid sequence of M13. Potential
glycosaminoglycan attachment sites are boxed. Cysteine residues are
circled. Arrowheads indicate potential cleavage sites of the signal
sequence (after Gly2 ) and the glycosylphosphatidylinositol attachment
signal sequence (after Asn 5 5 3 or SerB57). (See text for discussion.)
Sequences that correspond to M13 peptides (Table 1) are underlined.
The cerebroglycan cDNA sequence has been deposited in the
GenBank/EMBL database (accession number L20468).
GATCCATGrCOOGCTCCACCCGGCCCATTTCTC AGATGCCTCCTAGTCCAGCTACCOT•C•TOG4CT CAGTTTTGGGG 115
1 OGACPT ai...TGAT61G2C33CTT T CTC C A ACACTTTTTCTCTATCAC C GGAAGGAGAAGC235
236 ATGTCCGCGGTGCGACCTCTCCTOCTTOCTCT GGC• CATTC GTTGTOCAGAGACTCGOCAGTGCTOGGO 3
MSAVRP LrL LLL PLCPGPGPGEOSEAKVVRS ARTRQVLG o
356 GCCCOOGGATATAGCTTAAACCTTATCTCTCAGGTGAG ATCT ATATCC AT S
A R G Y S L N L I P P S LI 5 E• R L QI P Q C Y T • T E Q K L I R D
41 91 of
476 GCTGAGTCA CATTCACaC TOCLCCCCGAAAGTTTAACOAGGATCTTCTATATCCCAGCAT 59S
A VTPRO GL V D - S F LI T A A R f R K P N EF r R S L sI SQ H
01 1L 12
s9 TCTTTCTACATCC A TACCTTTCTGGCC CTTATAAA GGGGTTGT71
SLAQLPBSS$TORLYSQNAVIPNSLP5OLRDYYERGN LD
121 141 Is0
714 GACA3TTOT OcAOATTOAcCT- T o 3
D TL A D W A Q LL RA P LL P Q Y S P PD L L L T R T S T AD
141 1t 200
3C6 9C3CT3C A ACAGAT 0GTCTGACGAAATGTGTCAGCOAA 55
GS 0 P D S P R R R Q I T R A L V A A R A L V GL T G R N V V S
201 240
221
936 G -CATATCT GTACG TaTTOTOcC 1075
AE VP L R AL L O LOR 0 VP S P RF L N V A
241 2s M
1071 CAC TTCTCAO CAG TT TGGATATCTOT C T RACT GTCCATA 1195
a O L 8 R OLE P W Y L DO L LLL A X L O P PSP L A E S I
281 301 320
119GCT0TGAGAA rGGCGAGCACCA lt 1313
G V K IS G L ML Q N S V K V S A K VP Q EOO T P E P V Q SR N R R AP
1316 GCA1CG3GAAGAGACTA3CCrGTCTTGT-AA R CCAACAT CGCTGTTT••OOC AGCTTACCGA 13
APRE S R R A R P T T A A T N RLVW LRERL R
361
1436 GTGCQOOOCTT;O r• 5ACTTCCCOTTA TC T00CAATCTCCCAG GC ~COCCTATATGTCG 5133
V R O W AGL P V T V O R A A L SQ A A P W T V R G R Y K S
401 421 440
1 554 CC TOT TCACAOCTCCATAACCCaT••1O67ATACTIATCCCATCCACATCcC ACCCATCTCCACAcTACTCTCA TAG75
PV V V G S N Q L NP LD T PD V P T R R RR L A A T A R N
441 461 400
1747 OCCCC ..- CA?0CATOATaCOGATaAAaACOCCAOacroAOOo OTcn ACOCARCGCTOGAAACTo 0CAOCOCCTTOTOTrCCCCA 1795
A A A L G Q D L 0 N 3 D A D It D A E! 0 0 o Q Y A D D W I A 0 A A P V V P P
481 SolS
1794 GCC1AOCCTCCAACCCTC C TOTCTTOa--GT-aAGGAOA TOOCCCAAT ACAACCAOCCOGACAGGOAATc- 1915
ARP P R P P R P P R R DG G V R G 8 ARTNQ G R S RNL GS S V G  L
191s CATOsTCC*CCACOTOTCT-A. CC*G 2033
HA PRV FI LLP S A LTLL 0 L RSal
2156 GGTT TATTTTTTCA 2275
239s 5TTGA TTTC AACTCTGAGTATTACTTCTAAACCATTAT 152216 TTAAATATOOOOOAACOCA. ** - .AA TwO~~AcOOTOTTTA!TTGeAAATAAACAAmTOA•--••--A.-- •2431
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Figure 6. Cerebroglycan is a member of a family of glypican-related
HSPGs. (A) The protein deduced sequence of the CBG cDNA
(rCEREBRO) is shown aligned with the sequences of four other
molecules: the Drosophila protein, dally (dDLY); rat OCI-5 (rOCI-5);
mouse K-glypican (mK-GLYP); and rat glypican (rGLYP). The top line
represents the sequence of human glypican (hGLYP). The sequence of
human glypican is identical to the sequence of rat glypican except
where noted. All five molecules share a pattern of 14 conserved
cysteines (black, underlined). Conservative substitutions are indicated
with the use of colors, as indicated at the bottom of the figure. (B)
The percent identity of each molecule for the others is shown.
hGLYP G
rGLYP MELRARGWWLLCAAAALVACARGD--PAS ----------------------------------- S SSEVR
mK-GLYP MARLGLLALLCTLAALSASLLA ---- AEL ----------------------------------- SSCSEVP
rCEREBRO MSAVRPLLLLLLPLCPGPGPGHGS--EAKV----- ---------------------------------- VRSCAET
rOCI-5 MAGTV••TACLLVAMLLGLGCLG A PPPPP------------------------------------DATCH V
dDLY MAARSVRLA LLLFTLLCGFVGLSAAKHLDLDGIP= H-LH'SATTERRRL RDSRAKDAVGGSTH CDAVe
R HA R V M RSF
IYGA:.GFSLSDVP AEISGEHLRIC-P GYTC=ISEMEE LA HSRMELETALHDSSRAL ATLAT LHGID
ýLYVSKGF K DAPLYEI GDHLKIC-P DYTCCS EMEEKYSL SKDDFKTVVSE C KL AIFASRYKKFD
VLGARGYSL LIPPSLISGEHL IC-P EYTCCSSETE KLIRDAEVTFRGLVEDSGSFLIhTLAARHRKF
SFF •L PGLKWVPETPVPGSDL VCLPKGPTCCSRKMEEKY LTARL ME LL- SASMELKFLII AAV-
SYF---- -ESIDIKSSGTYSEKGAIC ---GG CC ATELELRDKAAGMFE LLH;PTSSLRGVLET AK F
AT E A S
D:F RLL DSEZiTL DAFPGAFGDLYT TRAFRDLYAEL ------------------ RLYYRGA LHLEETL
EFF:ELLE AEKSL DMFVKTYGHLYM SELFKDLFVEL ------------------ KRYYVAG V LEEML
EFF;EMLSIS HSLA LFSHSYGRLYS HAVIF SLFSGL------------------ RDYYEKSGEGLDDTL
--F EAFEIVVRHiAK YT AMFK YPSLTP AFEFVGEFFTDV---------------SLYILGSDI VDDMV
••VLELA ISE MTW=SLFSKVYTRMVPSS-MMI4 LYTEIM ELIYTS YT S G LG:RGIGSV S LEEAV
E
AEFWARLLEkLFK L-P L-----LLPDDYLDCLG. ---- AEALRPFGDAPREL.LRA'TRAFVAA3SFV GL
DFWARLLERMFiLV S Y----- FTDEYLECVSKY---- TE LKPFGDVPRKLKL VTRAFVAARTFA GL
ADFWA LLERAFPLLHP Y ----- SFPPDFLLCLTLTSTADGSL PFGDSPRRLRL ITRALVAARALV GL
ELFDSLFPVIYT MM PG---LPESVLDI E&LRGA ---- RRDLKVFGSFPKLIMT VSKSL VTRIFL AL
::;FFV LFPVAY': MVHLSK LGDLHEDYV CL : ---- FDEMHPFGDIP V S LGKSVHMS VFM AL
G L
GVASDVVRKVA-- VPLAPE-CSRAVKLVYCAXCRG --------- VPGARPCPDYC? VLKG.LA A-DLD
AVAiDVVSWVS--VV PTA -CTHALLKMIYCSE.CRG--------- LVTVKPCY YCS IMRGQLA G-DLD
ETGR VVSEAL--<VPMLEG-CR ALMRLIGPLCRG --------- VPSLMPRGF.L VAHGCLSSRG--LE
LGIEVI TTD--HLKFSKD-CGCMLTPMWYCSYC G--------- LMMOVKPCGGYC VVM GCMAGVV-EID
L AAEVLSEADALYGE LTDTCKLHLLKMHYCP C GHHSSSSET --- -KLCYGYC VMPGCSAEYAGLLD
T VS T R p
AEW: LLDSMVLITDKFWGP-SGAE VIGSVMMWLA--EAI AL D KDTLTAKVI GCG PKV---- PHGS
FEW FIDAMLMVAERLEGP-F IESVMDPIDVKIS--DAIM M D SV S KVF GCGPPKP----LPAGB
PEWGGYLDGLLLLAEKL GPFSF-ELAAESIGVKIS--EGLME-L E SVKVSAKVF ECGTPHPV SR RRAP
vYWl----EYILSLEELV GMYRIYDME VLLGLFSTIHDSI YV K GGKLTTTIGKLCAHS--- R YRSA
SPWSGVVDSL LVTTHILSDTGII VIKErL TYFS--EAIMAAMP GPELEKKVKFTCGTP --- SLTPYSS
PF R PPS V LT
GPEE.<-ý<G ---LAL EK--SSTGT---LEKLVSEAKA LRDI D----YWISLPGTL.SEKMAMSPASDD--
ISRSISESAF-- SARFRPYn-PE RPTTAAGTSLDRLVTDVKEKLK AKKFWSSLPSTVC DERMAAG E ED-
APREETERSWRSSAEEER--PTTAAGT LERLVWELRERLSRVRG ---- FWAGLPVTVCGDSRMAADLS EAA
YYPEDLFIDKKVLKVARVEHEETLS---SRB.--RELI KLKSFIS ----FYSALPGYICSHSPVAE DTL---
GEPDA:PPPPK V-KWATDPDPGMV------LFLSTIDKSKEFYT-------TIVD FCDE HSRDDFS---
MA R S9CW GIS-KGRYLPEVMGDGLA I PEVEVDITKPDMTIR IM LKIMIT RLRGAYGG----- DVDF D
DCW GKG-KSRYLFAVTG GLA G PEV VDTSKPDILILR IMALRVMTSKMK AY G----- DVDFFD
PCWTGVG-RGRYMSPVVVGSL E LH PEL--DTSSPDVPTRRRRLHLRAATAMKAA ALG ----- DLDMHD
-CW G ELVERYS KAXR GMbK F LHELKMKGPEPVVS IIDKLKHI LLRTMSVPKG----- KVVDSL
-CWSGDi-FGDYT LLI PGTDS RY PEVPF A-KA TGKL ELVDKLFFIRKSIGAAAPS SI ATHDI D
D L L K R SC
ASDDGSGSGSGGGCPDD--AGCRRVSKKSSSSRTPLTHALPGLSE EG-------------- KTSAATR--
ISDESSGEGSGSGCEY -- CPSEFEY ATD------HSGKSA EKAD----------------- SAGGA--
ADEDASGSGGG YADDWKAGAAPVVPPAPRPPRPPRPPRRDGLGVRGG--SGSARY GRSR LGSSVGL--
-DEEGLESGD---CGDDEDECIGS--SGDGMMKVK LRFLAELAYDLDVDDAPG K HG KD EITTSES
M GEGSGGGEG I-GDDEEEYGGAHGSGDGSGDGPHPIEESEGTTT EV--------- ESPDSGKTSGS--
PT L PL LF A TV
-------- PEPHYFF------------ LLFLFTLVLAAARPRWR*
--------.. AETKPY------------ LLAALCILFLAV GEWR*
-------- HAPRVFI------------ LLPSALTLL----- GLR*
VG MPSPLKILISVAIYVACFFSWCTDLPCPCLCCPAAPCGPPT*
-------- PLEGTA------------- TWMLLTLVTMLFSSCS*
R,K,H are :eu:.; E,D are red; F,W,Y,I,L,V,M are dark blue; S,T are cyan; Q,N are
C is black and underlined; G,A,P are black
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Figure 7. Southern analysis
10 p~g of rat genomic DNA was digested to completion with one of
three restriction enzymes, separated by electrophoresis, blotted to
nitrocellulose, and probed with an a 3 2P-dCTP labelled CBG probe.
Hybridization and subsequent washes were performed at high
stringency. The sizes of DNA standards are indicated. The restriction
enzymes used were HindIII (H), KpnI (K), and XhoI (X).
H1 n n
712f
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Figure 8. Northern analysis
:20 4tg of rat brain total RNA, isolated from embryonic day 18 (E18),
post-natal (PO), and adult (A) rats, was subjected to electrophoresis
through formaldehyde agarose and transferred to nitrocellulose.
Arrow: the 2.7 kb transcript detected with an a 32 P-dCTP labelled CBG
probe. Lower panel: reprobing of the blot with a GAPDH probe
demonstrated that a similar amount of RNA was present in each lane.
The positions of molecular weight markers and ribosomal RNA bands
are indicated.
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Figure 9. Comparison of mouse and rat cerebroglycan sequence
A mouse CBG cDNA fragment was isolated by PCR with the primers
OM13-165 and OCBG-137 and embryonic mouse brain cDNA. (A) The
sequence of the mouse CBG cDNA fragment (Mu) is shown compared
to the rat CBG (Rat) sequence. The numbers correspond to the
location of nucleotides in the rat CBG cDNA sequence shown in Figure
5. The primer sites of OM13-165 and OCBG-137 are indicated. (A):
the location of an intron in rat genomic CBG, discovered by the
fortuitous cloning of cDNAs from partially spliced CBG mRNA (see
Figure 12, and Results below). The primer sites of primers used to
amplify a mouse genomic CBG fragment for mapping CBG in the mouse
genome are enclosed by lines (see Results below). The primer site
upstream of the intron corresponds to primer muCBG-L, and the
primer site downstream of the intron corresponds to muCBG-R. (B)
The sequence of the deduced protein sequence of mouse CBG (Mu) is
shown compared to the corresponding sequence from rat (Rat). The
single amino acid substitution between the two sequences is shown
bold and underlined.
A
Mu ACTGGTGGCAGCCCGGGCCTTGGTCCAGGGTCTGGAGACTGGAAG
ocbg-137 I II II I I lI ll 11111
Rat(911) GCCTTGGTCCAGGGTCTGGAGACCGGAAG
AAATGTGGTCAGCGAAGCACTTAAGGTACCAGTGTTGGAAGGCTG
111111111111111111111111111111 1111111111111
940 AAATGTGGTCAGCGAAGCACTTAAGGTACCCATGTTGGAAGGCTG
CAGACAGGCCCTGATGCGTCTGATTGGCTGCCCTCTTTGTCGGGG
111111111111 ll1lill1ll 11111111 11111111111
985 CAGACAGGCCCTCATGCGTCTGATCGGCTGCCCACTTTGTCGGGG
AGTTCCTTCACTTATGCCCTGCCGGGGCTTCTGCCTCAATGTAGC
III II II IIIlI illllIlltIIlIII IIllllIllI II
1030 AGTACCCTCGCTTATGCCCTGCCGGGGCTTCTGCCTCAATGTGGC
CCATGGCTGCCTCAGCAGTAGGGGACTGGAGCCTGAATGGGGCGG
1075 CCACGGCTGTCTCAGCAGCAGGGGATTGGAGCCTGAATGGGGCGG
ATATCTGGATGGTCTCCTGCTGCTGGCTGAGAAACTCCAAGGACC
111111111111111111 1111111111111111111I 11111
1120 ATATCTGGATGGTCTCCTGCTGCTGGCTGAGAAACTCCAGGGACC
CTTTTCCTTTGAACTGGCTGCTGAGTCCATTGGGGTGAAGATCTC
II111111111 II IIIlIIIIIIIIlII IIllll lllli
1165 CTTTTCCTTCGAGCTGGCTGCTGAGTCCATAGGGGTGAAGATCTC
AGAAGGTTTGATGCACTTACAGGAAAACAGTGTAAAGGTGTCAGC
111111111111111111 11111111111 11111111111111
1210 AGAAGGTTTGATGCACTTGCAGGAAAACAGTGTAAAGGTGTCAGC
GAAGGTGTTTCAGGAATGTGGGACGCCTCA Mu
II IlIlIII oml3-165
1255 CAAGGTGTTTCA Rat
B
Mu : ALVQGLETGRNVVSEALKPPVLEGCRQALMRLIGCPLCRGVPSLM
Rat: 2 2 6 ALVQGLETGRNVVSEALKPVLEGCRQALMRLIGCPLCRGVPSLM
PCRGFCLNVAHGCLSSRGLEPEWGGYLDGLLLLAEKLQGPFSFEL
271 PCRGFCLNVAHGCLSSRGLEPEWGGYLDGLLLLAEKLQGPFSFEL
AAES IGVKISEGLMHLQENSVKVSAKVF
316 AAESIGVKISEGLMHLQENSVKVSAKVF
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Figure 10. Isolation of human cerebroglycan and K-glypican cDNA
fragments. Putative human CBG and K-glypican cDNA fragments were
isolated by PCR using a nested set of primers. The four primers
gdoL1, gdoL2, gdoR2, and gdoR3, were based on highly conserved
protein sequences in CBG, glypican, and K-glypican. (A) The protein
sequences upon which PCR primers were based. The sequences
represent the consensus sequence of CBG, glypican, and K-glypican;
numbered amino acids refer to the location of the amino acid in the
rat CBG protein sequence as shown in Figure 5. The arrows indicate
the directionality of the primers. See Materials and Methods for
details of the PCR reactions. The cDNA and deduced protein
sequences of human and rat CBG and human and rat K-glypican are
compared in (B) and (C) respectively. Both human cDNA sequences
are 81% identical to their rodent counterparts. The predicted
protein sequence of the human K-glypican fragment is 78% identical
to the mouse protein sequence, and the predicted protein sequence of
the human cerebroglycan fragment is 87% identical to the rat protein
sequence.
A
PO (G/D/E) YTCC 69-+ .. FWA (O/R) LLE1 72->. .
gdoLl gdoL2
. . . --
218TRA(F/L)VAAR. , <--341KV(I/F)O(G/E)CG
gdoR3 gdoR2
B
173R A F P L L H P Q Y S F P P D
rCBG 752AGAGCCTTCCCTTTGCTGCACCCACAATACAGTTTCCCTCCTGAT
II lI II ll 1111111111111 IIIll 11111 1111 I
huCBG AGAGTGTTCCCGCTGCTGCACCCACAGTACAGCTTCCCCTGAC
R y F P L L H P Q Y S F P P D
E L L C L T R L I S T A D G S
rCBG TTCCTGCTCTGCCTTACTCGGCTCACTTCAACTGCTGATGGCTCT
I I I I I I I I l l I I I I I I I l l I I I I I 1 1 Il 
huCBG TACCTGCTCTGCCTCTCACGCTTGGCCTCATCTACCGACGGCTCT
X L L C L S R L A S S T D G S
L Q P F G D S P R R L R L Q I217
rCBG CTCCAGCCCTTCGGGGACTCGCCCCGCCGCCTCCGCCTACAGATA
11 11111111 11111111 11111111111llllllllll 111111
huCBG CTGCAGCCCTTTGGGGACTCACCCCGCCGCCTCCGCCTGCAGATA
L Q P F G D S P R R L R L Q I
C
171R M F R L Y N a Q X H F 1 1 E
mKglyp 980CGCATGTTTCGCCTGGTGAACTCCCAGTACCATTTACAGATGAG
IlIlI llill I ll I Ill I I ll II II I 1 I
hKglyp CGGATGTTTCAGCTGATAAACCCTCAGTTACACTTCAGTGAAGAC
R M F Q L _ N E Q L H F J
Y L E C V S K Y T E Q L K P F
mnKglyp TACTTGGAATGTGTGAGCAAATATACAGAGCAGCTGAAGCCTTTT
Ill II III lIIII ll ll II II 11111111 11111 III
hKglyp TACCTGGAATGTGTGAGCAAATACACTGACCAGCTCAAGCCATTT
Y L E C V S K Y T Q Q L K P F
G D V P R K L K L Q V T R A E215
nmKglyp GGAGATGTCCCTCGGAAACTGAAGCTCCAGGTTACCCGCGCATTT
1 1 1 1 1 1 1 I I 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 I
hKglyp GGAGACGTGCCCCGGAAACTGAAGATTCAGGTTACCCGCGCCCTC
G D V P R K L K I Q V T R A L
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Figure 11. Partial restriction map of the cerebroglycan genomic locus
Overlapping CBG genomic clones were isolated by screening a mouse
genomic DNA library with fragments of the rat CBG cDNA, as
described in the text. A partial restriction map of the clones is shown.
The locations of the intron/exon boundaries, determined by
sequencing the clones, are indicated. This figure was courtesy of
Scott Saunders.
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Figure 12. Sequence of cDNA from partially unspliced CBG mRNAs
Two of the cDNA clones isolated from the primer extended rat brain
cDNA library (see Materials and Methods) were eventually shown to be
complementary to partially unspliced CBG mRNAs. (A) The combined
sequence of the clones. Splice donors and splice acceptors are shown
in bold italics. Coding sequence is underlined, and the translation is
shown. The numbers refer to the position of the amino acids in the
CBG protein sequence as shown in Figure 5. (B) Comparison of the 3'
splice acceptor upstream from va1244 to the 3' splice acceptor
consensus sequence (Mount, 1982). The invariant AG nucleotides are
bold. Of the 12 pyrimidines in the consensus sequence, 8 have been
substituted with purines in the endogenous splice acceptor.
A
GGTAATCCCACAAACGCAACCTCCACTCCAGTCCTGACTAACTGATAATCA
TTTTTGTGGGTTCGTTTTGTTTTGTTTTGTTTTTCTTTCTCATCTTCTTTC
CCTCCAGATAACCCGGGCACTGGTGGCAGCCCGGGCCTTGGTCCAGGGTCT
217I T R A L V A A R A L V Q G
GGAGACCGGAAGAAATGGTCAGCGAAGCACTTAAGGTTAGAGGGGTCCT
L E T G R N V V S E A L K243
GAATATGGACAGAGCCCAGGAAGTAAAGAAGACAGACACCAGCTGGCAGGA
GAGGCCTAGAGCTGTCTCTTACTTGTTCCTGGGCTCTGGTGCTCCAGAGGA
CATCTGGAAGGGAGGCCAAAGTCAGGCCTCCACGGGGTGTCTGACATGATC
TCCTGGGATTTCTGGTCTTCCCTCTGGTGACGCACATGCCTTCTGCTAGTC
TTTCCATAGCAGTTCAAGATTGTAGTGAACCCCTCAGTGCCCCTCCCTCCT
CCCAAAAGGCCTCTCTTCATCACTGGTCCTGTCCCTAGCCTCACCTCTCAC
CTCCTTCCTCTCTCCTCAGCCTGGACTCACTCTTGCCCCTGAATCTTTCCT
CACTACATCCTCCTCAGTAACACCCTAGTCAAACCCCTCTCATGAAGCAGA
ATCAGCAACCTTTTCTCTAGGTACCCTCCTTCTCAGTCCTGTATCACCGGG
TGCCACATGGGGTCACCAGCCACAGTTGCTCATATCCAGCTTCCAACAGAT
AGCCTGGGGAGGTACCCATGTTGGAAGGCTGCAGACAGGCCCTCATGCGTC
244V P M L E G C R Q A L M R
TGATCGGCTGCCCACTTTGTCGGGGAGTACCCTCGCTTATGCCCTGCCGGG
L I G C P L C R G V P S L M P C R
GCTTCTGCCTCAATGTGGCCCACGGCTGTCTCAGCAGCAGGGGATTGGAGC
G F C L N V A H G C L S S R G L E
CTGAATGGGGCGGATATCTGGATGGTCTCCTGCTGCTGGCTGAGAAACTCC
P E W G G Y L D G L L L L A E K L
AGGGACCCTTTTCCTTCGAGCTGGCTGCTGAGTCCATAGGGGTGAAGATCT
Q G P F S F E L A A E S I G V K I
CAGAAGGTTTGATGCACTTGCAGGAAAACAGTGTAAAGGTGTCAGCCAAGG
S E G L M H L Q E N S V K S A K V
TGTTTCAGGAATGTGGGACGCCTCA ....
F Q E C G T P H3 5 0 ...
B
TTTTTTTTTTT.TAG CONSENSUS 3'
CCCCCCCCCCC SPLICE ACCEPTOR
AGATAGCCTGGGGAG ENDOGENOUS 3'
SPLICE ACCEPTOR
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Figure 13. Partial exon organization of cerebroglycan
The location and relative size of the CBG exons identified so far are
shown schematically. Exons I and II were identified by sequencing of
CBG mouse genomic clones, and exon q was identified by sequencing
of fortuitously isolated, partially unspliced CBG rat cDNA fragments
(see Figure 12). The exon structure of the remaining regions, shown
by broken line, has not been determined. Structural features: shaded
regions indicate putative signal sequence (in exon I) and GPI cleavage
and addition signal (near carboxy terminus); arrows show the location
of conserved cysteine residues (C); "lollipops" indicate the location of
potential glycosaminoglycan (GAG) attachment sites. One potential
ser- gly GAG attachment site is split between exons I and II and is not
shown.
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Figure 14. Single stranded conformational polymorphism in B6 and
spretus mouse genomic CBG loci. Genomic CBG DNA fragments from
B6 (C57B16, Mus musculus) and spretus (Mus spretus) mice were
isolated by PCR (see text for details). Electrophoresis of the 32p-
dCTP-labelled fragments on a strand separating gel identified a single
stranded conformational polymorphism (SSCP) in the B6 and spretus
genomic CBG loci. The figure shows an example of a gel scoring the
SSCP in genomic DNA samples from the test cross NCI-Frederick #77-
122 (B6 X spretus) X B6. Numbers refer to DNA samples from
different animals from the test cross; "B" is the B6 pattern, and "S" is
the spretus pattern. Samples were scored as "b", the B6 pattern; "h"
the heterozygous B6 X spretus pattern; or "x" ambiguous. Samples
with a low yield in the PCR reaction were typically scored as
ambiguous since the presence or absence of a unique band in the (B6 X
spretus) pattern was the basis of the SSCP, and this band was difficult
to discern in low yield samples. Subsequent rounds of SSCP analysis
often resolved these amibiguities.
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Table 2 Genomic Mapping of Cerebroglycan
A single stranded conformational polymorphism (SSCP) in the
cerebroglycan loci of B6 and Spretus mice was used to map
cerebroglycan in the mouse genome. PCR reactions were performed
with genomic DNA of animals from the NCI-Frederick test cross (#77-
122), a (B6 X Spretus) X B6 test cross. a 3 2 P-dCTP labelled PCR
products were analyzed on a strand separating gel, and the SSCP was
scored either as B6 or heterozygous (het.); (n.c.) = no call possible,
ambiguous. The data shown above was analyzed with the program,
Mapmaker, resulting in the assignment of cerebroglycan to the distal
end of mouse chromosome 5 (see text for details).
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B6
het.
n.c.
het.
het.
B6
het.
n.c.
n.c.
n.c.
n.c.
n.c.
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CHAPTER 3
EXPRESSION OF CEREBROGLYCAN mRNA AND PROTEIN IN THE
DEVELOPING NERVOUS SYSTEM
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INTRODUCTION
The major stages of neural development -- neurogenesis, cell body
migration, axon outgrowth, and synaptogenesis -- all have the potential
to be regulated by cell surface heparan sulfate proteoglycans (HSPGs).
For example, FGF-1 and FGF-2 are expressed at several locations in
the developing nervous system, including the ventricular zone and
cortical plate of the developing rat cerebral cortex (Gonzalez et al.,
1990; Fu et al., 1991; Wilcox and Unnerstall, 1991). The activity of
these molecules, which have been shown to stimulate proliferation and
survival of neural cells in vitro (Walicke et al., 1986; Unsicker et al.,
1987; Walicke, 1988; Murphy et al., 1990; Hughes et al., 1993),
appears to require or at least to be greatly potentiated by the presence
of cell surface heparan sulfate (Rapraeger et al., 1991; Yayon et al.,
1991; Olwin and Rapraeger, 1992; Ornitz and Leder, 1992; Kan et al.,
1993). Immature cortical neurons migrate from the ventricular zone
to the cortical plate along radial glial fibers. The extracellular matrix
molecule fibronectin (FN), which is found closely associated with
these fibers, (Sheppard et al., 1991) is known to bind to heparin and
HSPGs, and a recent study has shown that neural cells can use a cell
surface HSPG to attach and spread on a peptide from the FN heparin-
binding domain (Haugen et al., 1992). Many cortical neurons
subsequently extend axons through the underlying layers containing
FN, laminin-1 (LN-1), and laminin-3/S-laminin (LN-3) (Sheppard et
al., 1991; Hunter et al., 1992), all of which have heparin-binding
domains, and LN-3 is present at the synaptic cleft of neuromuscular
junctions (Sanes et al., 1990), and appears to be important for
formation and maintenance of proper synaptic structure (Noakes et al.,
1995; Porter et al., 1995). Thus there are many potential ligands and
many potential roles for cell surface HSPGs in the development of the
nervous system.
Evidence that individual HSPG core proteins can participate in
distinct developmental events has come from studies of expression of
the syndecan family of HSPGs in non-neural tissues. For example, in
several embryonic epithelial structures, syndecan-1 expression is lost
during morphogenesis and re-expressed in the mature, stable
epithelium. Conversely, the mesenchymal cells underlying the
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embryonic epithelia are initially negative for syndecan-1, but become
syndecan-positive when they proliferate and condense around
epithelium undergoing morphogenesis, only to lose expression again
upon terminal differentiation (Trautman et al., 1991; Bernfield et al.,
1992) Thus syndecan-1 may play two distinct roles during epithelial
morphogenesis: its expression in epithelial cells is consistent with a
role in the maintenance of a stable epithelial structure, while its
expression in mesenchymal cells correlates with proliferation and
differentiation. Studies demonstrating that syndecan-1 acts as a
receptor for extracellular matrix molecules and, potentially, for
growth factors such as FGF-2, point to possible mechanisms of
syndecan function during development (Saunders and Bernfield, 1988;
Kiefer et al., 1990; Bernfield and Hooper, 1991; Sanderson et al.,
1992a).
Comparison of the patterns of syndecan-1 and syndecan-3
expression during development suggests an additional level of
specificity in the roles of the syndecans during embryogenesis. Both
molecules are expressed in distinct temporal and spatial patterns, that
are often reciprocal. For example, syndecan-1 is expressed in the
early neurectoderm (Sutherland et al., 1991), but then disappears,
while syndecan-3, is expressed later in the embryonic central nervous
system, including in the floor plate of the developing spinal cord
(Gould et al., 1995), and becomes highly expressed in the brain
around the day of birth, decreasing again in the adult brain (Carey et
al., 1992). Thus the different members of the syndecan family may
fulfill distinct roles during the development of a single tissue type.
Recently, the glycosylphosphatidylinositol (GPI)-anchored HSPG
glypican has also been shown to be expressed in a restricted pattern
that varies during development. In the developing bone, for example,
glypican appears to be expressed in differentiated osteoblasts, the
cells that deposit the bone matrix replacing the cartilaginous model
during osteogenesis. However, chondrocytes in the developing bone
do not appear to express glypican (Litwack, 1995).
In the early rat nervous system, glypican is initially highly
expressed in the ventricular zones containing proliferating neuronal
precursor cells (Litwack, 1995). At later stages, glypican expression is
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widespread in the developing nervous system, but by adulthood,
glypican expression has become restricted in the brain (Litwack et al.,
1994). Many adult rat brain structures that retain glypican expression
are populated by projection neurons (e.g. the dorsal thalamus, and
layers II, III, V, and VI of the cerebral cortex) (Litwack et al., 1994).
Preliminary experiments with whole brain extracts indicated that
cerebroglycan (CBG) protein and mRNA expression are limited to
development. To determine whether CBG's expression pattern
correlates with any of the known events in nervous system
development, we performed CBG in situ hybridization and
immunolocalization experiments on rat embryos of several
developmental stages. Surprisingly, CBG expression was found to be
restricted to the nervous system, making it the first tissue specific PG
to be identified. Close examination of CBG mRNA expression in
several neural structures strongly suggests that CBG is transiently
expressed by immature neurons, appearing around the time of their
final mitosis and vanishing after cell body migration and axon
outgrowth have been completed. Immunolocalization experiments
revealed that the CBG protein is particularly abundant in the axon
tracts of the developing rat brain.
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MATERIALS AND METHODS
In Situ Hybridization Protocols
In situ hybridization to rat embryos and neonates
Freshly dissected rat embryos were quick-frozen in isopentane on
dry ice and stored at -800C. PO rats were anaesthetized on ice and
decapitated; the heads were quick-frozen in isopentane on dry ice and
stored at -800C. P7 rats were anaesthetized with metofane and
decapitated. The brains were dissected out and quick-frozen as
described above. Prior to sectioning, samples were equilibrated to
-200C and embedded in OCT medium. 12-20 gm cryostat sections
were collected on gelatin-subbed slides or on Probe-On Plus slides
(Fisher Biotech; Pittsburgh, PA) and stored at -800C with dessicant.
Sections were equilibrated to room temperature, fixed in 4%
paraformaldehyde in PBS at room temperature for 5 min, and washed
twice in 2X SSC.
Riboprobes were synthesized using an RNA Transcription Kit
(Stratagene, Cat. # 200340). T7 or T3 RNA polymerase was used in
reactions with 3 5 S-UTP (DuPont, NEN), and linearized CBG templates.
The templates consisted of pBluescript subclones of the 301 bp SacI
fragment or the 223 bp ApaI/KpnI fragment of the M13-A CBG cDNA.
Probes made with the SacI fragment (from CBG coding region) and the
ApaI/KpnI fragment (from the 3' untranslated region) gave identical
results.
Prehybridization treatments, hybridization, and post-hybridization
washes were performed according to Simmons et al. (Simmons et al.,
1989), except that the proteinase K step was omitted. After
hybridization, sections were exposed to hyperfilm ~max (Amersham;
Arlington Heights, IL) for 5 to 7 days at -800C. Selected sections were
dipped in Kodak NTB-2 liquid emulsion that had been diluted 1:1 in
ddH2 0, and exposed for 12-21 days at -800C. Developed sections were
stained in Hoechst 33258 (bisbenzimide) at 1 gg/ml in ddH20 or
cresyl violet (0.5% in ddH20), and examined by fluorescence, bright
field, and dark field illumination on a Zeiss Axiophot microscope, or a
Nikon Diaphot microscope.
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In situ hybridization to mouse olfactory epithelium(OE) and OE
explants
Freshly dissected embryonic day 15 mouse embryos were
decapitated, and the heads were fixed overnight at 40C in freshly
prepared 4% paraformaldehyde in phosphate buffered saline (PBS).
To cryoprotect, the fixed heads were transferred to a fresh tube with
5% sucrose in PBS and stored overnight at 40C. The heads were then
transferred to 15% sucrose in PBS and stored overnight at 40C.
Finally, the heads were transferred to fresh 15% sucrose in PBS and
stored at 40C until sectioning.
Cryoprotected heads were gradually frozen in OCT mounting
medium and horizontal cryostat sections 20 p± thick were prepared
and collected on ProbeOn Plus slides (Fisher Biotech). Sections were
stored at -85oC with dessicant until in situ hybridization.
Sections were thawed in an EZ Breeze air dryer (Hoeffer) without
heat until dry, and post-fixed for 2 hours in fresh 4%
paraformaldehyde at 40C. After three 5 minute washes in PBS with
0.1% Tween-20 (PBT), sections were bleached for 90 minutes at room
temperature in 5:1 (V/V) methanol (MeOH): 30% H202, and stored
overnight at -200C in absolute methanol.
Sections were rehydrated by washing 5 minutes each in (1) 75%
MeOH/25% PBT, (2) 50% MeOH/50% PBT, (3) 25% MeOH/75% PBT,
(4) PBT, and (5) PBT. Sections were permeabilized by treating with
proteinase K (Boehringer Mannheim) at 10 gg/ml in PBT for 5
minutes at room temperature. Sections were next fixed for 5 minutes
at room temperature with 4% paraformaldehyde, 0.2% glutaraldehyde
in PBS, rinsed twice with PBT, and treated with 0.1% fresh sodium
borohydride in PBT for 20 minutes at room temperature.
Sections were pre-hybridized in hybridization buffer (HB): 50%
formamide, 5X SSC pH 4.5, 50 gg/ml yeast RNA, 1% SDS, 50 gg/ml
heparin, for 90 minutes at 60oC. Digoxigenin (DIG)-labelled
riboprobes were applied in HB at a concentration of 1 gg/ml, and
sections were coverslipped and incubated overnight at 600C in a
humid oven. Probes were synthesized from linearized templates
consisting of the muCBG-1 mouse CBG cDNA fragment (Figure 9
Chapter 2), subcloned into pCR1000 (Invitrogen) or pBluescript
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(Stratagene). The Genius RNA Labeling Kit (Boehringer Mannheim)
was used to synthesize the probes and estimate probe concentrations.
After hybridization, non-specific probe was removed by the
following treatments: (1) two 15 minute washes at 60oC in 50%
formamide, 5X SSC pH 4.5, 1% SDS; (2) two 5 minute washes in 0.5
M NaCI, 10 mM Tris-HC1 pH 7.5, 0.1% Tween-20; (3) a 40 minute
treatment 100 tg/ml RNase A in the same buffer as (2) above at 370C;
(4) a 5 minute wash in Tris buffered saline (pH 7.4) with 0.5% Tween-
20 (TBST) at room temperature, and a 60 minute wash in 50%
formamide, 2X SSC pH 4.5 at 60oC.
Sections were prepared for DIG immunohistochemistry by three 5
minute washes in TBST, followed by a 60 minute blocking step in
TBST with 10% heat-inactivated normal goat serum (HI-NGS).
Alkaline phosphatase conjugated, goat anti-DIG antibody Fab fragments
(Boehringer Mannheim) were pre-adsorbed with 10 mg/ml mouse
brain acetone powder (Sigma) in 1% HI-NGS, 2 mM levamisole
(Sigma), in TBST. The pre-adsorbed Fab fragments were applied to
the sections at a final concentration of 0.3 gg/ml in TBST, 1% HI-
NGS, with 2 mM levamisole and allowed to bind overnight at 40C.
Hybridized probe was detected by (1) washing five times, 10
minutes each in TBST with 2 mM levamisole; (2) washing three times,
10 minutes each in 0.1 M NaCl, 0.1 M Tris-HCl (pH 9.5), 50 mM
MgCl2, 1% Tween-20, and 2 mM levamisole (NTMT); (3) incubating
with NBT/BCIP (Nonradioactive Nucleic Acid Detection Kit,
Boehringer Mannheim) in NTMT with 2 mM levamisole until color
had developed.
For postnatal day 15 mouse, heads were dissected, the lower jaws
were removed, and the remainder was fixed as described above.
Muscle and bone overlying the OE were partially removed by further
dissection, and the heads were cryoprotected and processed for in
situ hybridization essentially as described above.
For OE explants, OE was isolated as described below from
embryonic day 14/15 mice, and plated on merosin coated coverslips.
At set times after plating, coverslips were fixed and processed for in
situ hybridization essentially as described above. For NCAM
riboprobes, a 391 bp EcoRI/Bcl I fragment from the coding region of
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the mouse NCAM cDNA was subcloned into the EcoRI and BamHI
cloning sites of pGEM. DIG-labelled NCAM riboprobes were
synthesized from linearized templates as described above, using SP6
or T7 RNA polymerase.
Tissue Culture Protocols
Olfactory epithelium explant culture
OE was dissected from E14/E15 mouse animals and purified as
previously described (Calof and Chikaraishi, 1989). Finely chopped
pieces of OE were cultured on laminin or merosin coated coverslips in
serum-free, low calcium (0.1 mM Ca 2 +) Dulbecco's modified Eagle's
medium supplemented with 5 mg/ml BSA, 10 ýtg/ml insulin, 10 ýtg/ml
transferrin, 20 nM progesterone, 100 gM putrescine, and 30 nM
selenium, as described (Calof and Chikaraishi, 1989; Calof et al.,
1991a).
Establishment of ?Y2, 3T3 cell and PC12 cell CBG expression lines
P2 cells were maintained at 8% CO02 in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% iron-supplemented calf
serum (FeSCS), glutamine, and penicillin/streptomycin. A CBG
expression vector, pLNCX-CBGA3', was constructed by subcloning the
1835 bp Eag I/Nar I restriction fragment of the full length CBG cDNA
into the cloning site of the pLNCX retroviral expression vector (Miller
and Rosman, 1989)(see Figure 9 for the cloning strategy). This
fragment is missing most of the 3' untranslated region of the CBG
cDNA. pLNCX uses a CMV promoter to drive expression of the
transgene, and the 5' LTR to drive expression of a neomycin
resistance gene.
'Y2 producer cell lines were made by transfecting '2 cells with
pLNCX-CBGA3' using the lipofectamine reagent (Gibco BRL) according
to manufacturers directions. Conditioned medium from the
transfected '2 cells was used to infect '2 cells treated with 200
ng/ml tunicamycin and 8 gLg/ml polybrene, creating stable, virus
producing, infected cell lines. Individual lines were selected by
growth in 1mg/ml G418 (Gibco BRL), and isolation of individual
colonies with cloning rings.
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3T3 cells were maintained identically to P2 cells. 3T3 cell lines
expressing CBG were generated by infecting 3T3 cells with
conditioned medium, containing 8 ig/ml polybrene, from P2
producer cell lines. Infected cells were selected by growth in 1
mg/ml G418 and maintained as an uncloned population by growth in
0.5 mg/ml G418. This population of cells was designated
3T3infuCBGA3'
PC12 cells were grown at 8% CO2 in RPMI with 10% heat-
inactivated horse serum (JRH), 5% fetal calf serum, glutamine, and
penicillin/streptomycin. PC12 cells were grown on Vitrogen
(Celltrix), coated plates (1:100 dilution of Vitrogen in PBS to coat
plates for 21 hour at 370C). Cells expressing CBG were generated as
with 3T3 cells, and maintained as an uncloned population
(PC 12infuCBGA3')
CBG Immunohistochemistry and Immunofluorescence
A rabbit polyclonal antiserum was raised against a peptide
(CRPPRPPRPPRRDGL) based on amino acids 521-535 of the CBG
protein sequence as shown in Figure 5, Chapter 2. The peptide
(designated "521") was coupled to keyhole limpet hemocyanin (KLH)
(Pierce) with the cross-linker sulfo-SMCC (Pierce). Rabbits were
injected intradermally with 2.5 mg of the KLH-521 in complete
Freund's adjuvant and boosted two times intramuscularly with an
additional 2.5 mg in Freund's incomplete adjuvant. Anti-521
antibodies were purified from serum using an affinity column of
peptide 521 coupled to Sulfo-link gel (Pierce). This antibody was
designated 521-2.
E13.5 mouse embryos, E13 rat embryos, and E19 rat heads were
processed for cryosectioning essentially as described above for OE in
situ hybridization experiments. For immunohistochemistry, sections
were incubated in block (2% BSA, 100 mM Tris-HC1 pH 7.4, 0.15 M
NaCl, 0.3% TritonX-100), and then washed twice in Tris-buffered
saline (TBS), twice for 30 minutes in 0.3% H202, and once more in
TBS. 521-2 was applied at 2.5 gg/ml in block and allowed to bind
overnight at 4oC. After washing in TBS, a biotin-conjugated goat-anti
rabbit secondary antibody (Vector) was applied at 1:300 in block and
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allowed to bind 4 hours to overnight at 40C. Sections were washed in
TBS and incubated in ABC reagent (Vector) diluted in block, washed
again and then developed in 50 gg/ml DAB, 0.3% H202, 50 mM Tris
pH 7.4. Sections were washed in H20, dehydrated through xylenes,
and coverslipped in Permount. Some sections were counterstained in
methyl green.
3T3infuCBGA3' cells and PC12infuA3' cells were grown on LN or
FN-coated coverslips (proteins were coated at 20 pg/ml in PBS
overnight at 40C.). Cells were rinsed once in pre-warmed DMEM or
RPMI and then fixed for 10 minutes at room temperature in 4%
paraformaldehyde. After 20 minutes in block (as above), 521-2 was
applied at 5 ig/ml in block and allowed to bind for 60 minutes at
room temperature. Coverslips were rinsed 3 times with TBS, and a
Cy-3 conjugated goat-anti-rabbit secondary antibody (Jackson
Immunoresearch) was applied in block at a 1:100 dilution. Hoechst
33258 was added with the secondary antibody at 2.5 gg/ml to stain
nuclei. After a 40 minute incubation at room temperature, coverslips
were washed 3 times in TBS and mounted in Aquamount.
Isolation of 3T3 Cell PG Fractions
Freshly confluent plates of 3T3 cells and 3T3infuCBGA3' cells were
harvested by scraping into homogenization buffer A (see Chapter 2
Materials and Methods, Purification and protein sequencing of PO rat
brain HSPGs). Membrane-associated PGs were isolated essentially as
described in Chapter 2. PGs were re-bound to DEAE-Spectragel
(Pharmacia) and iodinated on the beads as previously described
(Herndon and Lander, 1990). 1 2 5 I-labelled PGs were digested with
chondroitinase ABC and/or heparitinase as described (Herndon and
Lander, 1990) and analyzed on SDS-PAGE minigels.
For immunoprecipitation experiments, 3.9 X 106 cpm aliquots of
1 2 5 I-labelled PGs from 3T3 cells and 3T3infuCBGA3' cells were either
treated with chondroitinase ABC and heparitinase, or were treated
with neither enzyme in a mock digest. The PGs, in a volume of 75 l1,
were diluted to 500 il in TBS with 0.5% CHAPS, along with 20 4l
(packed volume) of protein A sepharose beads (Sigma). The PGs were
precleared for 40 minutes with rotation at 40 C. After centrifugation
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to pellet the beads, the supernatants were transferred to a fresh tube
along with 6.75 tg of affinity purified 521-2 anti-CBG antibody. The
immune complexes were collected with another 20 Cl of protein A
sepharose beads after an overnight binding step at 4oC. The beads
were washed with (1) TBS, 0.5% CHAPS for 30 minutes at room
temperature with rotation, (2) 0.5M NaCI, 50 mM Tris-HCI (pH 7.4),
0.5% CHAPS for 20 minutes at room temperature, and (3) 50 mM
Tris-HCI (pH7.4), 0.5% CHAPS briefly at room temperature. The
beads were counted in a y-counter, demonstrating that while an
average of 16,000 cpm had been collected in immunoprecipitates
from parental 3T3 cells, an average of 375,000 cpm had been
collected immunoprecipitates from 3T3infuCBGA3' cells. The protein
A-sepharose beads from the 3T3infuCBGA3' immunoprecipitations
were boiled in SDS-PAGE loading buffer and the supernatants analyzed
on SDS-PAGE minigels along with the diagnostic digests of labelled
PGs from the two cell lines.
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RESULTS
Developmental expression of cerebroglycan
The CBG core protein is observed in the membrane fraction of
embryonic day 18 (E18) and newborn (PO) rat brain, but not in the
adult (Herndon and Lander, 1990). As shown in Chapter 2, the CBG
mRNA is expressed in a similar pattern. To localize CBG expression in
the developing animal, in situ hybridization was performed. The 306
bp SacI or the 223 bp ApaI-KpnI pBluescript subclones of the CBG
cDNA, M13-A (Figure 4, Chapter 2), were used to generate a 3 5S-UTP
labelled RNA probes. Figure 1 shows the results obtained when these
probes were hybridized to fresh-frozen sections of embryonic day 14
(E14), 16 (E16), and 19 (E19), and newborn (PO) animals. The
results are presented as "reverse contrast" images, printed directly
from autoradiograms of the sections.
In E14 and E16 animals (Panels B and D of Figure 1), strong CBG
expression occurs along the entire neuraxis, including the brain,
spinal cord, dorsal root ganglia, and cranial nerve ganglia. No
expression in any non-neural tissue could be detected. By E19 (Figure
1, panel F), expression in the spinal cord and dorsal root ganglia is
dramatically lower than in the many regions of the brain that still
express high levels of CBG message, including the cerebral cortex,
hippocampus, corpus striatum, inferior colliculus, and pontine nuclei.
As at earlier stages, hybridization to non-neural tissues was not above
background. In the PO head (Figure 1, panel I), expression persists in
the cerebral cortex, hippocampus, striatum, inferior colliculus, and
cerebellar cortex, but only weak expression if any is seen elsewhere in
the brain. Again, expression was not observed outside the nervous
system. Panel G shows an example of the results obtained when the
opposite strand control probe was hybridized to a nearly adjacent
section (in this case, in the E19 animal). No hybridization above
background was observed in any tissue.
As Figure 1 illustrates, CBG is globally expressed in the nervous
system at early stages. As neural development proceeds, expression is
selectively lost from certain structures while remaining in others. A
closer examination of the pattern of expression suggested that CBG
mRNA remains in structures for several days after neurogenesis--the
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production of post-mitotic neurons--has ended (see Discussion). This
raised the possibility that CBG expression might be associated with
neuronal precursors and/or immature neurons.
To more accurately examine the relationship between CBG
expression and neuronal development, in situ hybridization was
carried out using sections of postnatal day 7 (P7) brain. At this age,
the generation and early development of neurons has finished in most
of the brain, but persists in three late-developing areas: the external
granule layer of the cerebellum, the dentate gyrus of the hippocampus,
and interneurons of the olfactory bulb (Jacobson, 1991). As shown in
Figure 2, CBG is expressed at this stage in precisely these three areas:
the folia of the cerebellum, the dentate gyrus of the hippocampus, and
the olfactory bulb. As with the earlier experiments, no hybridization
with the opposite-strand control probe was detected (not shown).
A higher magnification view of the cerebellum (Figure 3A) reveals
that CBG-expressing cells are found in the external granule layer
(EGL), the zone in which granule cells (cerebellar interneurons) are
generated and undergo intitial stages (-28 hours) of development
(Fujita, 1967). In contrast, the internal granule layer (IGL), which
contains mature granule cells, was essentially devoid of hybridization.
A higher magnification view of the olfactory bulb (not shown) revealed
that CBG-expressing cells are localized to the subventricular zone, the
site of postnatal production of olfactory bulb interneurons [granule
cells and periglomerular cells (Luskin, 1993)]. In contrast, layers
containing mature olfactory bulb neurons were devoid of CBG
hybridization (these layers lie anterior to the indicated region of
hybridization in Figure 2, and were visualized by Hoechst 33258
fluorescence [not shown]).
These results suggest that, at least in these tissues, expression of
CBG is restricted to an early stage in the development of neurons. An
indication of how early CBG appears can be obtained by examining the
distribution of cells within the external granule layer of the
cerebellum. As shown in figure 3A, CBG-expressing cells are strongly
concentrated within the deeper half of the external granule layer, the
so-called premigratory zone (Fujita, 1967). This zone consists of
newly generated, post-mitotic neurons, whereas the superficial half of
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the external granule layer contains the proliferating cells that give rise
to those neurons. This result indicates that CBG expression begins in
neurons at or about the time they become post-mitotic.
To further test this hypothesis, in situ hybridization was used to
examine CBG expression in the embryonic day 12 (E12) spinal cord.
At this stage, the spinal cord consists of a large central proliferative
zone (the ventricular zone), from which newly post-mitotic neurons
migrate laterally to form the nascent ventral and dorsal horns (Altman
and Bayer, 11984). As Figure 3B illustrates, CBG is strongly expressed
by regions of the E12 spinal cord that contain post-mitotic neurons,
but weakly expressed, if at all, by the still-proliferating neural
precursors of the ventricular zone. In addition, expression can be
seen in the dorsal root ganglia (DRG) located on either side of the
spinal cord. These structures also contain recently post-mitotic
neurons (Altman and Bayer, 1984), the progeny, in this case, of neural
crest cells.
Immunolocalization of CBG protein in the developing nervous system
CBG in situ hybridization experiments in the P7 cerebellum showed
that, in that structure, CBG mRNA expression colocalizes with a
population of neurons that are undergoing axon outgrowth and cell
body migration. In the PO cortical plate, which is also CBG positive,
neuronal cell bodies are, as a population, in their final locations.
However, the process of axon outgrowth by these cells is still
incomplete alt this stage. Thus the question of whether CBG
expression correlates best with cell body migration, axon outgrowth,
or both, remains open. To gain a more complete picture of CBG
expression in the developing nervous system, the CBG protein was
localized in sections from embryos of several stages using an affinity
purified, polyclonal antibody, "521-2," raised against a CBG peptide
(see Materials and Methods; this antibody has previously been shown
to specifically recognize the CBG core protein in Western blots of a
crude rat brain membrane preparation (Litwack, 1995).) Figure 4
shows some examples of these experiments.
As was seen by in situ hybridization, CBG immunolocalization
demonstrates that the CBG protein is nervous system-specific. In
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Figure 4A, a saggital section of an E19 rat head, only the brain is
stained with the 521-2 anti-CBG antibody. Additionally,
immunolocalization revealed that CBG expression is largely associated
with axon tracts. In Figure 4A, the most strongly stained structure is
the intermediate zone, a region containing cortical and thalamic
axons. Strong CBG expression is also seen associated with the axons of
the optic tract. In a coronal section from a PO rat brain (Figure 4B),
CBG expression is observed in the internal capsule, which contains
cortical and thalamic axons, and in the tract containing the
hippocampal commisural fibers. In the E13 rat spinal cord (Figure
4C), CBG localizes to the commisural axon tracts on the lateral
surfaces of the spinal cord, and in the ventral root, which contains the
axons of the spinal cord motoneurons.
Cerebroglycan expression in the olfactory epithelium
The data from in situ hybridization strongly suggest that CBG mRNA
appears in neurons around the time of their final mitosis, raising the
possibility that CBG may be involved in facilitating the transition from
proliferating neuronal precursor to differentiating neuron, and/or in
the early steps of neuronal differentiation. Immunolocalization of the
CBG protein is consistent with a role for CBG in the growth of axons.
One structure where the process of neurogenesis and neuronal
differentiation has been well characterized is the olfactory epithelium
(OE). The OE has the unusual feature of being a neural structure in
which neurogenesis and neuronal differentiation continue even in
adult animals (Graziadei and Graziadei, 1978). To gain additional
insight into the timing of CBG expression relative to neurogenesis, and
into potential roles for CBG in neuronal differentiation, CBG
expression in the OE was examined.
As a first step in characterizing CBG expression in the OE, a CBG in
situ hybridization was performed on sections of developing and mature
OE. At embryonic day 15 (E15) in the mouse, the OE is relatively
unstructured, and neurogenesis is occurring across the width of the
entire epithelium (Smart, 1971). The CBG mRNA is expressed
throughout the E15 OE, although not as highly as in some other neural
structures such as the retinal neuroepithelium (Figure 5).
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By postnatal day 15, the OE has achieved an essentially adult
organization (Figure 6A). In the mature OE, NCAM positive olfactory
receptor neurons lie over a thin layer of keratin positive, NCAM
negative basal, epithelial cells (Calof and Chikaraishi, 1989). The
NCAM positive neurons can be further subdivided into immature
neurons (in the process of axon outgrowth), and mature neurons (in
contact with targets in the olfactory bulb). GAP-43, a neuron-specific
marker whose expression correlates with neuronal development
(Benowitz and Routtenberg, 1987), is present on immature but not
mature neurons, and OMP (olfactor marker protein) is only present on
mature olfactory neurons (Verhaagen et al., 1989). CBG mRNA
localizes to near the basal surface of the OE in the postnatal day 15
mouse (Figure 6B). This region corresponds to the area where
olfactory receptor neurons are born and begin differentiation. Thus,
CBG expression in the OE appears to be consistent with the
expression pattern that had been observed elsewhere (e.g. the P7
cerebellum) in that CBG mRNA was found in a zone that contains
immature neurons in the early stages of differentiation.
An in vitro model of OE development is available that recapitulates
many of the essential features observed in the OE in vivo (Calof and
Chikaraishi, 1989; Calof et al., 1991a). In the model, pieces of
purified E14/15 mouse olfactory epithelium are cultured as explants
on laminin (LN) or merosin (MN) coated coverslips (see Figure 7).
Immature neuronal precursors (INPs) sort out from the explant, and,
under proper conditions, a substantial fraction migrate away from the
explant onto the LN or MN substrate. Typically, the INPs divide once
to give rise to two NCAM-positive, immature neurons (Calof and
Chikaraishi, 1989). Subsequently, these neurons extend neurites, and
depending on the culture conditions, may even express markers
indicative of mature olfactory receptor neurons (Calof et al., 1993).
To further characterize the timing of CBG expression with respect
to neurogenesis, CBG in situ hybridizations were performed on OE
explants. For comparison, hybridization with a probe for mouse NCAM
was also performed.
By six hours in culture, substantial cell migration has occurred in
the explant cultures. The NCAM probe detected several NCAM-
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positive cells on the substrate away from the explant (Figure 8, A and
B), indicating that, as had been observed previously, many of the
migrating cells were INPs, which divide to give rise to NCAM-positive,
immature neurons. The NCAM probe also detected substantial
numbers of positive cells at the perimeter of the explants; this is the
normal consequence of the fact that, in any given culture, as many as
50% of the INPs remain near the explant boundary after sorting out.
When these explant-associated INPs are dissociated with a mild
trypsin treatment and plated on fresh coverslips, they differentiate in
a manner indistinguishable from that of the INPs that migrate (Anne
Calof, unpublished observations).
In contrast, the CBG probe never detected CBG-positive cells on
the substrate away from the explant (Figure 8, C and D). The opposite
strand control probe gave little background hybridization (Figure 8, E
and F). Significant CBG expression was, however, detected associated
with the explant. As shown in Figure 8 (G and H), large numbers of
the cells that sorted out from the basal epithelial cell ball, but that
remained at the lateral surfaces of the explant, showed substantial
hybridization to the CBG probe. The negative control probe showed
only a low level of background hybridization to cells at the explant
boundary (data not shown). After 26 hours, strong NCAM expression
is still detected throughout the culture, but CBG expression has largely
disappeared (not shown). Thus, although the INPs around the explant
and the INPs on the substrate both differentiate into NCAM-positive
neurons, only those associated with the explant were observed to
express CBG at detectable levels (See Discussion).
Cerebroglycan expression in cell lines infected with a CBG retroviral
expression vector
Several questions about CBG expression and structure might best be
addressed by cell culture experiments. For example, although several
PG core proteins (e.g. syndecan-1 (Rapraeger et al., 1985), syndecan-4
(Shworak et al., 1994a), and serglycin (Seldin et al., 1985)) are known
to attach both heparan sulfate (HeS) and chondroitin sulfate GAG
chains, members of the glypican family of PGs appear to be substituted
only with HeS. The (presumably) structural features of the glypican
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family core proteins that are responsible for the specifity for HeS
attachment have yet to worked out.
Additionally, in several instances, glycosylphosphatidylinositol
(GPI)-anchored molecules have been found to be sorted to distinct
domains of the cell membrane (Dodd et al., 1988; Dotti et al., 1991;
Faivre-Sarrailh et al., 1992), including caveolae, protein microdomains
that are involved in cellular uptake of small molecules (Anderson et al.,
1992), and that contain several cytoplasmically oriented signalling
molecules including members of the src family of protein tyrosine
kinases (Sargiacomo et al., 1993; Lisanti et al., 1994). It would be of
interest to determine if CBG, as a GPI-linked HSPG, is sorted
preferentially to a particular membrane domain.
To address the question of whether the CBG cDNA obtained in
Chapter 2 is in fact expressed as an HSPG in cell lines, NIH 3T3 cells
and PC12 cells were infected with a CBG retroviral expression vector.
This vector, LCNX-CBGA3' (see Figure 9), contains the CBG cDNA
minus most of its 3' untranslated region, inserted downstream of the
cytomegalovirus (CMV) promoter. LNCX-CBGA3' also contains a
neomycin resistance gene under the control of the retroviral 5' LTR
promoter.
The infected 3T3 and PC12 cells, maintained as an uncloned,
neomycin-resistant population, were tested for CBG expression with
the 521-2 affinity purified, anti-CBG polyclonal antibody. Binding of
521-2 was detected with a Cy-3 conjugated fluorescent secondary
antibody. High levels of expression were observed in both cell types,
as shown in Figure 10 (A and C). Controls omitting the 521-2
antibody, and parental cell lines gave a low background of non-specific
binding (Figure 10, B and D).
To obtain a preliminary assessment of CBG localization within CBG-
expressing cell lines, cells were examined at high power on a confocal
microscope with the aperture nearly closed to produce the thinnest
possible optical sections. For CBG-expressing 3T3 cells
(3T3infuCBGA3') plated on laminin (LN), strong CBG signal, typically
with a punctate quality, was often detected at the level of cellular
attachment to the substrate (Figure 11A). The middle section of the
cells showed reduced signal (Figure 11B), and high levels of punctate
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signal were again detected at the dorsal cell surface (Figure 11C). The
relatively higher levels of signal at the levels of the dorsal and ventral
cells surfaces was suggestive of a cell surface localization of CBG in
these cells.
3T3infuCBGA3' cells plated on fibronectin (FN), were much more
spread, and appeared to be much flatter when examined on the
confocal microscope. Consequently, it was not possible to estimate
CBG localization in these cells. Interestingly, these cells, as an overall
population, appeared to be more uniformly positive for CBG (not
shown), and signal in individual cells was detected throughout the
entire cell, even in the space occupied by the nucleus (as determined
by Hoechst fluorescence) (Figure 11, D-F).
CBG-expressing PC12 cells (PC12infuCBGA3') plated on LN showed
comparable signal at the substrate level, and an intermediate level, but
little signal at the dorsal surface, over the nucleii. (Figure 11, G-I). It
was difficult to discern whether the signal at the substrate level in
these cells was truly associated with the ventral cell surface, or was
merely bleed-through from the intermediate levels above. However,
the 521-2 antibody did detect CBG expression in the numerous short
processes and micro-extensions of PCinfuCBGA3' cells (see for
example, Figure 11G, and Figure 10C).
To determine whether the CBG cDNA is expressed as an HSPG, PGs
were prepared from the membrane fraction of 3T3infuCBGA3' cells by
the method described in Chapter 2. The PG profiles of these two cell
lines were not identical; however it is possible to discern an HSPG
core protein, similar in size to the CBG core, that is present in
3T3infuCBGA3' cells but not in the parental cell line (Figure 12).
Immunoprecipitations of CBG from 3T3infuCBG3' cells, although
contaminated with some other PGs, contain a prominent PG core
protein of appropriate molecular weight that comigrates with the
novel HSPG core in the preparations of 3T3infuCBGA3' cell PGs, and
that is absent from PGs prepared from parental 3T3 cells (Figure 12).
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DISCUSSION
Cerebroglycan expression marks a distinct stage in neuronal
development
Examination of patterns of cerebroglycan message expression by in
situ hybridization suggests that cerebroglycan mRNA 1) is produced
by neurons, 2) appears at around the time of a neuron's terminal
mitosis, and 3) disappears by the time that neuronal migration and
axonal extension have been completed.
Strong support for this interpretation comes from examination of
the developing cerebellum, in which neuronal birth, migration and
maturation occur in distinct anatomical layers (Sidman and Rakic,
1973). In that structure, cells that proliferate in the superficial part of
the external granule layer give rise to post-mitotic neurons that reside
in the deep part of the same layer, and these in turn migrate rapidly
through the molecular layer to reach their final positions in the
internal granule layer. The concentration of cerebroglycan mRNA in
the deep half of the external granule layer (Figure 3A) implies that
cerebroglycan begins to be expressed around the final mitosis, while
its absence from the internal granule layer implies that cerebroglycan
message disappears by the time cell body migration has finished.
From studies of the timing of cerebellar neuron migration (Fujita,
1967), it can be concluded that the window of cerebroglycan mRNA
expression in granule cells is -36 hours or less.
The view that cerebroglycan is first expressed around the time
neurons become post-mitotic is supported by results in the early
spinal cord, in which mRNA is found only in regions containing newly
generated neurons (Figure 8B), and by the fact that all sites of
cerebroglycan mRNA expression throughout the nervous system
contain neurons that have been generated within the preceding 2-3
days (e.g. E12-E16 spinal cord and DRG [Fig. 1,3 (Altman and Bayer,
1984)]; E14-PO cerebral cortex [Fig. 1; (Bayer and Altman, 1987)];
E19-PO inferior colliculus [Fig. 1; (Altman and Bayer, 1981)1; E19
pontine nuclei [Fig. 1; (Altman and Bayer, 1978)]; E15 mouse retina
[Fig. 5; (Young, 1985)]; and P7 hippocampus and olfactory bulb [Fig. 2;
(Bayer, 1980; Bayer, 1983)]). In contrast, little if any cerebroglycan
mRNA is found in the proliferating neural precursors that form the
158
ventricular zone, both in the E12 spinal cord (Figure 3B) and
throughout the developing brain (not shown).
The time of disappearence of cerebroglycan message in at least one
structure other than the cerebellum also correlates with completion of
neuronal migration: Cells expressing cerebroglycan are found in the
subventricular zone pathway along which olfactory bulb interneuron
precursors migrate (Luskin, 1993), but not in the layers of the
olfactory bulb that contain interneurons that have completed their
migration. In other parts of the nervous system, however, a simple
correlation between cerebroglycan expression and neuronal cell body
migration cannot be drawn. The ventral horn of the spinal cord, the
dorsal root ganglia, the E19 thalamus, the superficial layers of the E19
and PO cerebral cortex, and the dentate gyrus of the hippocampus
(Figures 1-3), all primarily consist of neurons that have reached their
final positions, yet express cerebroglycan. Interestingly, although the
cell bodies of these neurons are not migrating at these times, their
axons are generally still growing. If the same cells are examined after
their axons have reached target areas, cerebroglycan message is
undetectable [e.g. after E20 for thalamus (Erzurumlu and Jhaveri,
1992); E18 for dorsal root ganglia (Killackey et al., 1990); and P2-P5
for cerebral cortex (O'Leary et al., 1990)]. Since axon growth and cell
migration are both forms of cell motility (Wilcox and Unnerstall, 1991;
Cypher and Letourneau, 1992), the data suggest a general correlation
between cerebroglycan expression and periods of time during which
neurons engage in motile behaviors.
Although the data presented cannot rule out the possibility that
some glial cells transiently express cerebroglycan, neither the timing
nor pattern of expression of cerebroglycan match the timing or sites
of glial production in the brain, which is largely postnatal (Jacobson,
1.991). In addition, several of the structures in the developing brain
that highly express cerebroglycan mRNA contain few if any glial cell
bodies, e.g. the external granule layer of the cerebellum (Figure 3) and
the E15 mouse retina (Figure 5). Interestingly, recent evidence
indicates that, in the adult rat brain, glypican is also expressed largely,
if not exclusively, by neurons (Litwack et al., 1994).
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Cerebroglycan is expressed in axon tracts of the developing nervous
system
Immunohistochemistry with an affinity purified anti-CBG antibody
confirmed that the CBG core protein, like the CBG mRNA, is
restricted to the nervous system. Additionally, the antibody revealed
that CBG protein is primarily associated with axon tracts (Figure 4).
The localization of CBG to axon tracts, together with the fact that the
CBG mRNA appears to be expressed during axon outgrowth in many
neuronal populations, suggests that CBG may have a role in guidance of
elongating axons. Consistent with this possibility, CBG -- as well as
glypican -- has recently been shown to be enriched in biochemical
preparations of growth cone particles from neonatal rat brain (Ivins et
al., 1995).
A recent study has shown that glypican is also expressed in axon
tracts of the developing rat central nervous system (Litwack, 1995).
One possible function of the GPI lipid anchor in glypican and CBG
could be to target these molecules to axons. Several other GPI-linked
molecules are known to be expressed on axons (Dodd et al., 1988;
Furley et al., 1990; Xue et al., 1990; Dotti et al., 1991; Faivre-Sarrailh
et al., 1992), and it has been demonstrated for some polarized
epithelial cells in culture that GPI-linked molecules are preferentially
sorted to the apical cell surface, which in neurons may be analogous to
the axonal cell surface (Olwin and Rapraeger, 1992). For glypican, it
has not been possible to address unambiguously whether expression is
actually restricted to axons. However, one study recently suggested
that CBG is in fact expressed on the axons but not the dendrites of a
particular cell type, the granule cell neuron of the dentate gyrus
(Litwack, 1995).
CBG expression in the olfactory epithelium: evidence of regulation by
extrinsic factors
The pattern of CBG expression in the olfactory epithelium in vivo is
consistent with what has been observed in other parts of the
developing nervous system. In the E15 OE, the ordered layers
present in the adult OE have not yet arisen (Smart, 1971).
Consequently, neurogenesis and early neuronal differentiation are not
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localized within the OE at this stage. Likewise, CBG expression in the
El15 OE is detected throughout the entire width of the structure.
In contrast, by P15, the adult structure of the OE has essentially
been established. In the P15 OE, neurogenesis is restricted to near
the basal surface of the epithelium, and neuronal differentiation is
restricted to the bottom one third to one half of the epithelium, as
marked by staining with GAP-43, a marker for neurons in the process
of neurite outgrowth [(Verhaagen et al., 1989), and Anne Calof,
unpublished observations]. CBG mRNA was found to be highly localized
to near the basal surface of the OE (Figure 6B). It is possible, on the
basis of CBG mRNA expression, that CBG may be even more restricted
than GAP-43 in the P15 OE. In the future it will be of interest to
determine the relationship of GAP-43 expression and CBG expression
in the OE using co-immunolocalization experiments.
In OE explant cultures, CBG was not expressed in the expected
pattern. It is known that, in these cultures, a large number of
immediate neuronal precursors (INPs) migrate away from the explant
and divide once to give rise to two NCAM-positive, immature neurons.
Based on CBG expression in the OE and elsewhere in vivo, we
predicted that CBG expression would also appear in the daughter
neurons of the INP divisions. However, no CBG-positive cells were
detected on the substrate away from the explant in any of the cultures.
Many CBG positive cells were detected, but these were always
associated with the perimeter of the explant, in clusters near the
keratin-positive ball of basal epithelium.
One reason, a priori, for the failure to see CBG-positive cells on the
substrate away from the explant would be if the window of CBG
expression in these cells is so short that finding a CBG expressing cell
would be a very rare event. However, the large numbers of CBG-
positive cells around the explant suggest that an extremely short
window of expression is not a fundamental feature of CBG expression
in these cells, and points to the possibility that other factors may be
involved.
One possibility is that cell-cell contact is important for the normal
expression of CBG. In experiments with cerebellar granule cells,
culturing cells as cellular reaggregates, as apposed to dispersed cells,
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caused a ten fold increase in DNA synthesis. The addition of astroglial
cells or cell membranes to the reaggregates arrested DNA synthesis in
a dose dependent manner (Gao et al., 1991). This experiment points
out the possible importance of homotypic interactions among
proliferating neuronal precursors in regulating proliferation and early
differentiation. In the OE explant cultures, cells that migrate away
from the explant must complete proliferation and differentiation
without the benefit of the cell-cell contacts that cells remaining with
the explant, and cells in vivo, normally enjoy.
Another possibility is that a factor supplied by basal epithelial cells
is required for normal CBG expression. In an experiment in which
dissociated OE cells were plated with cells from the olfactory bulb (the
normal target of olfactory receptor neurons), a fraction of the OE cells
were found to express carnosine, a putative neurotransmitter for
olfactory receptor neurons. These carnosine-positive neurons were
always found associated with clusters of keratin-positive basal
epithelial cells, suggesting association with basal epithelial cells may
influence the differentiation of OE receptor neurons (Perroteau et al.,
]L 994).
Nevertheless, INPs that migrate off the explant can, under the
proper culturing conditions, differentiate into neurons that express
markers of mature olfactory receptor neurons such as OMP (olfactory
marker protein) (Calof et al., 1993). The fact that these cells were not
observed to express CBG raises the possibility that CBG is not required
for the neurite outgrowth by of these cells. However, unlike INPs in
culture, which extend neurites at random, immature neurons in the
OE in vivo must extend axons to a defined target, the olfactory bulb.
Thus if CBG is involved in axon outgrowth in vivo, it may function in
axon guidance rather than the growth of axons per se. The
enrichment of CBG in preparations of growth cone particles (Ivins et
al., 1995) is consistent with a potential role for CBG in axon guidance
(See Chapter 6 for a further discussion of potential functions for CBG
in the nervous system).
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The CBG cDNA is expressed as a membrane-associated HSPG in cell
lines
PC 12 and NIH3T3 cell lines expressing CBG were obtained by
infection with a CBG retroviral expression vector. Preliminary
experiments demonstrated CBG expression in these cells by
immunofluorescence, using an affinity purified anti-CBG antibody and a
fluorescent secondary antibody. 3T3infuCBGA3' cells, the 3T3 cells
expressing CBG, were plated on both laminin (LN) and fibronectin
(FN). When plated on laminin (LN), 3T3infuCBGA3' cells were less
fully spread than when plated on FN. Differences in adhesiveness to
LN and FN has been reported before for fibroblasts (Botti et al., 1987;
Codogno et al., 1988). In one study with mouse B82L fibroblasts, the
parental cell line adhered to well FN but not at all to LN. However,
individual clones were isolated that had upregulated expression of a6
integrin subunit and become adherent and migratory on LN. Adhesion
and motility of the transfected clones to LN could be inhibited by an
antibody to the a6 integrin subunit (Lin and Bertics, 1995).
Interestingly, OE neurons also adhere poorly to LN and well to FN,
but are migratory on LN but not on FN. As with the 3T3 cell in the
study mentioned above, migration of OE neurons on LN can be
inhibited by an antibody to the a6 integrin subunit (Calof and Lander,
1991b; Calof et al., 1994). Thus it is possible that the differences in
cell shape of 3T3infuCBGA3' cells on LN and FN is the result of LN and
FN binding to distinct integrin receptors that convey different signals
to the cells (e.g., stimulation of migration vs. attachment and
spreading).
The differences in cell shape of 3T3infuCBGA3' cells on LN and FN
were accompanied by differences in CBG staining. On LN, several cells
showed substantial, punctate CBG staining near the ventral and dorsal
cell surfaces (Figure 11, A-C). At intermediate levels, less staining was
observed, suggestive of a cell surface localization for CBG in these cells.
The abundant amount of CBG found near the substrate level in these
cells raises the possibility that CBG was concentrated at the basal
surface by interacting with LN on the substrate.
LN is a good candidate ligand for CBG in vivo because it is
expressed in the developing nervous system in several areas now
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known to be traversed by axons in CBG-positive axon tracts. For
example, CBG expression is associated with axons of the optic tract,
axons in the intermediate zone of the cerebral cortex, and the axons of
spinal cord motoneurons (Figure 4), all of which are known to navigate
in areas containing LN (Rogers et al., 1986; Cohen et al., 1987;
McLoon et al., 1988; Hunter et al., 1992).
On FN, 3T3infuCBGA3' cells exhibited a flat, fully spread
morphology that made any estimation of CBG levels in cytoplasm
versus on the cell membrane impossible (Figure 11, D-F).
Surprisingly, even the space occupied by the nucleus stained positive
for CBG. Whether it is an artifact of fixation and permeabilization, or
whether the epitope was actually imported into the nucleus by the
cells, the significance of this observation remains to be determined.
No CBG signal was detected in the nucleii of 3T3 and PC12 cell lines
plated on LN, indicating that the unusual staining is not a typical
consequence of the staining protocol employed. Examination of the
3T3infuCBGA3' cells as a population suggested that they were more
uniformly positive for CBG when plated on FN (not shown). It is
possible that, on FN, for reasons not understood, CBG turnover is
slower, and the high level of CBG expression by the constitutive CMV
promoter results in "overflow" of CBG, or CBG breakdown products,
into other cellular compartments. There have been some reports of
heparan sulfate (HeS), biochemically demonstrated to be in the
nucleus of some cell types (Fedarko and Conrad, 1986; Ishihara and
Conrad, 1989), although the findings in some cases may be artifacts of
the way the nuclei were prepared (Hiscock et al., 1994). However,
one set of experiments has shown HeS with a rare modification is
apparently selectively enriched in the nucleii of confluent hepatocytes,
a finding that argues against non-specific contamination (Fedarko and
Conrad, 1986; Ishihara et al., 1986; Fedarko et al., 1989). In one
instance, an antibody to HeS was found to stain a small number of
neuronal cell nucleii in Alzheimer's brain, whereas no nuclear staining
was seen in normal brain (Su et al., 1992), suggesting that, in some
cases, the presence of HeS in cell nucleii is a pathological response.
For PC12infuCBGA3' cells plated on LN, high levels of CBG
expression were typically detected at the level of the substrate, and in
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the intracellular space around the nucleii (Figure 11, G and H).
However, unlike 3T3infuCBGA3' cells, PC12infuCBGA3' cells did not
show strong CBG staining on their dorsal cell surfaces (Figure 11 I).
The staining often illuminated many small micro-extensions on ventral
and lateral surfaces of these cells. In lightly stained cells, viewed at
lower magnification, this fringe of stained processes was often the
predominant feature of CBG staining (Figure 10C). In the future, it
would be of interest to determine whether these micro-extensions
also contain actin or other submembranous cytoskeletal components
such as ezrin or moesin, indicative of microspikes or filopodia.
Analysis of the PGs in the membrane fraction of 3T3infuCBGA3'
cells revealed that an HSPG core protein of a Mr -53 kDa is present
that is not found in the membrane fraction PGs of parental 3T3 cells.
This same core protein is the most prominent band in
immunoprecipitations of 3T3infuCBGA3' cell membrane PGs using the
affinity-purified 521-2 anti-CBG antibody (Figure 12). Taken together,
the data strongly suggest that the CBG cDNA obtained in Chapter 2
encodes a membrane associated HSPG. In the future it will be
important to demonstrate that CBG can be released from these cells by
treatment with PIPLC (phosphoinositol-specific phospholipase C) an
enzyme that cleaves GPI anchors.
In summary, in situ hybridization and immunolocalization
experiments have demonstrated that CBG expression is restricted to
the developing nervous system. CBG mRNA appears in immature
neurons around the time of their final mitosis and disappears shortly
after cell body migration and axon outgrowth have been completed,
raising the possibility that CBG plays a role in these motile behaviors.
The fact that the CBG core protein is localized to axon tracts is also
suggestive of a role for CBG in axon outgrowth.
Expression of CBG in olfactory epithelium (OE) in vivo is consistent
with patterns observed elsewhere in the developing nervous system:
CBG expression colocalizes with populations of newly post-mitotic
immature neurons. However, CBG expression in OE explants in vitro
suggests that: extrinsic factors, possibly homotypic cell-cell contact of
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neurons or precursors within the OE, or a factor(s) derived from the
basal epithelium, are required for proper CBG expression.
Expression of CBG in cell lines strongly suggests that the CBG cDNA
obtained in Chapter 2 encodes a membrane associated HSPG core
protein. These cell lines or others like them could be used to address
questions of CBG structure such as where glycosaminoglycans are
attached. Although many cell lines naturally express the related
HSPG, glypican, the use of CBG in these experiments would have the
advantage that modified versions of CBG could be expressed and
isolated without the use of an epitope tag since no cell line tested,
including PC12, 3T3, C6 glioma, and NBA1 neuroblastoma, has been
found to express a detectable level of CBG (not shown). Further, it
may prove interesting to compare the structure of CBG with that of
endogenous glypican produced by the same cell type.
The apparent concentration of CBG at the substrate level observed
in CBG-infected 3T3 cells plated on LN suggests CBG on the surface of
these cells may bind to LN on the substrate. This is of potential
importance because LN is an excellent candidate ligand for CBG in
vivo. As discussed above, many examples exist of CBG expression
associated with axons that navigate through LN rich regions. The fact
that CBG appears to be expressed specifically during periods of axon
outgrowth in the nervous system serves to underscore the possibility
that these two molecules interact in vivo.
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Figure 1. CBG expression in the developing nervous system
A, C, E, and H: cresyl violet stained sections. B, D, F, G, I: reverse
contrast images printed directly from autoradiograms of the same
sections hybridized to a 3 5 S-UTP labelled, in vitro transcribed, CBG
RNA probe. A and B: embryonic day 14 whole embryo; C and D:
embryonic day 16 whole embryo; E, F, and G: embryonic day 19 whole
embryo; H and I: neonatal head. (s)--spinal cord; (te)--telencephalon;
(cx)--cerebral cortex; (cb) cerebellar cortex; (d)--dorsal root ganglia;
(p)--pontine nuclei; (i)--inferior colliculus, (ob)--olfactory bulb; (hi)--
hippocampus; (st)--striatum, (th)--thalamus. Panel G shows the result
when a sense orientation (negative control) probe was hybridized to an
adjacent section of the embryonic day 19 animal; the image was
)printed at high contrast to allow visualization of the faint background.
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Figure 2. Expression of CBG in postnatal rat brain
Darkfield photomicrograph of a postnatal day 7 rat brain saggital
section after in situ hybridization with an a 3 5 S-UTP labelled CBG RNA
probe. Hybridization is detected in the cerebellum (cb), the dentate
gyrus of the hippocampus (dg), and in migrating granule cell
precursors of the olfactory bulb (arrowhead). No hybridization was
detected with the sense orientation (negative control) probe (not
shown). Bar = 1 mm. Top is dorsal; right is rostral.
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Figure 3. CBG is expressed by post-mitotic neurons
Simultaneous visualization of CBG mRNA (darkfield optics) and cell
nuclei (Hoechst blue fluorescence). (A) P7 cerebellum, sagittal
section. Hybridization is localized to the external granule layer, and is
concentrated in the premigratory zone, which contains newly
postmitotic granule neurons. EGL, external granule layer; ML,
molecular layer; IGL, internal granule layer; pz, proliferative zone;
pmz, premigratory zone. (B) E12 spinal cord, transverse section.
Hybridization is detected in the forming dorsal horns (DH), and
ventral horns (VH) of the spinal cord, and the dorsal root ganglia
(arrowheads), but not the ventricular zone (VZ). The cleft in the
ventricular zone of the spinal cord was an artifact of sectioning. No
signal was detected in adjacent sections hybridized with sense
orientation (negative control) probe (not shown). Bar = 100 gm.
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Figure 4. The CBG protein core is localized to fiber tracts
(A) Sagittal section of an E19 rat head stained with the 521-2 affinity
purified anti-CBG antibody and developed with a horseradish
peroxidase conjugated secondary antibody. Top is dorsal; left is
rostral. (B) Coronal section of a PO rat brain stained for CBG with 521-
2. Top is dorsal; left is lateral. (C) Transverse section of an E13 rat
spinal cord stained with 521-2. Top is dorsal. Open arrows points to
spinal cord commisural axons. Abbreviations: c, hippocampal
commisural fibers; d, dorsal root ganglion; h, hippocampus; i, internal
capsule; iz, intermediate zone; m, motoneurons; o, optic tract; vr,
ventral root. Scale bars: (A) and (B), 200 rLm; (C), 50 rim.
This Figure courtesy of E. David Litwack (Litwack, 1995).
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Figure 5. CBG expression in E15 mouse olfactory epithelium
Three nearly, adjacent, horizontal sections from an embryonic day 15
mouse head are shown. (A) A cresyl violet stained section. OE,
olfactory epithelium; R, retinal neuroepithelium. (B) A section
hybridized with a digoxigenin-labelled CBG riboprobe reveals strong
CBG expression in the retinal neuroepithelium, as well as expression
throughout the olfactory epithelium. (C) The opposite strand control
probe showed no background hybridization.
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Figure 6. Expression of CBG in the P15 mouse olfactory epithelium
(A) A schematic showing the organization of the mature olfactory
epithelium (OE). B, keratin positive basal epithelial cells; GB, globose
basal cells are morphologically distinguishable from other basal cells,
and are believed to be the neuronal precursor cells in the OE; ORN,
immature olfactory receptor neurons in the process of axon outgrowth
are NCAM + , GAP43 + , but olfactory marker protein (OMP)-; MORN,
mature olfactory receptor neurons have made contact with their
target, the olfactory bulb in the brain, and are NCAM+ , OMP + , GAP43-;
S, sustentacular cells are a glial cell type in the OE.
(B) High magnification view of a postnatal day 15 mouse OE,
hybridized with a digoxigenin CBG riboprobe. m, the mesenchyme
underlying the olfactory epithelium; oe, the olfactory epithelium; lu,
the lumen of the airway at the apical surface of the OE. CBG
expression is localized to near the basal surface of the OE.
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Figure 7. Proliferation and differentiation of olfactory neurons in vitro
Figure 7 is after Calof et. al. (1993). The culture of purified olfactory
epithelium explants from embryonic day 14 or 15 mice is represented
schematically. (A) 30 minutes after plating to laminin or merosin
coated coverslips. (B) 6 hours after plating, immediate neuronal
precursors have sorted out from the ball of basal epithelial cells, and
many have migrated onto the substrate. Several of the neuronal
precursors have already divided to give rise to NCAM+ immature
neurons. (C) 24 hours after plating, most of the neuronal precursors
have divided to give rise to immature neurons, and many GAP43+
neurons are extending neurites. Abbreviations: INP, immediate
neuronal precursors; ORN, olfactory receptor neurons.
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Figure 8. CBG expression in olfactory epithelium explants
(A), (C), (E), (G): differential interference contrast (DIC) views of
olfactory epithelium (OE) explant cultures. (B), (D), (F), and (H):
bright field views of the same fields as in (A), (C), (E), and (G), to allow
visualization with truer color. In (A) and (B), a 6 hour explant has been
hybridized with a digoxigenin (DIG)-labelled NCAM riboprobe. In (C)
and (D), a 6 hour explant has been hybridized with a DIG-labelled CBG
riboprobe. (E) and (F): hybridization with the opposite strand
negative control probe. (G) and (H): A view at a higher focal plane of a
6 hour explant hybridized with a CBG riboprobe, revealing CBG-
positive cells at the top lateral surface of the explant. Negative control
probes showed little hybridization to cells at this level (not shown).
Cells on the substrate below are out of the plane of focus.
Abbreviations: be, basal epithelium cells.
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Figure 9. Construction of a CBG expression vector
The cloning strategy and structural features of the CBG expression
vector LNCX-CBGA3' are shown schematically. Vector sequences are
shown in white, CBG cDNA is shaded, and the CBG coding region is
black. The start and stop codons for CBG coding sequence are
indicated. Abbreviations: pBS, pBluescript plasmid (Stratagene);
pSL301, Super-linker plasmid (Invitrogen); LTR, long terminal repeat;
Amp, ampicillin resistance selectable marker; Neo, neomycin
resistance selectable marker; CMV, cytomegalovirus promoter.
Arrows indicate direction of transcription. The orientation of the CBG
cDNA in LNCX-CBGA3' was verified by restriction digest using Eag I,
and by sequencing with primers based on vector sequence on either
side of the insert.
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Figure 10. CBG expression in 3T3 and PC12 cell lines
NIH3T3 cells and PC12 cells were infected with the CBG expression
vector LNCX-CBGA3' to create the cell lines 3T3infuCBGA3' and
PC12infuCBGA3', which were maintained as uncloned populations in
selective medium. (A) and (B): 3T3infuCBGA3' cells plated on
fibronectin, and viewed with the 40X objective of a confocal
microscope. (A) Cells stained with the 521-2 anti-CBG antibody; (B)
No first antibody negative control. (C) and (D) PC 12infuCBGA3' cells
plated on laminin and viewed with the 40X objective of a confocal
microscope. (C) PC 12infuCBGA3' cells stained with 521-2; (D)
parental PC12 cell line stained with 521-2. Bar = 50 pm.
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Figure 11. Distribution of CBG protein in cells of CBG expression lines
(A-C) 3T3infuCBGA3' cells were plated on laminin, and CBG
protein was visualized by staining with the 521-2 anti-CBG antibody
and a Cy-3 conjugated secondary antibody. Cells were viewed with a
100X objective, 2X zoom, with the aperture nearly closed to allow for
the thinnest possible optical sections. (A) View at the substrate level.
(B) View at an intermediate level. (C) View at the dorsal cell surface.
Bar = 10 pm.
(D-F) 3T3infuCBGA3' cells plated on fibronectin, stained with 521-
2, and viewed with the 63X objective of a confocal microscope. (D and
E) Staining was observed throughout the entirety of these cells, even
in the nucleus (compare to A and B above, where the nucleus is readily
visualized by lack of staining; also, compare Figure 10A to Figure 10C).
(F) The same cell as in (E) but at a slightly different focal plane and
higher contrast to illustrate the nuclear staining in this cell. Bar = 25
}Im.
(G-I) PC12infuCBGA3' cells plated on laminin, stained with 521-2,
and visualized with the 100X objective of a confocal microscope, with
the aperture nearly closed. (G) View at substrate level. (H) View at
an intermediate level. (I) View at the dorsal cell surface. Bar = 25
pm.
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Figure 12. The CBG cDNA is expressed as a membrane associated
HSPG in 3T3 cells
PGs were isolated (as in Chapter 2) from the membrane fraction of
'3T'3 cells and the 3T3 cell line 3T3infuCBGA3', that had been infected
with the CBG retroviral expression vector. PGs were labelled with
1.25I as previously described (Herndon and Lander, 1990) and
analyzed by SDS-PAGE after digestion with heparitinase or
chondroitinase, to visualize PG core proteins. Additionally, undigested
and digested. PGs from 3T3infuCBGA3' cell membrane fraction were
immuno-precipitated with the 521-2 anti-CBG antibody and the
i:mmuno-precipitates were analyzed on the same SDS-PAGE minigel.
Abbreviations: U, undigested PGs; C, chondroitinase ABC digested
PGs; H, heparitinase digested PGs; CH, PGs digested with both
heparitinase and chondroitinase; 3T3, PGs from parental 3T3 cell
membrane fraction; Inf, PGs from the 3T3infuCBGA3' cell membrane
fraction; Ip, PGs from 3T3infuCBGA3' cell membrane fraction,
immunoprecipitated with 521-2. The large arrow at the side and the
small arrows within the gel indicate the CBG core protein bands.
Molecular weight markers are indicated. The table below shows the
cpm recovered from immunoprecipitations with the 521-2 antibody of
membrane fraction PGs from 3T3infuCBGA3' cells and parental 3T3
cells.
cell line cpm input Icpm recovered
3T3 3.9 x 106 16,000
3T3infuCBGA3' 3.9 x 106 375,000
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CHAPTER 4
HIGH AFFINITY INTERACTION
OF CEREBROGLYCAN WITH LAMININ-1
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INTRODUCTION
The previous chapters have described the identification, cloning,
and developmental expression of a novel cell surface heparan sulfate
proteoglycan (HSPG) that we have named cerebroglycan (CBG). CBG is
expressed only in the nervous system, and only during development.
CBG expression appears in neurons around the time of their final
mitoses, and disappears shortly after cell body migration and axon
outgrowth have been completed. Immunolocalization of the CBG
protein core has revealed that CBG is highly expressed in axon tracts
throughout the developing nervous system, and, in one favorable case
-- the granule. cell neurons of the dentate gyrus -- it has been possible
to demonstrate that CBG may actually be polarized to axons (i.e.,
expression was found associated with axons and not cell bodies or
dendrites) (Litwack, 1995).
The available data are consistent with the possibility that CBG plays
a role in axon outgrowth during neuronal development. CBG
expression is associated with axons during the period when outgrowth
is occurring, but is not present later, when outgrowth has been
completed. Biochemical data have also demonstrated that CBG (as
well as glypican and syndecan-3) is enriched in growth cone particles
(GCPs) (Ivins et al., 1995). These particles morphologically resemble
growth cones when visualized by electron microscopy (Pfenninger et
al., 1983) and are enriched for markers such as GAP-43 that are
known to be localized to growth cones (Skene et al., 1986). The
apparent abundance of CBG protein in growth cones, the sensory
structures responsible for axon guidance, is further evidence that CBG
may be involved in the growth of axons.
As a cell surface HSPG, CBG has the potential to interact with
several extracellular cues in the developing nervous system that may
influence axon outgrowth. The heparin-binding molecules fibronectin,
netrins 1 and 2, thrombospondin, vitronectin, and laminins 1 and 3
have all been, implicated in axon outgrowth and are all expressed in
the developing nervous system at places and times that overlap with
CBIG expression (Cohen et al., 1987; McLoon et al., 1988; Rogers et al.,
1989; Neugebauer et al., 1991; Sheppard et al., 1991; Hunter et al.,
1992; Kennedy et al., 1994; Serafini et al., 1994). To begin to assess
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the potential of CBG to serve as a receptor for such molecules, we have
chosen to focus on laminin-1 (LN-1).
LN-1 is a good candidate ligand for CBG for several reasons. LN-1
contains multiple heparin-binding domains, potentially capable of
interacting with a cell surface HSPG (Sung et al., 1993; Colognato-
Pyke et al., 1995). The basement membrane HSPG perlecan
copurifies with LN-1 (Lander et al., 1985), and perlecan heparan
sulfate (HeS) chains bind to LN-1 (Yurchenco and O'Rear, 1993)
suggesting that at least one of these domains actually binds HSPGs in
vivo. LN-1 has potent neurite outgrowth promoting and guiding
activity in vitro (Rogers et al., 1983; Gundersen, 1987) and is
expressed in vivo in CBG-positive axon tracts, such as the subplate of
the developing cerebral cortex, and the optic tract [(Cohen et al.,
1987; McLoon et al., 1988; Hunter et al., 1992); Chapter 3, this
thesis].
Evidence that LN-1 is actually used as a substrate for axon
outgrowth in vivo has come from studies of the avian optic tract. LN-1
is expressed in the avian optic tract during the time when retinal
ganglion cells (RGCs) are extending axons through the tract to targets
in the optic tectum. At embryonic day 6 (E6), RGC axon outgrowth in
vivo is occurring, and E6 RGCs respond to a LN-1 substrate in vitro by
extending neurites. By E11, RGC axon outgrowth in vivo is essentially
complete, and E 11 RGCs cultured in vitro no longer respond to a LN-1
substrate (Cohen et al., 1986; Cohen et al., 1987). Interestingly, the
loss of RGC responsiveness to LN-1 correlates with the downregulation
of a6 integrin subunit by these cells (deCurtis et al., 1991). This same
integrin subunit has been implicated in motile responses of olfactory
receptor neurons (Calof et al., 1994) and fibroblasts (Lin and Bertics,
1995) to LN-1.
Despite the potential for cell surface HSPG/LN-1 interactions in the
developing nervous system, little is known about cell surface HSPG
binding to LN-1. We report here on studies that demonstrate that CBG
binds to LN-1 with sub-nanomolar affinity, around four hundred-fold
better than the affinity of heparin for LN-1. This high affinity binding
to LN-1 requires an intact CBG core since trypsin digestion of CBG
produced fragments that bound with affinities similar to that of
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heparin. In addition, two other neuronal HSPGs, glypican and
syndecan-3/N-syndecan, were also found to bind LN-1 with high
affinity. These results are consistent with the view that cell surface
HSPGs could serve as LN-1 receptors or coreceptors in the developing
nervous system.
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MATERIALS AND METHODS
Materials
Laminin- 1 was purified from Engelbreth-Holm-Swarm (EHS)
sarcoma according to published methods (Kleinman et al., 1982;
Timpl et al., 1982). The recombinant G domain (rG) of LN-1 was the
gift of Dr. Peter Yurchenco, (Dept. of Pathology, UMDNJ-Robert Wood
Johnson Medical School, Piscataway, NJ.) FGF-2 (bFGF) was purified
fiom bovine brain (Lobb and Fett, 1984). Immunopurified 1251-
labelled syndecan-3 from postnatal day 0 (PO) rat brain growth cone
particles (see below) was kindly supplied by John Ivins (UCI, Irvine,
CA). Syndecan-3 was precipitated using the mAb MSE-3 (Kim et al.,
:1994), supplied by the lab of Merton Bernfield (Children's
Hospital/Harvard Medical School, Boston, MA). Metabolically labelled
heparan sulfate (HeS) chains were supplied by Mary Herndon (Dept. of
Pathology, Harvard Medical School, and were prepared essentially as
described in the Materials and Methods section of Chapter 5, this
thesis). Thrombospondin-1 was supplied by Jack Lawler, Dept. of
Pathology, Harvard Medical School). Porcine intestinal heparin was
from Sigma. Trypsin was from Worthington Biochemical Co.
Chondroitinase, heparitinase, pepstatin A, PMSF (phenylmethyl-
sulfonyl fluoride), DEAE-Sephacel, and CHAPS (3-[(3 Cholamidopropyl)
dimethyl-ammoniol-l-propanesulfonate) were obtained as described in
Chapter 2. All other chemicals were obtained from Mallinkrodt
except where noted.
Preparation of 1 2 5 I-Labelled, Low Molecular Weight Heparin
Heparin was substituted with tyramine as described in San
Antonio, et al. (1993). 3-10 ýpg of heparin in 50 pl of 0.25 M NaPO4,
pH 7.5 and 2-5 mCi of Na 1 2 5 1 (NEN) were mixed in a 13 x 75 mm
glass tube, that had previously been coated with 20 jig of Iodogen
(Pierce) (50 pl of 0.4 mg/ml lodogen in dichloromethane). 1251_
labelled GAGrs were separated from free iodine by filtration over a 2 ml
G-25 (Pharmacia) column that had been pre-blocked with 200 gg of
crystalline BSA. For isolation of low molecular weight heparin (LMW-
heparin), 12 5I-labelled heparin was further fractionated over a G-100
(Pharmacia) gel filtration column: the low molecular weight pool
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(Mr<6000) was isolated as the last 11% of the heparin peak to elute
(San Antonio et al., 1993). 12 5 I-labelled LMW-heparin was
radioprotected with the addition of 0.25 mg/ml crystalline BSA,
aliquotted, and stored at -800C. LMW-heparin is the heparin used in
all of the binding assays described below.
Preparation of Anti-Cerebroglycan and Anti-Glypican Affinity Matrices
Affinity purified anti-CBG (521-2) and anti-glypican
(343-1) polyclonal antibodies were isolated as described [Chapter 3,
this thesis; (Litwack, 1995). 521-2 and 343-1 antibodies were bound
to protein-A sepharose and crosslinked with dimethyl-pimelimidate
(DMP) according to instructions, using an Immunopure Protein A IgG
Orientation Kit (Pierce). The resulting affinity matrices contained 0.6
mg/ml (packed volume) of 521-2 antibody, and 0.3 mg/ml (packed
volume) of 343-1 antibody.
Proteoglycan Isolation, Purification, and Analysis
PGs were isolated from the membrane fraction of embryonic day 16
(E16) rat brain using a protocol described previously [(Herndon and
Lander, 1990); Chapter 2, this thesis]. PGs were labelled with 1251
according to Hemdon and Lander (1990). 12 5 1-labelled PGs from the
membrane fraction of the 3T3 cell line 3T3infuCBGA3', that has been
infected with a CBG retroviral expression vector, were prepared as
described in Chapter 3.
Growth cone particles (GCPs) were isolated from PO rat brains
essentially as described previously (Pfenninger et al., 1983). Briefly,
PO rat brains were homogenized in 0.32 M sucrose, 1 mM MgCl2, 1
mM TES ([N-Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid)
(pH7.3) in a teflon-on-glass homogenizer. The homogenate was
centrifuged at 1660 g for 15 minutes, and the supernatant was loaded
onto a discontinuous sucrose gradient and centrifuged for 40 minutes
at 242,000 g. The GCPs were collected from the interface between
the sample load and the first step (0.75 M sucrose) in the gradient.
This fraction is substantially enriched for GCPs, but is also heavily
contaminated with soluble protein (Pfenninger et al., 1983).
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To isolate PGs from GCPs, GCPs at -1 mg/ml total protein in 1 mM
TES, 1 mM MgC12, -0.65 M sucrose, were made 50 mM in Tris-HCl
IpH 7.4], 0.15 M in NaC1, and 1.0% in CHAPS, and vortexed for 1
minute. After centrifuging for 3 minutes at 12,000 g in a microfuge,
the supernatant was recovered and pepstatin A and PMSF were added
at 1 pg/ml and 0.4 mM respectively. The supernatant was then loaded
to a DEAE-Sephacel column, and PGs were isolated as described
previously (Hemdon and Lander, 1990). After elution, PGs were
radiolabelled with 1251 as previously described (Herndon and Lander,
1990).
Immunopurified cerebroglycan and glypican were prepared using
the affinity matrices described above. 12 5 1-labelled PGs from E16 rat
brain or from PO rat brain growth cone particles, both in 0.75 M NaC1,
50 mM Tris-HCl [pH7.4], 0.5% CHAPS, were diluted five fold with 50
mM Tris-HCI1, 0.5% CHAPS, and crystalline BSA (ICN) was added to a
final concentration of 0.1 mg/ml; 0.05 to 0.1 volumes (packed beads)
of affinity matrix were added, and PGs were allowed to bind overnight
at 40C. Beads were washed for 20-60 minutes with rotation at room
temperature with 1 ml each of (1) 50 mM Tris-HCl, 0.15 M NaC1,
0.5% CHAPS; and (2) 0.5M NaCl, 50 mM Tris-HCl, 0.5% CHAPS, and
then briefly with 10 mM Tris-HC1, 0.5% CHAPS. Bound PGs were
eluted with 100 mM NaH2PO4/H3PO4 [pH 2.5], 0.5% CHAPS for 10
minutes and immediately neutralized with 0.2 volumes of 0.5 M
Na2HPO4-
For reduction and alkylation, 10 C1 of 1M Tris-HC1 [pH 8.5], 50 pC of
8M urea, and 10 p• of 0.2 M dithiothreitol were added to 30 py
(-~90,000 cpm) of immunopurified CBG, prepared as described above
from the E16 rat brain membrane fraction. After 30 minutes at 37 0C,
10p1 of 0.5M iodoacetamide was added and the sample was incubated
for an additional 45 minutes at 37 0C. The sample was diluted with 1.9
ml of 50 mM Tris-HC1 [pH 7.4], 0.5% CHAPS, and loaded to a
Centricon-30 tube (Amicon) that had been pre-blocked with 0.5
mg/ml crystalline BSA in Tris/CHAPS. The buffer was exchanged to
50 mM Tris-HC1, 0.5% CHAPS, and the sample was concentrated by
succesive rounds of dilution and centrifugation.
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For trypsin digestion, 6 L1 (36 jig) of freshly prepared trypsin
(TRTPCK grade, Worthington Biochemical Co.) in phosphate buffered
saline (PBS) was added to 30 tl (-90,000 cpm) of immunopurified
CBG, prepared as described above, and the sample was incubated for 2
hours at 370C. 12 Cl (72 jgg) of soybean trypsin inhibitor in PBS was
added, and the sample was incubated an additional 1 hour at 370C.
Aliquots of the digest were analyzed on an 18% SDS-PAGE minigel,
with or without prior digestion with heparitinase [as previously
described, (Herndon and Lander, 1990)]. At least one 12 5 1-labelled,
glycanated peptide was obtained which migrated as a smear with a Mr
of -40 kDa prior to digestion, and as a -7.5 kDa band after
heparitinase digestion.
Affinity coelectrophoresis (ACE) and Analysis
Affinity co-electrophoresis (ACE) and its analysis was carried out
essentially as described (Lee and Lander, 1991; Lim et al., 1991) (See
also, Figure 2). ACE buffer was 50 mM MOPSO [3-(N-morpholino)-2-
hydroxypropane-sulfonate], 125 mM NaAcetate pH 7.0. Dried ACE
gels were exposed in a phosphorimager cassette (Molecular Dynamics,
Sunnyvale, CA), analyzed using ImageQuant Software (Molecular
Dynamics) and quantified manually or as described in San Antonio et
al. (1993), using Microsoft Excel. Kaleidagraph (Synergy Software)
was used to fit electrophoretic mobility data to equilibrium equations.
Briefly, R values (retardation coefficient, the electrophoretic mobility
of bound PG or heparin in a given lane normalized to the mobility of
unbound PG or heparin) were graphed with respect to the protein
concentration for each lane and the resulting curve was fit to the
equation:
R = 1 + (K d/[Pto;
where R, = R value when the PG or heparin is maximally shifted,
Kd = Equilibrium dissociation constant, [G][P]/[G-P], for the reaction:
G (PG or heparin) + P (test protein) t G-P (complex of PG/heparin
with test protein); [Ptot] = Protein concentration in each lane of the
ACE gel (at equilibrium, this value should actually be ([Ptot] - [G-P]),
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but because PG concentrations are so low under normal ACE
conditions (<0.1Kd), the G-P term is negligible); n = Number of
protein molecules binding to each PG or heparin molecule, i.e. order
of binding mechanism (usually taken to be 1).
Overruns (cases where the PG or heparin migrates out of the
protein-containing zone of a particular lane) were compensated for
using methods also outlined in Lim et al. (1991).
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RESULTS
Cerebroglycan binds to laminin-1 with high affinity
To begin to assess the potential for CBG-laminin-1 (LN-1)
interactions, immunopurified CBG was prepared from embryonic day
16 (E16) rat brain for use in binding studies. 12 5 I-labelled PGs
isolated from E16 rat brain (a rich source of CBG; data not shown)
were immunoprecipitated using a 521-2 anti-CBG affinity matrix, as
described in Materials and Methods. As shown in Figure 1 this step
resulted in a substantial purification of CBG. The eluate from the
affinity matrix contained a single HSPG core protein of Mr -53 kDa,
similar to the size previously observed for the CBG core protein
(Herndon and Lander, 1990). Several non-PG proteins including one
that comigrates with the CBG core protein -- compare the
"undigested" lanes in starting material and CBG samples in Figure 1 --
were substantially removed by the immunopurification step.
Immunopurified CBG was tested for binding to LN-1 using affinity
coelectrophoresis (ACE). In ACE, a horizontal, 1% agarose gel is cast
with 9 lanes arranged orthogonally to a thin sample well (see Figure
2). A test protein at nine different concentrations is mixed with
agarose and embedded in the 9 lanes. A PG or glycosaminoglycan
(GAG) that has been radioiodinated or metabolically labelled is loaded
into the sample well and driven by electrophoresis through the lanes
containing the test protein. If a binding interaction occurs, the PG or
GAG will be retarded to an extent that depends on the dissociation
constant (Kd) for the interaction (Lee and Lander, 1991; Lim et al.,
1991).
Figure 3A shows the result when 12 5 I-labelled CBG is tested for
binding to LN-1 by ACE; CBG is found to bind LN-1 with a high affinity.
Tlhe CBG sample is near maximally retarded by concentrations of LN-1
as low as 5 nM, but 1 2 5 I-heparin run in parallel is not significantly
retarded by concentrations of LN-1 lower than 50 nM, and is not
maximally retarded even at 200 nM, the highest concentration tested
(Figure 3B). The affinity patterns in Figure 3 (A and B) were converted
to the binding isotherms, as described in Materials and Methods. As
shown in Figure 3C, CBG bound to LN-1 with an apparent Kd of 0.18
nM while a Kd of 203 nM (similar to values reported by others (San
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,Antonio et al., 1993)) was obtained for heparin -- a 1000-fold
difference in. affinities.
The high affinity interaction of CBG with LN-1 requires an intact CBG
core protein.
To further characterize the interaction of CBG with LN-1,
immunopurified 12 5 1-labelled CBG was digested exhaustively with
trypsin. The resulting material contained at least one glycanated,
12 5 I-labelled peptide with a Mr of -7.5 kDa, as determined by SDS-
PAGE, with or without prior heparitinase digestion (not shown).
Tryptic CBG fragments bind LN-1 with an affinity similar to that of free
heparin, much lower than that of intact CBG run in parallel (Figure 4),
indicating that an intact CBG core protein is required for high affinity
Ibinding to LN-1. Interestingly, trypsinized CBG and intact CBG bind to
FGF-2 (bFGF) with very similar affinities (Figure 4). This indicates that
an intact core protein is not a requirement for maximal binding of CBG
to all GAG-binding proteins, and suggests that trypsin treatment did
not non-specifically decrease the affinity of CBG for GAG-binding
molecules (e.g. by damaging the HeS chains).
Further characterization of LN-1 binding to cell surface HSPGs
To more completely assess the potential for LN-1 binding to cell
surface HSPGs, LN-1 affinity for several additional molecules was
tested. The results of these experiments are presented in Table 1. In
addition to CBG, two other neuronal HSPGs were found to bind LN-1
with high affinities. Glypican and syndecan-3 were immuno-
precipitated from PO rat brain growth cone particles using the
polyclonal 343-1 anti-glypican antiserum (Litwack, 1995) and the
monoclonal antibody MSE-3 (Kim et al., 1994). Immunopurified
glypican and syndecan-3, with Kds of 2.2 and 2.7 nM respectively,
both bound to LN-1 with much higher affinities than does heparin.
CBG isolated from other sources also binds to LN-1 with high affinity,
including CBG immunopurified from 3T3 cells infected with a CBG
retroviral expression vector. Taken together, these results suggest
that high affinity binding may be a common feature of LN-1
interactions with PGs.
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In further experiments aimed at elucidating the basis of the high
affinity interaction of LN-1 with CBG, CBG that had been reduced and
alkylated was tested for affinity to LN-1. While the diffuse migration of
reduced CBG made it difficult to accurately fit a single binding
isotherm to the resulting ACE binding pattern, it was clear that
reduction and alkylation had substantially reduced the over-all affinity
of CBG for LN-1, (Figure 5 and Table 1), suggesting that tertiary
structure is important for high affinity CBG binding to LN-1.
To explore the LN-1 structural requirements for a high affinity
interaction with CBG, CBG affinity for the recombinant G (rG) domain
of LN-1 was tested. The G domain of LN-1 is at the carboxy terminus
of the LN-1 a 1l chain (formerly the A chain), and contains two heparin
binding sites (although one of these sites may be masked in the intact
LN-1 molecule) (Sung et al., 1993). The rG domain is the G domain of
LN-1 expressed in a baculovirus system in Sf9 cells, and has been
shown to possess heparin binding properties similar to that of the G
domain isolated proteolytically from murine LN-1 (Sung et al., 1993).
ACE analysis revealed that, although heparin binds to rG and LN-1
with similar affinity, CBG's affinity for rG is much lower than its affinity
for intact LN-1 (Table 1). CBG binds to rG with a Kd of 29 nM, only
about nine-fold better than the affinity of heparin for rG. This suggests
that structural elements in LN-1 outside of the G domain are required
for high affinity binding by CBG.
For comparison, the binding of CBG and syndecan-3 to
thrombospondin-1 (TSP-1) was also examined. TSP-1 is another
example of a large, multidomain, extracellular matrix glycoprotein that
contains multiple heparin binding sites (Adams and Lawler, 1993). As
shown in Table 1, both CBG and syndecan-3 bind TSP-1 with an
affinity higher than that of metabolically labelled HeS chains isolated
from neonatal rat brain material; however, the the affinity of the intact
molecules is only around four to five-fold higher than the affinity of the
free chains, much less dramatic than the difference seen with LN-1.
Finally, free HeS chains isolated from neonatal rat brain bound LN-1
with a lower affinity than the 12 5 I-labelled heparin used as a control
in most of the CBG binding experiments described above. This result
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suggests that the difference between the binding of free HeS and
intact HSPGs to LN-1 is even greater than first estimated.
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DISCUSSION
High affinity interactions between cell surface HSPGs and laminin-1
In the present study, the binding of three neuronal cell surface
HSPGs to LN- 1 has been measured. Glypican, syndecan-3, and CBG
were all found to bind LN-1 with high affinity -- Kds were 2.2, 2.7, and
0.5-0.7 nM for glypican, syndecan-3, and CBG respectively. These
affinities are several hundred fold better than the affinity of heparin or
brain heparan sulfate for LN-1. This result demonstrates that the
binding of heparin or HeS to a ligand cannot be taken to be an
accurate indicator of the affinity of an HSPG for the same ligand. In
some cases (e.g. FGF-2, and TSP-1; Table 1) the affinities for HSPGs
and HeS are similar, whereas for other molecules such as LN-1, the
affinities are dramatically different. An accurate picture of HSPG
binding to various ligands will require a case by case investigation, and
will probably depend not only on the particular molecules involved, but
the source from which they are derived.
For example, in one recent report, a glycosylphosphatidylinositol-
anchored cell surface HSPG from Schwann cells (subsequently
identified as glypican) was found to bind LN-1 with an affinity of only -
1 iM (Carey et al., 1990). It is possible that the lower affinity is due to
experimental differences -- binding of the Schwann cell PG to LN-1
was measured by equilibrium gel filtration with LN-1 present
throughout the elution buffer, which was 0.1 M Tris-HC1, pH 7.5. With
time, solutions of LN-1 at low ionic strength can experience
substantial non-specific losses (data not shown); such losses would
result in an underestimation of LN-1 affinity. However, it is also
possible that the discrepancy is simply the result of the different
source of the glypican used in the binding experiments.
A more clear-cut example of a case where the same HSPG from two
different sources exhibits two different affinities for the same ligand
has also been recently reported (Sanderson et al., 1994). Syndecan-1
derived from MPC-11 myeloma cells binds to type I collagen with an
affinity 20-fold better than does syndecan-1 derived from P3 cells,
another myeloma cell line. This difference is observed even though
the core proteins from the two sources are indistinguishable, and the
HeS chains are of a similar size and net charge. Interestingly, the
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difference in the affinities appears to have a tangible effect at the level
of whole cells: MPC-11 cells adhere to type I collagen while P3 cells
do not (Sanderson et al., 1994).
The binding of syndecan-1 to LN-1 has also been investigated.
Several authors have reported on experiments in which syndecan-1
failed to bind to LN-1 in solid phase binding assays [ c.f. (Saunders and
Bernfield, 1988; Sanderson et al., 1992a)], a result that further
underscores the importance of testing HSPGs individually for binding
to a given ligand. However, solid phase assays have also indicated that
although syndecan-1 binds type 1 collagen, it fails to bind to type IV
collagen [for review see (Bernfield et al., 1992)], whereas affinity
coelectrophoresis (ACE) has demonstrated that syndecan I binds type
IV' and type I collagens equally well (San Antonio et al., 1994). This
serves to point out an advantage of the ACE technique: ligands can be
tested for PG binding without adsorption to plastic or chemical
crosslinking, either of which might significantly alter the biochemical
properties of the ligand.
The molecular basis of CBG binding to LN-1
The binding of CBG to LN-1 occurs with an affinity that is -300 fold
higher than heparin affinity for LN-1, and -1500 fold higher than the
affinity of HeS from PO rat brain membrane associated PGs for LN-1
(Table 1). These data indicate that a single HeS chain binding by itself
to LN-1 is unlikely to account for the measured affinity of intact CBG
for LN-1. Two possible reasons for the high affinity binding of CBG to
LN-1 are (1) the HeS chain(s) of CBG bind simultaneously to multiple
sites in LN-1, and (2) the CBG core protein contributes to the overall
affinity by interacting with LN-1. While the experiments described
above do not, distinguish between these possibilities, several of the
findings do bear on this issue.
For example, TSP-1 is a large multidomain glycoprotein of the
extracellular matrix composed of three subunits, each of which
contains two known heparin binding domains (Adams and Lawler,
1L993). However, CBG, heparin, and HeS all bind to TSP-1 with similar
affinities (Table 1). This indicates that the mere presence of multiple
heparin-binding sites within a molecule is not sufficient for high
affinity binding (relative to heparin) by CBG. If high affinity binding by
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CBG is the result of multivalent HeS interactions, the arrangement of
the HeS binding sites within the ligand would have to be important
since both LN-1 and TSP-1 contain multiple HeS binding sites but only
LN-1 is bound with high affinity. A similar argument can be made on
the basis of CBG binding to the recombinant G (rG) domain of LN-1; rG
also contains multiple heparin binding sites (Sung et al., 1993), but
binds CBG only nine fold better than it binds heparin (Table 1).
Many factors could render the arrangement of heparin binding sites
important. For example, HeS structure is known to be characterized
by clusters of highly sulfated residues separated by spans of largely
unmodified residues (Gallagher et al., 1992). The number of sites on
any given HeS chain capable of interacting with HeS binding sites in a
ligand molecule is therefore likely to be limited. If each chain
contains an average of only one ligand binding site, multiple chains
would be required to take advantage of multiple HeS binding sites on
the ligand. If the HeS binding sites were spaced too close together,
electrostatic repulsion between HeS chains could prevent both sites
from being utilized simultaneously.
Even if multiple ligand binding sites were present on any one HeS
chain, the spacing of the sites might preclude more than one site per
chain from binding to a ligand. Given the fact that HeS and HeS
binding molecules both have distinct domain structures, the unique
geometry of ,each HeS-binding ligand seems likely to have a profound
effect on its affinity for various HSPGs.
The fact that trypsinized CBG shows such a dramatically reduced
affinity for LN-1 (Table 1) suggests that, if multiple interactions of HeS
with LN-1 are indeed the basis of the high affinity binding of CBG to
LN-1, then these interactions would have to be mediated by multiple
HeS chains: if a single HeS chain were capable of binding to LN-1 with
the same high affinity as intact CBG, then trypsin digestion of CBG
would be unlikely to have such a dramatic effect on the Kd. HeS
chains isolated from PO rat brain also bind LN-1 with a much lower
affinity than any of the intact HSPGs tested. This further supports the
idea that CBG would need multiple HeS chains for high affinity binding
to LN-1 if the high affinity were strictly due to multiple HeS chain
interactions with LN-1.
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An alternative basis for the high affinity of CBG for LN-1 is that an
interaction between the CBG core protein and LN-1 contributes to the
overall binding. The fact that reduction and alkylation of the CBG core
has a marked effect on binding to LN-1 would seem to support this
hypothesis. However, the issue of geometry raised above also applies
in this case. It is possible that the tertiary structure of CBG is
required for maximal LN-1 binding not because of a protein-protein
interaction, but because the conformation of native CBG is necessary to
present the HeS chains in the optimum geometry for LN-1 binding.
If a protein-protein interaction is responsible for the high affinity
binding of CBG to LN-1, it appears to be relatively specific to LN-1
since the binding of CBG to rG and TSP-1 is only marginally better, if
at all, than the binding of heparin or HeS, and the affinities of CBG and
trypsinized CBG for FGF-2 are essentially identical. Examples of PGs
that bind their ligands via the core protein have been reported
elsewhere [e.g. the binding of TGF-P3 by the PG betaglycan, and the
binding of collagen fibrils by decorin (Vogel et al., 1984; Krusius and
Ruoslahti, 1986; Cheifetz and Massague, 1989).]
Summary
CBG, glypican, and syndecan-3 all bind to LN-1 much more strongly
than would be predicted on the basis of heparin's affinity for LN-1.
This result is consistent with the possibility that these neuronal cell
surface HSPGs could serve as receptors or coreceptors for LN-1
during nervous system development. In the case of CBG, the high
affinity binding requires an intact, native core protein suggesting that
the conformation of CBG is important either for a core protein binding
to LN-1, or for proper presentation of HeS chains for optimal LN-1
binding. High affinity binding (relative to heparin) is not a general
feature of CBG interactions with all potential ligands, since CBG's
affinity for TSP-1, FGF-2, and the rG domain of LN-1 is similar in each
case to that of heparin. Regardless of whether LN-1 is an authentic
ligand for CBG in vivo, these findings illustrate the importance of
testing intact HSPGs for binding to individual ligands rather than
relying on heparin affinity as an indicator of the potential for an
interaction.
221
ACKNOWLEDGEMENTS
John Slover assisted with the intial testing of CBG affinity for LN-1 by
ACE. Mary Hemdon provided data for Table 1. Jon Ivins provided
radiolabelled growth cone particle PGs.
222
References
Adams, J. and J. Lawler. 1993. The thrombospondin family. Curr.
Biol. 3:188-190.
Bernfield, M., R. Kokenyesi, M. Kato, M.T. Hinkes, J. Spring, R.L. Gallo,
and E.J. Lose. 1992. Biology of the syndecans: a family of
transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol.
8:365-393.
Calof, A.L., M.R. Campanero, J.J. O'Rear, P.D. Yurchenco, and A.D.
Lander. 1994. Domain-specific activation of neuronal migration and
neurite outgrowth-promoting activities of laminin. Neuron 13:117-
130.
Carey, D.J., D.M. Crumbling, R.C. Stahl, and D.M. Evans. 1990.
Association of cell surface heparan sulfate proteoglycans of Schwann
cells with extracellular matrix proteins. J. Biol. Chem. 265:20627-
:20633.
Cheifetz, S. and J. Massague. 1989. The TGF-P receptor proteoglycan:
cell surface expression and ligand binding in the absence of
glycosaminoglycan chains. J. Biol. Chem. 264:12025-12028.
0Cohen, J., J.F. Burne, C. McKinlay, and J. Winter. 1987. The role of
laminin and the laminin/fibronectin receptor complex in the
outgrowth of retinal ganglion cell axons. Dev. Biol. 122:407-418.
Cohen, J., J.F. Burne, J. Winter, and P. Bartlett. 1986. Retinal
ganglion cells lose response to laminin with maturation. Nature
322:465-467.
Colognato-Pyke, H., J.J. O'Rear, Y. Yamada, S. Carbonetto, Y.-S. Cheng,
and P.D. Yurchenco. 1995. Mapping of network-forming, heparin-
binding, and a lpl integrin recognition sites within the a-chain short
arm of laminin-1. J. Biol. Chem. 270:9398-9406.
deCurtis, I., V. Quaranta, R.N. Tamura, and L.F. Reichardt. 1991.
]Laminin receptors in the retina: Sequence analysis of the chick
integrin a6 subunit. Evidence for transcriptional and posttranslational
regulation. J. Cell Biol 113:405-416.
Gallagher, J.T., J.E. Turnbull, and M. Lyon. 1992. Patterns of
sulphation in heparan sulfate: polymorphism based on a common
structural theme. Int. J. Biochem. 24:553-560.
223
Gundersen, R.W. 1987. Response of sensory neurites and growth
cones to patterned substrata of laminin and fibronectin in vitro. Dev.
Biol. 121:423-431.
Herndon, M.E. and A.D. Lander. 1990. A diverse set of
developmentally regulated proteoglycans is expressed in the rat
central nervous system. Neuron 4:949-961.
Hunter, D.D., R. Llinas, M. Ard, J.P. Merlie, and J.R. Sanes. 1992.
Expression of S-laminin and laminin in developing rat central nervous
system. J. Comp. Neurol. 323:238-251.
Ivins, J.K., E.D. Litwack, A. Kumbasar, C.S. Stipp, A. Yang, and A.D.
Lander. 1995. Cerebroglycan and glypican are cell surface heparan
sulfate proteoglycans expressed on axons and growth cones in the
developing rat nervous system. Soc. Neurosci. Abstracts 21:795.
Kennedy, T.E., T. Serafini, and J.R.d.l. Torre. 1994. Netrins are
diffusible chemotropic factors for commissural axons in the embyronic
spinal cord. Cell 78:425-435.
Kim, C.W., O.A. Goldberger, R.L. Gallo, and M. Bernfield. 1994.
Members of the syndecan family of heparan sulfate proteoglycans are
expressed in distinct cell-, tissue-, and development-specific patterns.
Mol. Biol. Cell 5:797-805.
Kleinman, H.K., M.L. McGarvey, L.A. Liotta, P.G. Robey, K. Tryggvason,
and G.R. Martin. 1982. Isolation and characterization of type IV
procollagen, laminin, and heparan sulfate proteoglycan form the EHS
sarcoma. Biochemistry 21:6188-6193.
Krusius, T. and E. Ruoslahti. 1986. Primary structure of an
extracellular matrix proteoglycan core protein deduced form cloned
cDNA. Proc. Natl. Acad. Sci. USA 83:7683-7687.
Lander, A.D., D.K. Fujii, and L.F. Reichardt. 1985. Purification of a
factor that promotes neurite outgrowth: isolation of laminin and
associated molecules. J. Cell Biol. 101:898-913.
Lee, M.K. and A.D. Lander. 1991. Analysis of affinity and structural
selectivity in the binding of proteins to glycosaminoglycans:
development of a sensitive electrophoretic approach. Proc. Natl. Acad.
Sci. (USA) 88:2768-2772.
Lim, W.A., R.T. Sauer, and A.D. Lander. 1991. Analysis of DNA-protein
interactions by affinity coelectrophoresis. Meth. Enzymol. 208:196-
210.
224
Lin, M.L. and P.J. Bertics. 1995. Laminin responsiveness is associated
with changes in fibroblast morphology, motility, and anchorage-
independent growth: A cell system for examining the interaction
between laminin and EGF signaling pathways. J. Cell Physiol.
164:593-604.
Litwack, E.D. (1995). Expression and function of proteoglycans in the
nervous system: Massachusetts Institute of Technology).
Lobb, R.R. and J.W. Fett. 1984. Purification of two distinct growth
factors from bovine neural tissue by heparin affinity chromatography.
Biochemistry 23:6295-6299.
McLoon, S.C., L.K. McLoon, S.L. Palm, and L.T. Furcht. 1988.
Transient expression of laminin in the optic nerve of the developing
rat. J. Neurosci. 8:1981-1990.
Neugebauer, K.M., C.J. Emmett, K.A. Venstrom, and L.F. Reichardt.
1991. Vitronectin and thrombospondin promote retinal neurite
outgrowth: developmental regulation and role of integrins. Neuron
6:345-358.
Pfenninger, K.H., L. Ellis, M.P. Johnson, L.B. Friedman, and S. Somlo.
1983. Nerve growth cones isolated from fetal rat brain: Subcellular
fractionation and characterization. Cell 35:573-584.
Rogers, S.L., P.C. Letourneau, S.L. Palm, J. McCarthy, and L.T. Furcht.
1].983. Neurite extension by peripheral and central nervous system
neurons in response to substratum-bound fibronectin and laminin.
Dev. Biol. 98:212-220.
Rogers, S.L., P.C. Letourneau, and I.V. Pech. 1989. The role of
fibronectin in neural development. Dev. Neurosci. 11:248-265.
San Antonio, J.D., M.J. Karnovsky, S. Gay, R.D. Sanderson, and A.D.
Lander. 1994. Interactions of syndecan-1 and heparin with human
collagens. Glycobiology 4:327-332.
San Antonio, J.D., J. Slover, J. Lawler, M.J. Karnovsky, and A.D. Lander.
1993. Specificity in the interactions of extracellular matrix proteins
with subpopulations of the glycosaminoglycan heparin. Biochem.
32:4746-4755.
Sanderson, R.D., T.B. Sneed, L.A. Young, G.L. Sullivan, and A.D. Lander.
1.992a. Adhesion of B lymphoid (MPC-11) cells to type I collagen is
mediated by the integral membrane proteoglycan, syndecan. J.
Immunol. 148:3902-3911.
225
Sanderson, R.D., J.E. Turnbull, J.T. Gallagher, and A.D. Lander. 1994.
Fine structure of heparan sulfate regulates syndecan-1 function and
cell behavior. J. Biol. Chem. 269:13100-13106.
Saunders, S. and M. Bernfield. 1988. Cell surface proteoglycan binds
mouse mammary epithelial cells to fibronectin and behaves as a
receptor for interstitial matrix. J. Cell Biol. 106:423-430.
Serafini, T., T.E. Kennedy, M.J. Galko, C. Mirzayan, T.M. Jessell, and
M. Tessier-Lavigne. 1994. The netrins define a family of axon
outgrowth-promoting proteins homologous to C. elegans UNC-6. Cell
78:409-424.
Sheppard, M.M., S.K. Hamilton, and A.L. Pearlman. 1991. Changes in
the distribution of extracellular matrix components accompany early
morphogenetic events of mammalian cortical development. J.
Neurosci. 11:3928-3942.
Skene, J.H.P., R.B. Jacobson, G.J. Snipes, C.B. McGuire, J.J. Norden,
and J.A. Freeman. 1986. A protein induced during nerve growth
(GAP-43) is a major component of growth-cone membranes. Science
233:783-786.
Sung, U., J.J. O'Rear, and P.D. Yurchenco. 1993. Cell and heparin
binding in the distal long arm of laminin: Identification of active and
cryptic sites with recombinant and hybrid glycoprotein. J. Cell. Biol.
123:1255-1268.
Timpl, R., H. Rohde, L. Risteli, U. Ott, P.G. Robey, and G.R. Martin.
1982. Laminin. Meth. Enzymol. 82:831-838.
Vogel, K.G., M. Paulsson, and D. Heinegard. 1984. Specific inhibition
of type I and type II collagen fibrillogenesis by the small proteoglycan
of tendon. Biochem. J. 223:587-597.
Yurchenco, P.D. and J.J. O'Rear. (1993). . In Molecular and Cellular
Aspects of Basement Membranes, D. H. Rohrback and R. Timpl,
editors. (New York: Academic Press), pp. 19-47.
226
Figure 1. Immunopurification of CBG from embryonic day 16 rat brain
membrane fraction. 12 5 1-labelled PGs from E16 rat brain membrane
fraction were immunoprecipitated with the 521-2 affinity matrix as
described in Materials and Methods. The eluate from the
immunoprecipitate was digested with chondroitinase ABC,
heparitinase, or both enzymes and compared to total PGs from the
E16 membrane fraction that had been similarly treated. Abbreviations:
mem., E16 membrane fraction PGs; Ip, the eluate from the 521-2
affinity matrix; u, undigested; c, chondroitinase digested; h,
heparitinase digested; d, double digest. The position of the molecular
weight markers is indicated. The open arrowhead indicates the CBG
core protein, which migrated with an Mr of 53 kDa, similar to what
had been observed previously (Herndon and Lander, 1990).
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Figure 2. Affinity coelectrophoresis
A schematic of an affinity coelectrophoresis (ACE) gel is shown as
viewed from above. Labelled PGs and GAGs migrate through lanes
containing test ligand at various concentrations, embedded in 1% low
melting point agarose. Under these conditions, there is little or no
sieving of the PG or GAG by the agarose. Due to a high net negative
charge, PGs and GAGs typically migrate with a high mobility relative to
the test ligand. An interaction with the ligand results in the formation
of a lower mobility complex. The extent to which the PG or GAG
migration is retarded, as a function of ligand concentration, can be
used to calculate a Kd for the interaction.
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Figure 3. CBG binds to LN-1 with high afflnity
12 5 1-labelled, immunopurified CBG from E16 rat brain was compared
with 12 5 1-labelled low molecular weight (LMW-heparin) for binding to
LN-1 using affinity coelectrophoresis (ACE). (A) The affinity pattern
obtained for CBG. (B) The affinity pattern obtained for LMW-heparin.
The concentrations of LN-1 in each lane are indicated. (C) The
binding isotherms derived from the affinity patterns in (A) and (B).
CBG bound to LN-1 with an apparent affinity of 0.18 nM, while the
measured affinity of LMW-heparin was 203 nM. For LMW-heparin, Ro,
the R value for maximally retarded PG or GAG, was constrained to 1.0
during curve fitting, based on values obtained from subfractions of
heparin with higher affinity for LN-1 that acheive maximal retardation
within the range of LN-1 concentrations tested (San Antonio et al.,
1993). Ro for CBG was not constrained during curve fitting, and was
0.92 for the binding isotherms in this experiment.
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Figure 4. Binding of CBG and trypsin-digested CBG to LN- and FGF-2
Immunopurified, 12 5 I-labelled CBG from embryonic day 16 rat brain
was digested exhaustively with trypsin as described in Materials and
Methods. The affinities of trypsinized CBG (A and C) and intact CBG (B
and D) for LN-1 (A and B) and FGF-2 (C and D) were compared using
affinity coelectrophoresis. Trypsin treatment reduced CBG affinity for
LN-1 by a factor of 400, but had no effect on CBG affinity for FGF-2.
See Table 1 for Kds, which were calculated as described in Materials
and Methods.
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Table 1. continued...
The table summarizes the affinities of CBG, glypican (GPN), and
syndecan-3 (SYN-3) for LN-1, the recombinant G domain (rG) of LN-1,
FGF-2, and TSP-1, as measured using affinity coelectrophoresis (ACE)
in several separate experiments. Abbreviations: (red.), reduced and
alkylated; (tryp.), trypsin digested; (HeS), metabolically labelled
heparan sulfate; (E16 mem.), embryonic day 16 rat brain membrane
fraction; (PO GCP), neonatal rat brain growth cone particles; (PO
mem.), neonatal rat brain membrane fraction; (3T3 cells), membrane
fraction of the CBG-expressing 3T3 cell line 3T3infuCBGA3'.
For comparison, the affinity of low molecular weight (LMW)-heparin
(heparin) for was also measured in many cases. The ratio of the Kd of
heparin to the Kd of a particular PG or GAG appears in the columns
labelled (Kdhep)/(Kd). Numbers in this column >1.0 indicate that the
PG binds stronger than LMW-heparin to a particular ligand, and
numbers <1.0 indicate weaker binding than LMW-heparin.
Footnotes: (a) the average of 3 separate determinations. (b) the
average of 2 separate determinations. (c) these values courtesy of
Mary Herndon.
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Figure 5. Reduction and alkylation of the CBG core protein results in
decrease in affinity for LN-1. 12 5 1-labelled, immunopurified CBG was
reduced and alkylated as described in Materials and Methods, and its
affinity for LN-1 was compared to the affinity of untreated CBG using
affinity coelectrophoresis. (A) Affinity pattern of reduced and alkylated
CBG. (B) Affinity pattern of untreated CBG. The concentrations of LN-
1 in each lane are indicated. The affinity pattern of reduced and
alkylated CBG could not be accurately converted into a single binding
isotherm, but was estimated to be in the range of 10-100 nM (see also,
Table 1).
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CHAPTER 5
DETERMINATION OF THE MOLECULAR WEIGHT OF INTACT
CEREBROGLYCAN
239
INTRODUCTION
Heparan sulfate proteoglycans (HSPGs) have the potential to
interact with a diverse set of molecules including growth factors,
extracellular matrix glycoproteins, cell adhesion molecules, proteases
and antiproteases. As a result, HSPGs may play roles in a wide variety
of cell behaviors including cell adhesion, migration, axon outgrowth,
cell proliferation and cancer [for reviews, see (Kjellen and Lindahl,
1991; Bernfield et al., 1992; Wight et al., 1992)]. Where investigated,
interactions of HSPGs with their ligands have often been found to be
mediated by the heparan sulfate (HeS) chains of HSPGs (Jackson et al.,
1991). This raises the possibility that one way cells regulate their
interactions with their environment is by altering the number or
composition of the glycosaminoglycan (GAG) chains presented by PGs
at the cell surface.
Support for this idea has come from studies of the cell surface PG
syndecan-1, which can be substituted with both HeS and chondroitin
sulfate (CS) chains. Several examples have been documented in which
the HeS/CS ratio, the size of the GAG chains, and potentially, the
average number of chains attached per core have been found to change
during development, from tissue to tissue, or in response to growth
factor exposure in vitro (Rasmussen and Rapraeger, 1988; Sanderson
and Bernfield, 1988; Sanderson et al., 1989; Brauker et al., 1991;
Sanderson et al., 1992b). For example, syndecan-1 from simple
epithelia (e.g. gastric, cutaneous) and syndecan from stratified
epithelia (e.g. uterus) have been shown to have different structures.
The syndecan in simple epithelia has larger HeS and CS chains than
syndecan from stratified epithelia, and intact syndecan from simple
epthelia migrates with an apparent molecular weight (Mr) in SDS-
PAGE gels that is significantly higher than that of syndecan from
stratified epithelia (Sanderson and Bernfield, 1988).
One limitation in the structural characterization of PGs arises from
the anomalous electrophoretic behavior of intact PGs in SDS-PAGE
gels. It has long been established that glycosylation can result in an
inaccurate estimate --typically an overestimation -- of molecular
weight by SDS-PAGE [c.f. (Leach et al., 1980)]. Without an accurate
estimate of the molecular weight of the intact PG, guesses about the
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average number of chains attached per PG core protein are likely to be
incorrect.
In the previous chapter, we demonstrated that the neuronal cell
surface HSPGs cerebroglycan (CBG), glypican (GPN), and syndecan-3
all bind to laminin-1 (LN-1) with unexpectedly high affinity (on the
order of 0.5-2 nM). The basis of CBG's high affinity for LN-1 (which
was 400-fold higher than the affinity of heparin for LN-1) was explored
further and found to require an intact, native CBG core protein. Two
possible reasons for this requirement are (1) the high affinity binding
is the result of multiple HeS chains binding to multiple sites on LN-1,
and an intact core is required to tether the chains and possibly to hold
them in the optimal conformation for binding, and/or (2) an intact
core protein is required for a protein-protein interaction with LN-1
that contributes to the observed high affinity binding.
To distinguish between these possibilities, it would be helpful to
know how many HeS chains on average are attached to each CBG core
protein. We report here on studies in which the molecular weight of
intact CBG and GPN are determined by a combination of gel filtration
chromatography and sucrose density centrifugation in H20 and
deuterium oxide (D20). These results, combined with an independent
estimate of HeS chain size by gel filtration, are consistent with a
model where each CBG and GPN core protein is substituted with, on
average, a single HeS chain, although substitution with two HeS chains
per core could not be ruled out. This finding favors the hypothesis
that it is an interaction of the CBG core protein with LN-1 that
improves the affinity of CBG for LN-1 from values of -200 to 800 nM
(seen for heparin, trypsin-digested CBG, and free HeS) to the value of
0.5 nM, seen for intact CBG. This view is further supported by studies
of LN-1 binding by recombinant ryudocan/syndecan-4 isoforms
expressed in L cells. A form of ryudocan with two HeS chains attached
was found to bind to LN-1 no better than a form with a single chain
attached. Interestingly, ryudocan binding to LN-1 occurred with a
substantially lower affinity than that observed for the other cell surface
HSPGs tested so far, suggesting a level of specificity in the interactions
of LN-1 with HSPG core proteins.
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MATERIALS AND METHODS
Preparation of Cerebroglycan and Glypican for Molecular Weight
Determination
Growth cone particle PGs were isolated and radiolabelled as
described in Chapter 4. To eliminate the complication of detergent
binding in the molecular weight determinations, the
glycosylphosphatidylinositol (GPI) lipid anchors of CBG and GPN were
removed by digestion with phosphoinositol-specific phospholipase C
(PIPLC, Boehringer Mannheim). 50 p1 of 12 5 I-labelled PGs
(containing 2 X 107 cpm) in 50 mM TrisHC1, 0.75 M NaC1, 0.5%
CHAPS were diluted with 3910 p1 of 50 mM Tris-phosphate pH 7.5,
0.1% TritonX-114 ( TX-114, Pierce), with 1 mM EDTA, and 1pg/ml
pepstatin A, and 40 1l PIPLC (200 U) was added. After a 1 hour
digestion at 370C, another 200 U of PIPLC was added, and incubation
was continued for an additional hour. The reaction was stopped by the
addition of 240 p1 of 5 M NaC1, and the reaction was extracted with
TX-114 to remove any uncleaved CBG and GPN: 800 ýtl of 10% TX-
.1114 was added, followed by a 5 minute incubation at 370C. Under
these conditions, TX-114 resolves into a separate phase, and integral
membrane proteins are selectively enriched in the detergent phase.
After centrifugation to clarify the detergent and aqueous phases, the
aqueous phase was removed and subjected to a second round of TX-
114 extraction. The second aqueous phase was loaded into a
Centricon-30 microconcentrator (Amicon) that had been pre-blocked
with 1 mg/mnl BSA and rinsed. The PGs were concentrated from a
volume of -4, ml to a volume of 290 t1. To remove residual TX-114,
the PGs were passed over a 200 p1 column of Extractigel D (Pierce)
that had been pre-equilibrated in TBS (50 mM TrisHC1 pH 7.4, 0.15 M
NaC1) withl mg/ml crystalline BSA. By monitoring the absorbance at
275 nm before and after the Extractigel D step, it was determined
that the concentration of TX-114 had been reduced from 0.08% to
0.01%, below the critical micelle concentration of -0.02%
(Neugebauer, 1990).
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Gel Filtration of Cerebroglycan and Glypican
6 X 106 cpm (114 p1) of the PGs prepared as described above were
loaded to a Sepharose CL-6B (Pharmacia) column along with 32 gg of
E. Coli P-galactosidase (p-gal, Sigma) and 1 ptCi of Na2 3 5 SO4 (to
measure the included volume, Vt) in a buffer with 5% glycerol and
0.015% phenol red in a final volume of 150 ptl. The dimensions of the
column were: 28.5 cm X 0.7 cm dia. The column was eluted with TBS
at a rate of 3.9 cm/hour. In subsequent runs, the column was
calibrated with bovine thyroid gland thyroglobulin (Sigma), bovine liver
catalase (Worthington), and rabbit muscle glyceraldehyde phosphate
dehydrogenase (GAPD, Worthington)(see below for enzyme assays). 3-
gal and 3 5 SO4 were included in each run to allow all runs to be
normalized. The void volume (Vo) was measured by the leading edge
of Blue Dextran 2000 (Fluka) and was found to correspond with a
sharp peak of 12 5 I-labelled PGs that eluted ahead of CBG and GPN and
that contains HSPGs with core proteins of 120 kDa and higher (not
shown). CBG and GPN were located in the elution profile by
heparitinase digestion and SDS-PAGE, performed as described in
previous chapters. The CBG and GPN bands were quantified using a
phosphorimager (Molecular Dynamics).
Sucrose Density Gradient Centrifugation
4.7 ml linear gradients of 5 -4 20% sucrose in TBS were prepared
in H20 or D 20 (ICN) using a Model J5 Gradient Former (Jule Inc.,
New Haven, CT) in 5 ml ultracentrifuge tubes. The tubes were
covered with parafilm, and the gradients were allowed to age for 3
hours at 40C. Samples containing 1 X 106 cpm of labelled PO GCP
PGs, prepared as described above, in a 100 Cl volume were overlaid
onto the gradients. Bovine pancreatic trypsin inhibitor (BPTI,
Worthington), aggregate-free bovine pancreatic ribonuclease A (RNAse
A, Worthington), human erythrocyte carbonic anhydrase B (CAH,
Sigma), pig heart mitochondrial malate dehydrogenase (MDH,
Worthington), and calf intestinal alkaline phosphatase (AP, Sigma)
were included in the samples as protein standards (see below for
enzyme assays). The gradients were centrifuged for 20 hours at
45,000 rpm, 4oC in a Sorvall AH650 swinging bucket ultracentrifuge
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rotor (o02 t = 1.60 X 1012 s-l). Fractions were collected from the
bottom of the tubes using a fraction collector (Hoeffer). The locations
of CBG and GPN in the gradient were determined by SDS-PAGE after
heparitinase digestion, as described for the gel filtration experiments
above. A separate run of GCP PGs in a 5 -4 20% sucrose gradient in
TBS/H20 performed on a different day gave an essentially identical
sedimentation profile as did parallel runs of CL-6B purified CBG and
GPN performed at the same time as the run described above. The run
described above was used as the basis for molecular weight
calculations because the smaller number of cpm in the CL-6B purified
pool made the quantification of the CBG and GPN bands by
phosphorimager more difficult.
Enzyme Assays
BPTI was assayed by measuring the inhibition of trypsin
(Worthington) activity using Chromozyme TH (Boehringer Mannheim)
as a substrate and measuring absorbance at 405 nm (A405) of timed
reactions. RNase A was measured by monitoring the digestion of poly-
cytidylic acid (Fluka cat.#81306) as described by Zimmerman and
Sandeen (1965). This assay proved to be extremely sensitive, linear
and highly reproducible. CAH and MDH were assayed
densitometrically after SDS-PAGE and silver staining. AP was assayed
with p-nitrophenyl phosphate (Sigma) by monitoring A410 of timed
reactions. Thyroglobulin was assayed by measuring A278 of aliquots of
selected column fractions. P-gal was assayed with o-nitrophenyl-f-D-
galactopyranoside (Sigma) by monitoring A405 of timed reactions.
Catalase was assayed with 0.2% H202 by monitoring A240 of timed
reactions, and GAPD was assayed with DL-glyceraldehyde-3-phosphate
and P-nicotinamide adenine dinucleotide (NAD+ ) by monitoring A340
of timed reactions. The bases of the enzyme assays and composition of
the buffers are described in the Worthington Enzyme Manual
(Worthington, 1993) which can be obtained upon request from
Worthington Biochemical Corp. Table 1 lists the protein standards
used in this study along with the relavent hydrodynamic constants.
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Molecular Weight Calculations
The basis of the molecular weight determinations is the Svedberg
equation which relates the hydrodynamic properties of a molecule to
its molecular weight: M = sRT/D(1-Vp); where M is molecular weight
(in grams/mol); s is the sedimentation coefficient in svedberg units(1
svedberg is 10-13 sec); R is 8.31 X 107 erg mol-1 deg-1; T is
temperature in degrees Kelvin; D is the diffusion coefficient in cm 2
sec-1; V is the partial specific volume in cm 3 g- 1 ; and p is the density
of the solution in g cm- 3 . As described by Clarke (1975), an
adaptation of the Svedberg equation is M = (Sapp, Ravg)( 6 n)(T1app,
Ravg)(a)(N)/(1 - VpRavg). In this equation, Sapp,Ravg is the apparent
sedimentation coefficient for the molecule at Ravg, the position of half
distance of travel of the molecule in the gradient, [Sapp,Ravg = ((r -
ro)/t/(02Ravg) ; where r = the distance of the peak at time t, (the end of
the run), ro is the distance of the applied band at time zero, and Ravg
=- (r + ro)/2]. rlapp,Ravg is the apparent viscosity of the solution at Ravg;
P'Ravg is the density of the solution at Ravg; "a" is the Stokes radius,
and N is Avagadro's number. In the present study, the Stokes radius
was calculated by gel filtration chromatography as described above
using protein standards of known Stokes radii to calibrate the column.
Although the reader is referred to Clarke, (1975) for a more
complete discussion, some additional features of the calculations are
described below. Values of Tlapp,Ravg were determined for CBG and
GPN by including in each run protein standards with a known s20,w
(sedimentation coefficient at 20oC in H20) and a known V. The value
of sapp,Ravg, measured for each standard, along with the s20,w and V
values, was used to calculate values of Tlapp,Ravg for each protein
standard. The values of Tlapp,Ravg for CBG and GPN were determined
by interpolating between the values of Tlapp,Ravg calculated for the
protein standards. In this way the apparent viscosity, as a function of
the position in the gradient, becomes a general correction factor
which gives the system self-consistency (Clarke, 1975).
The values of V for CBG and GPN were determined on the basis of
their differing rates of sedimentation in D20 and H20: the measured
values of sapp,Ravg, rlapp.Ravg
, and pRavg for CBG and GPN in D20 and
FH20 were used to calculate V , using equations from Clarke, (1975).
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In Clarke, (1975), values relating to the amount of detergent bound by
the molecules enter into these equations; these values are equal to
zero in the present study since sedimentation and gel filtration were
performed in the absence of detergent.
Preparation of Labelled Heparan Sulfate from a Neonatal Rat Brain
Membrane Fraction
Dissections of neonatal (PO) rat brains and removal of meninges was
accomplished as outlined in Chapter 2. Meninges-free whole brains
were cut into 1mm x 350 gim prisms with a McIlwain Tissue Chopper,
then settled through Hanks buffered salt solution (HBSS, Gibco).
Serum free, sulfate free Dulbecco's modified Eagle's medium (SSF-
DMEM) was formulated to GIBCO/BRL specifications for DMEM - but
without sulfate - using culture supplements and 10X Earle's Balanced
Salt Solution from GIBCO. SSF-DMEM was supplemented ("labelling
medium") to 50 jiM with unlabeled Na2SO 4 , 10 9g/ml insulin, 5 mg/ml
crystalline BSA, 10 gg/ml transferrin, 20 nM progesterone, 100 jM
putrescine, 30 nM selenium, and 250 mCi/ml Na23 5SO4 (ICN).
Labelling medium was added to tissue prisms at 20 ml per ml tissue
(settled volume) and prisms were cultured 16-20 hours in 5% C02
with gentle gyratory rocking (Nutator).
PGs were isolated from the membrane fraction of labelled prisms as
previously described [(Herndon and Lander, 1990); Chapter 2 this
thesis]. To the PG pool, in a volume of 1.7 ml, 32 Il of 5 M NaOH and
16 gl of fresh Na2BH4 in 10 mM NaOH were added to liberate
glycosaminoglycan (GAG) chains by [-elimination. After 90 minutes at
45 0C, 3 gl of 0.5% phenol red were added to monitor neutralization
with -32 Il of 5 M HC1. The reaction was chilled on ice and
centrifuged for 10 minutes at 12,000 g to remove insoluble, denatured
protein. The supernatant was transferred to a fresh tube and
precipitated on ice for 30 minutes with the addition of 10 jil of 10
mg/ml hyaluronate and 5.9 ml of ice cold 100% ethanol. After
centrifugation for 20 minutes at 40 C, 12,000 g, the pellet was
resuspended in 450 il of H20, and reprecipitated with 1440 jil of
ethanol. The final pellet was resuspended in TBS and stored at -80 0C
until use. Labelled GAGs were treated with chondroitnase ABC to
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eliminate chondroitin sulfate contamination, in a reaction performed
essentially as previously described (Herndon and Lander, 1990),
overnight at 370C.
Gel Filtration of 3 5 S04-Labelled Heparan Sulfate Chains
Labelled heparan sulfate (HeS) chains, prepared as described above,
were sized by gel filtration chromatography using a Sephadex-G100
column (Pharmacia). The dimensions of the column were 18 cm by
0.5 cm dia. The column was eluted at a flow rate of 4 cm/hour; the
running buffer was TBS. HeS chains were loaded in a volume of 100 ll
in a buffer containing 5% glycerol, 0.015% phenol red, and 1 pCi of
free 3 5 SO4 2 -, which was included to ensure a peak at the included
volume, Vt. The column had been previously calibrated using
fluorescein isothiocyanate (FITC)-conjugated dextrans of known modal
molecular weight (Sigma), the elution of the FITC-dextrans was
monitored by reading A493 of portions of selected fractions in a
spectrophotometer. The void volume of the column was measured as
the elution volume of the leading edge of Blue Dextran 2000 (Fluka).
To verify that labelled HeS was being sized, an aliquot of the material
was digested overnight at 37oC with heparitinase, essentially as
described (Herndon and Lander, 1990), and run on the G100 column.
Column fractions from both runs were assayed by counting aliquots of
each fraction in a scintillation counter (LKB-Wallach).
Preparation and LN-I Affinity Coelectrophoresis of Ryudocan Isoforms
Growth and metabolic labelling of the mouse L cell lines, L215 and
L218 were performed essentially as previously described (Shworak et
al., 1994a). These cell lines express epitope-tagged ryudocan isoforms
with two or one GAG acceptor site respectively. Immunopurification
of 3 5 S-labelled ryudocan isoforms was performed as described
(Shworak et al., 1994a) except that immunoprecipitates were eluted
with a low pH step, as described for CBG and GPN in Chapter 4. The
affinity of the ryudocan isoforms for LN-1 was measured by affinity
coelectrophoresis, as described in Chapter 4.
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RESULTS
Cerebroglycan and glypican molecular weight determination
In a previous study, cerebroglycan (CBG) and glypican (GPN) were
found to bind to laminin-1 (LN-1) with high affinity (0.5 and 2 nM
respectively) (Chapter 4). The molecular basis of these high affinity
interactions is unknown. To obtain a more accurate picture of the
structure of intact CBG and GPN, the molecular weights of these two
related molecules were determined. Because of the aberrant
electrophoretic behavior of glycosylated molecules in SDS-PAGE
(Leach et al., 1980), an accurate measure of the molecular weight
(Mw) of intact PGs is unlikely to be obtained using this method. We
have chosen instead a method based on the Svedberg equation which
relates Mw to the hydrodynamic behavior of molecules. The Svedberg
equation allows a determination of Mw that is independent of the
details of molecular shape (Cantor and Schimmel, 1980).
The hydrodynamic parameters that must be measured to make use
of the Svedberg equation are (1) Stokes radius, (2) the sedimentation
coefficient, and (3) the partial specific volume. The Stokes radii of
CBG and GPN [isolated from neonatal (PO) rat brain growth cone
particles (GCPs) (Pfenninger et al., 1983) and labelled with 1 2 5 1] were
measured by gel filtration on Sepharose CL6B. Heparitinase digestion
followed by SDS-PAGE analysis of the column fractions allowed the
fractions containing CBG and GPN to be identified (Figure 1). CBG and
GPN core proteins were easily distinguishable in this assay as had been
previously observed (Herndon and Lander, 1990). The identities of
these bands were confirmed by SDS-PAGE with immunopurified CBG
and GPN in subsequent experiments (not shown). Figure 2A shows
the elution profile of CBG and GPN, as determined by densitometric
quantification of the CBG and GPN core protein bands. Also shown are
the elution positions of the protein standards that were used to
calibrate the column. Comparison of the CBG and GPN elution profiles
to the calibration curve generated by the standards yielded values of
Stokes radii of 6.51 and 6.57 nm respectively (Figure 2B).
To determine the sedimentation coefficients (s) and the partial
specific volumes (V) of CBG and GPN, sucrose density gradient
centrifugation in H20 and D20 was performed (Clarke, 1975). To
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calibrate the gradients, protein standards of known s20,w (the s value
at 200C in water) and V were included in the sedimentation runs.
Figure 3 (A and B) shows the sedimentation profiles of the standards.
Plots of s versus fraction number derived from these profiles were
linear, demonstrating that the gradients were effectively linear (Figure
3, C and D). The apparent s values of the standards in the
sedimentation runs, and their previously determined values of s20,w
and V were used to determine apparent viscosity as a function of
position in the gradients (Clarke, 1975), one of the parameters
required for the subsequent calculations of s and V. The
sedimentation profiles of CBG and GPN were determined by SDS-
PAGE after heparitinase digestion as described for the analysis of the
CL6B fractions above (Figure 4). The apparent s values of CBG and
GPN, their s20,w values, and their V values were calculated from the
CBG and GPN sedimentation profiles as described in Clarke, (1975).
These values and the molecular weights calculated from them are
summarized in Table 2. The calculated Mw for CBG was 100 kDa,
while the Mw of GPN was calculated at 103 kDa. With the core
protein contribution subtracted, these Mw values imply that both CBG
and GPN carry an average of -42 kDa of HeS per core protein.
Estimation of the average size of HeS from the neonatal rat brain
membrane fraction
To obtain an estimate of the average number of HeS chains per core
protein for CBG and GPN, the size of HeS isolated from PO rat brain
membrane fraction was measured. To prepare labelled HeS for these
experiments, finely chopped prisms of PO rat brain were cultured in
vitro in a defined medium containing 35SO42-. HeS was isolated from
the membrane fraction of the labelled prisms as described in Materials
and Methods. Labelled HeS was analyzed by gel filtration
chromatography with or without prior digestion with heparitinase
(Figure 5). Comparison of the elution profile of intact HeS with the
elution volumes of fluoresceinated dextrans of known molecular
weight allowed the size of the PO HeS chains to be estimated (Figure
5). The bulk of the PO HeS eluted as a relatively broad peak, centered
at -40 kDa, suggesting that the entire amount of HeS found on average
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on each CBG and GPN core protein could be accounted for by a single
HeS chain (See discussion).
The binding of one and two chain ryudocan isoforms to LN-1
Ryudocan is a member of the syndecan family of cell surface HSPGs
and contains three potential glycosaminoglycan (GAG) attachment
sites. A recent study has characterized these sites, demonstrating that
all three are utilized and all three can be substituted with both HeS
and chondroitin sulfate (CS) (Shworak et al., 1994a). This was
accomplished by generating ryudocan isoforms in which the three
GAG attachment sites had been systematically eliminated by changing
the serine acceptor residues to threonines, and expressing them in
mouse L cells.
The molecular weight calculations presented above suggest that
CBG and GPN may be, on average, substituted with a single HeS chain
per protein core. Since free HeS binds to LN-1 with a much lower
affinity than intact CBG and GPN (Chapter 4 this thesis), it is unlikely
that a single HeS chain binding to LN-1 by itself could account for the
observed affinities of CBG and GPN for LN-1. This raises the possibility
that CBG and GPN core proteins bind to LN-1, contributing to the
overall affinity observed for the intact PGs. If the strong binding of
CBG and GPN observed in Chapter 4 results from an extra contribution
to binding by the core protein, it raises the possibility that the number
of GAG chains per core protein may not be an important determinant
of a PG's affinity for LN-1. To test this possibility the binding of
ryudocan isoforms with one or two GAG chains to LN-1 was measured.
Exponentially growing L cell lines were used for metabolic labelling
and isolation of the ryudocan isoforms, as previously described
(Shworak et al., 1994a). Under conditions of exponential growth, -
90% of the GAG chains attached to ryudocan are HeS chains (Nicholas
Shworak, personal communication) minimizing any potential effect of
CS chain substitution. (In a separate experiment using total L cell PGs,
pretreatment with chondroitinase ABC resulted in no difference in the
binding pattern or electrophoretic migration in ACE.) The LN-1
affinity of immunopurified ryudocan with a single HeS chain was
compared to the affinity of ryudocan with two HeS chains using affinity
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coelectrophoresis as described in Chapter 4. Both ryudocan isoforms
were found to bind LN-1 with similar affinities (Kd of ~120-140
nM)(Figure 6). This result provides further support for the idea that
factors other than multivalent HeS chain interactions are responsible
for the high affinity binding of CBG and GPN to LN-1.
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DISCUSSION
Determination of the molecular weights of cerebroglycan and glypican
An estimate for the molecular weights (Mw) of intact CBG and GPN
has been obtained based on the measurement of hydrodynamic
properties. The basis of the calculations was the Svedberg equation
that permits a calculation of Mw that is independent of the details of
molecular shape, provided that the various hydrodynamic
measurements were made under conditions as similar as possible
(Cantor and Schimmel, 1980). The sedimentation coefficients and the
partial specific volumes of CBG and GPN were measured by
sedimentation on a 5 -* 20% sucrose gradients in H20 and D20. In
this technique, the positions of CBG and GPN in the gradient are
determined at only one time point -- the end of the sedimentation
run. A more rigorous method would require monitoring the positions
optically at all times during the run (Cantor and Schimmel, 1980).
Nevertheless, the uncertainty in measurements by the sucrose
gradient method have previously been estimated to be ±8%, and much
of this was due to uncertainties about amounts of detergent bound to
the proteins (Hartshorne et al., 1980). Since we took steps to
minimize the contribution of bound detergent, the uncertainty in our
measurements may be lower still.
The Mw values that were obtained for CBG and GPN were 100 and
103 kDa respectively. These values are substantially lower than the
estimated ~200,000 kDa apparent molecular weight of the undigested
molecules by the SDS-PAGE method (for example, see Figure 1,
Chapter 4). This result is not surprising since the overestimation of
the molecular weights of glycosylated proteins by SDS-PAGE has been
reported before (Leach et al., 1980). The aberrant electrophoretic
behavior of PGs may be related to an unusually large hydrodynamic
radius. In the gel filtration experiments described above, CBG and
GPN Stokes radii were measured at 6.51 and 6.57 nm respectively,
about as large as that of P-galactosidase, a protein of 540 kDa. These
results demonstrate that estimations of PG molecular weight based
soley on SDS-PAGE or gel filtration are unlikely to be accurate.
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Heparan sulfate chain number for CBG and GPN
When the sizes of the core proteins are substracted from the total
molecular weights determined for CBG and GPN in this study, a value
of -42 kDa is obtained for the amount of HeS attached on average to
each core protein. An independent measurement of HeS chain size
from PO rat brain membrane fraction resulted in a broad peak
centered at -40 kDa. Thus it is possible that the entire mass of HeS
attached on average to CBG and GPN core proteins could be accounted
for by a single HeS chain, although the peak was sufficiently broad to
permit the possibility of substitution with two smaller chains. This
result is different from an earlier assessment for GPN from human
lung fibroblasts (David et al). Although a similar size for the HeS
chains was reported, the estimation of the Mw of intact GPN was
based on SDS-PAGE, and was set at -200,000, leading to the
conclusion that several HeS chains must be attached to each GPN
protein core ((Lories et al., 1989; David et al., 1990)). As discussed
above, SDS-PAGE is likely to result in an overestimate of the size of
intact PGs.
Another source of disagreement is in the estimation of HeS chain
size. One earlier study reported a value for brain HeS of -~ 14-15 kDa,
significantly lower than the value of -40 kDa reported here (Ripellino
and Margolis, 1989). A possible source for this discrepancy is
developmental age. In the earlier study, HeS chains were isolated
from adult rat brain. In the present study HeS was isolated from
neonatal rat brain. Variation of HeS chain size with developmental
stage has been reported before. For example, in the mouse lung
epithelium, the average size of HeS chains is 51 kDa on embryonic day
14, but has decreased to only 28 kDa by embryonic day 18 (Brauker et
al., 1991). In this study, HeS chains were prepared by an in vitro
labelling protocol similar to the one employed in our experiments.
Another study reported that when mouse keratinocytes stratify in
vitro, the average size of HeS chains decreases from 34 to 21 kDa
(Sanderson et al., 1992b). It is possible that a similar decrease in
average size of HeS chains occurs during brain development. The
value of -40 kDa obtained in the present study is similar to the value of
40 kDa obtained from HeS isolated from the retinal neuroepithelium
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of embryonic chick (Cole and Burg, 1989); thus the value we report is
not an unprecedented size for neuronal HeS, and demonstrates that,
at a minimum, HeS chains in the size range of 40 kDa are present as a
substantial fraction of material derived from PO rat brain.
Determination of the size of HeS chains attached to
immunopurified CBG and GPN will be necessary to resolve this issue.
The elution profile shown in Figure 5 is sufficiently broad that chain
sizes of ~20 kDa could be present in significant quantities. If for some
reason HeS from CBG and GPN was smaller on average than total HeS,
it would be possible for more than one HeS chain to be attached to
each core protein. It will also be important to include
glycosaminoglycan (HeS or CS) chains of defined size in future
calibrations since the dextrans used in the present study may not be
the most suitable standards because of differences in structure (i.e.
sulfation) between dextrans and GAGs.
Thus, the results of the present study cannot conclusively
distinguish between a model where each CBG or GPN core protein is
substituted with one HeS chain or a model in which each core is
substituted with two HeS chains. However, they do establish that HeS
chains derived from neonatal rat brain contain a broad range of sizes,
including a substantial fraction that appears to be 40 kDa or larger.
Implications of CBG and GPN structure on binding to laminin
In the previous chapter, we demonstrated that CBG and GPN bind
to LN-1 with high affinity. Experiments aimed at determining the
basis of the high affinity interaction demonstrated that an intact CBG
core protein was required. Since trypsin treatment liberated
glycanated CBG peptides that bound to LN-1 with much lower affinity,
is appears unlikely that high affinity binding of CBG to LN-1 is
mediated solely by a single HeS chain. One possibility is that multiple
chains attached to a single CBG core protein interact with multiple
binding sites on LN-1. However, as discussed above, it is possible that
at least some CBG and GPN cores may bear only one HeS chain.
An alternative hypothesis is that a core protein interaction with LN-
1 contributes to the overall affinities of CBG and GPN for LN-1. The
observation that reduction and alkylation appear to significantly reduce
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CBG affinity for LN-1 (Chapter 4), is consistent with this hypothesis.
Further support for this view comes from the binding of ryudocan
isoforms with defined numbers of HeS chains to LN-1. Although the
HeS chains on these isoforms are just as large or larger (51 kDa,
(Shworak et al., 1994a)), than those on GPN or CBG, the presence of
two chains on a single ryudocan core protein did not improve
ryudocan's affinity for LN-1.
It is interesting to note that the contribution of a putative core
protein interaction to overall affinity needn't be that large in terms of
binding energy to make a substantial difference in the value of the Kd.
This is because of the exponential relationship between Kd and the
standard free energy of binding (Kd = e(AGo/RT). For example, for a
Kd of 500 nM (in the range of heparan sulfate binding to LN-1), the
value of AGo is -4.63 kcal/mole. For a Kd of 500 pM (in the range of
CBG binding to LN-1), AGo is -6.82 kcal/mole. The difference between
these two values, -2.18 kcal/mole, is well within the range of the
binding energy that could be provided by single hydrogen bond.
However, it is important to emphasize that the contribution to binding
energy from a putative core protein interaction could be significantly
higher or lower than this value. In the absence of an independent
measurement of the Kd for core protein binding to LN-1 it is
impossible to estimate any contribution of the core protein to the
binding energy. The above discussion serves only to illustrate that
such a contribution needn't be large in order to have a substantial
impact on Kd. In fact, the contribution of the core protein to binding
could be so small that it would be impossible to measure by ACE, since
the concentrations of LN-1 required would become prohibitive.
In conclusion, the available data are consistent with a model where
CBG both with its HeS chain(s) and its protein core, resulting in a high
affinity interaction. Although the putative contribution of the protein
core in binding to LN-1 needn't be large to have an effect on the Kd of
intact CBG for LN-1, it appears to be relatively specific: the affinity of
CBG for FGF-2, TSP-1, and the recombinant G domain of LN-1 was
only marginally better, if at all, than the affinity of heparin for the same
three molecules (Chapter 4). In addition, ryudocan binding to LN-1 is
of substantially lower affinity than CBG binding (Figure 6 above), which
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suggests that LN-1 may exhibit some selectivity in which core proteins
it binds.
The vast majority of putative ligands for HSPGs have been identified
on the basis of binding to heparin or HeS chains. The results reported
here suggest that protein-protein interactions involving PG core
proteins could be more widespread than previously appreciated, and
emphasize the importance of taking the core protein into account
when analyzing the structures and functions of proteoglycans.
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Table 1. Hydrodynamic constants for protein standards
The hydrodynamic data for the protein standards used in the
experiments described below are shown. S20,w is the Svedberg
coefficient at 200C in water and is reported in svedbergs (1 S =10-13
sec). V is the partial specific volume. Mw is the molecular weight.
References for the values reported in this table were (a) Creighton,
(1984), (page 268); (b) Fosset et al, (1974); (c) compiled in Clarke et
al, (1975), from earlier references; and (d) In Gel Filtration.
Principles and Methods, 6th edition, (page 103), published by
Pharmacia Biotech, and available upon request from Pharmacia.
Stokes S20,w
Molecule Source radius S20,w V(cm 3 g) Mw (kDa) refs.
(nm) (S)
Trypsin bovine 1.66 1.0 S 0.718 6.67 ainhibitor pancreas
RNaseA bovine 2.0 1.78 0.703 13.6 a
pancreas
Carbonic human 2.0 3.23 0.729 27.0 a
anhydrase B erythrocyte
Malate pig 3.72 4.53 0.742 73.9 aDehydrog. heart
Alkaline calf - 6.45 0.756 140 bPhosphatase intestine
Glycerald. rabbit
phosphate muscle 3.92 - - 140 c
dehydrog.
catalase bovine 5.22 - - 232 dliver
beta- E. Coli 6.9 - - 540 cgalactosidase
Thyroglobulin bovine 8.5 - - 669 d
thyroid
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Figure 1. Gel filtration of cerebroglycan and glypican
12 5 1-labelled, PIPLC-treated PO rat brain PGs isolated from growth
cone particles were analyzed by gel filtration chromatography on CL6B
Sepharose. To determine the elution profiles, portions of selected
column fraction were digested with heparitinase and separated on
SDS-PAGE minigels; an example of one such gel is shown. The
numbers refer to CL6B column fractions. For comparison an aliquot of
fraction 34 that had not been treated with heparitinase was included.
The positions of the CBG and GPN bands, which appear in response to
heparitinase treatment, are indicated by open arrowheads. The
molecular weight markers are also shown. The relative abundance of
GPN compared to CBG is typical for this stage in development, a time
when CBG mRNA and protein are beginning to disappear from the rat
brain [Chapter 2, this thesis; (Herndon and Lander, 1990)].
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Figure 2. Determination of the Stokes radii of CBG and GPN
The elution volumes of CBG and GPN, analyzed by gel filtration on
Sepharose CL6B, were determined by densitometry of the gel shown
in Figure 1. (A) The elution profiles of CBG and GPN. The positions
of the void volume (Vo) and the included volume (Vt) are indicated, as
are the positions of the peaks of the protein standards used to
calibrate the column. The precise points of the CBG and GPN peaks
were determined by constructing a symmetrical curve based on the
peak fraction and the two fractions adjacent to the peak fraction. (B)
Comparison of CBG and GPN elution to the calibration curve derived
from the standards. Calculated values of Stokes radii for CBG and GPN
were 6.51 and 6.57 nm respectively. Abbreviations: TGB,
thyroglobulin; P3-gal, beta-galactosidase; CSE, catalase; GAPD,
glyceraldehyde-phosphate dehydrogenase.
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Figure 3. Calibration of sucrose density gradients
To determine the sedimentation coefficients and the partial specific
volumes of CBG and GPN, sucrose density gradient centrifugation was
performed in H20 and D20. (A) The H20 sedimentation profiles of
the standards used to calibrate the gradients is shown. The protein
standards were AP, alkaline phosphatase; MDH, malate
dehydrogenase; CAH, carbonic anhydrase; RNase, RNase A; BPTI,
bovine pancreatic trypsin inhibitor. The bottom and top of the
gradient were oriented as indicated. (C) A plot of the Svedberg
coefficient versus fraction number demonstrates that the gradient was
effectively linear. (B and D) As with (A) and (C) but in D20 rather
than H20.
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Figure 4. Sedimentation profiles of CBG and GPN in H20 and D20
sucrose density gradients. The sedimentation profiles of CBG and GPN
were determined by densitometry of CBG and GPN bands on SDS-
PAGE minigels, as described in Figure 1. (A) H20 sedimentation
profiles. (B) D20 sedimentation profiles. The locations of the protein
standards in the gradients is also indicated: BPTI, bovine pancreatic
trypsin inhibitor; RNase, RNase A; CAH, carbonic anhydrase; MDH,
malate dehydrogenase; AP, alkaline phosphatase. (top and bottom):
indicates the orientation of the tops and bottoms of the gradients.
These profiles were used to calculate the values of S20,w, V, and Mw,
reported in Table 2, using equations from Clarke, (1975).
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Stokes radius
Calculated
Molecular
Weight of
intact PG
Core
"- protein
N-linked
oligosac-
charides(predicted)
Total Predicted
Molecular
Weight of GAG
Cerebroglycan
4.15 x 10"13sec
0.693 Q g
6.51 nm
100 kDa
-58 kDa
- 0kDa
42 kDa
Glypican
4.28 x 1013sec
0.690 cd g'
6.57 nm
103 kDa
-56 kDa
- 3-7 kDa
40-44 kDa
Table 2. Hydrodnamic data and moleclar weight calclatio
The hydrodynamic data obtained for cerebroglycan (CBG) and glypican (GPN)
is summarized. Stokes radus was obtained by gel filtration; S2o.w, the
Svedberg coeffcients, and V. the partial specific volumes were obtained by
sucrose density gradient centrifugation in H20 and D20 as described in
Materials and Methods. The molecular weights were calculated using the
Svedberg equation. The total amount of glycosaminoglycan (GAG) attached
per protein core was estimated by substracting the molecular weights of the
core proteins. In the case of glypican, this number also includes an unknown
amout of N-linked oligosaccharide. There are two potential N-glycosylation
sites in GPN, and the number above is an estimate based on typical N-linked
oligosaccharide structure (as described in Darnell et al. 1986), assuming
either one or both sites are utilized. It has been previously reported that the
GPN core protein shifts from Mr -64 kDa to -56 kDa in SDS-PAGE gels after
treatment with N-glycanase (DeBoeck et al, 1987).
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Figure 5. Gel filtration of 3 5S-labelled HeS from PO rat brain
membrane fraction. Finely chopped prisms of PO rat brains were
cultured overnight in defined medium with Na2 3 5 SO4. 3 5 S labelled
HeS was isolated from the membrane fraction of metabolically labelled
prisms as described in Materials and Methods. The diamonds show
the elution profile of labelled HeS analyzed on a Sephadex G100
column; undigested HeS eluted in a broad peak centered at -40 kDa.
The squares show the elution profile of this same material after
heparitinase digestion. The locations of the void volume (Vo), the
included volume (Vt), and the FITC-labelled dextrans used to calibrate
the column are indicated. For the FITC-dextrans, molecular weight
values as determined by low angle scattering (Sigma technical
services) are given in kDa. The elution profile of the undigested HeS
is not shown beyond 3800 il because free 35SO4, included in the run
to ensure an accurate determination of Vt, obscured the HeS elution
profile beyond this point. The material in the digested sample which
elutes ahead of Vt likely consists of oligosaccharides remaining after
digestion with heparitinase. Heparitinase does not cleave within
highly sulfated domains of heparan sulfate, and even after heparitinase
digestion, some oligosaccharides remain that are large enough to be
precipitated with ethanol (Mary Herndon, unpublished observations).
In addition, the reaction products of the chondroitinase ABC digestion
were also still present in these samples.
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Figure 6. LN-1 affinity coelectrophoresis with ryudocan isoforms
containing one or two HeS chains. 3 5 S-labelled, immunopurified
ryudocan isoforms with one or two HeS chains were tested for binding
to LN-1 using affinity coelectrophoresis, as described in Chapter 4.
(A) Ryudocan with one HeS chain. (B) Ryudocan with two HeS chains.
(C) 1 2 5 I-labelled low molecular weight heparin. The concentrations
of LN-1 in each lane are indicated as well as the dissociation constants
(Kd) calculated from the affinity patterns.
0 0 0 0 LO C~ L 0
10 CU 6
[LN] nM
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143 nM
118 nM
152 nM
*,- ,-ýý-- " . , ,, k 1.
273
CHAPTER 6
CEREBROGLYCAN EXPRESSION IN THE DEVELOPING
NERVOUS SYSTEM: CONCLUSIONS AND FUTURE DIRECTIONS
274
Cerebroglycan Structure, Expression, and Possible Functions in the
Developing Nervous System: A Comparison to other Gypican Family
HSPGs
This study reports on the identification, cloning, expression
pattern, and biochemical characterization of a novel cell surface HSPG,
cerebroglycan (CBG). CBG was found to be related to the
glycosylphosphatidylinositol (GPI)-linked cell surface HSPG glypican.
While this work was in progress, data on neuronal expression of
glypican, as well as other newly discovered glypican family members,
were reported. The section below summarizes what has been learned
about CBG structure and expression in the developing nervous system
by way of comparison to other members of the glypican family.
Structure
The HSPG glypican, cloned from human lung fibroblasts, was the
first member of the glypican family to be characterized at the protein
level (David et al., 1990). Glypican was found to be anchored to the
cell surface by a glycosylphosphatidylinositol (GPI) lipid anchor.
Another family member, OCI-5, had been previously identified as a
developmentally regulated transcript in a rat primitive intestinal
epithelial cell line (Filmus et al., 1988). However, the relationship
between glypican and OCI-5 was not immediately recognized. With
the cloning from neonatal rat brain of cerebroglycan (CBG), the third
glypican family member (Chapter 2, this thesis) and, more recently, K-
glypican from mouse kidney (Watanabe et al., 1995), it has become
possible to identify the common structural features of the glypican
family members. All members of the family have, in addition to an
amino-terminal signal sequence, a stretch of hydrophobic amino acids
near the carboxy terminus that can serve as a cleavage and addition
signal for the GPI-anchor. In addition, glypican family members all
have at least one conserved, putative GAG attachment site in a cluster
near the carboxy terminus.
Elsewhere, the homology between glypican family members is
moderate but extensive, being characterized by blocks of identity or
conservative substitutions separated by stretches of divergent
sequence (See Figure 6 of Chapter 2). Most striking is the absolute
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conservation of a pattern of 14 cysteine residues, found in all family
members so far identified. This conserved pattern of cysteines
suggests that these PGs may have similar, compact tertiary structures,
stabilized by disulfide bonds. This view is supported by the fact that
both glypican and cerebroglycan show a dramatic increase in apparent
molecular weight in SDS-PAGE gels upon reduction (Herndon and
Lander, 1990). In addition, a proteolytic fragment obtained in some
preparations of K-glypican can be only be observed in SDS-PAGE gels
upon reduction (Watanabe et al., 1995).
More recently, the product of the Drosophila gene dally was
found to encode a protein related to the ancestor of the glypican
family PGs (Nakato et al., 1995). The pattern of 14 cysteine residues
found in the mammalian glypicans is present in the daily protein as
well, indicating that this well conserved structural motif is of an
ancient origin. It is also of interest to note that the mature
polypeptides of human glypican and rat glypican are 91% identical at
the amino acid level (Litwack et al., 1994). In contrast, the
ectodomains of the human and mouse syndecan-1 are only 70%
identical; only a protease susceptible domain near the plasma
membrane and the regions surrounding the GAG attachment sites are
strongly conserved (Bernfield et al., 1992). This suggests that while a
primary function of the syndecan family ectodomains may be to
present GAG chains at the cell surface, the protein cores of the
glypican family members may serve a more complex function that has
constrained their evolution.
Among the mammalian glypican family members, glypican, K-
glypican, and cerebroglycan are all more closely related to each other
than to OCI-5. This suggests that there may be a subfamilies within
the glypican family. It will be interesting to see if, in the future,
additional glypican family members are identified.
Expression
At a gross level, northern blot analyses have shown that all four
mammalian glypican family members are expressed in the rat brain
[Chapter 2, Figure 8, this thesis; (Lisanti et al., 1994; Watanabe et al.,
1995)]. Glypican mRNA levels are roughly constant across
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development. OCI-5 and K-glypican mRNAs, abundant in embryonic
rat brain, are present at lower levels in neonates, and adults, and CBG
mRNA is only detected in embryonic and early postnatal rat brain.
In situ hybridization and immunolocalization experiments have
revealed a complex pattern of glypican mRNA and protein expression.
In early embryos (e.g. embryonic day 14 rat), glypican mRNA
expression is primarily associated with the nervous system
(Karthikeyan et al., 1994; Litwack, 1995). In particular, high levels of
expression are found in the ventricular zones where proliferating
neuronal and glial precursors are found (Litwack, 1995). Much lower
levels of expression are observed outside the nervous system at this
stage (Litwack, 1995). By embryonic day 18, glypican mRNA
expression is widespread throughout the nervous system in a pattern
that generally correlates with the number of cell bodies (Litwack,
1995).
Widespread non-neuronal expression of the glypican mRNA is also
apparent at this stage. For example, in the developing bones of
embryonic day 18 rats, glypican mRNA is detected in a pattern
consistent with expression by differentiated osteoblasts, the cell type
responsible for deposition of the bone matrix during bone formation
(Litwack, 1995). Other cell types in the developing bones, such as
chondrocytes, appear to be glypican-negative.
In the post-natal stages, neuronal glypican mRNA expression
begins to be restricted, disappearing from some structures such as the
corpus striatum and the cerebellar granule cell layer, until the adult
pattern of expression is achieved (Litwack, 1995).
In the adult rat nervous system, the highest levels of glypican
expression are found in the hippocampus, the dorsal thalamus, and
motor nerve nuclei (Karthikeyan et al., 1994; Litwack et al., 1994).
Many brain regions express no glypican mRNA above background. A
common feature of many of the glypican positive brain structures in
the adult is that they contain projection neurons, neurons with long
axons projecting to distant targets, rather than local circuit neurons
whose shorter axons contact close neighbors (Litwack et al., 1994). In
structures where neurons and glia are morphologically distinguishable
(such as hippocampus and dorsal root ganglia), glypican mRNA
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expression is associated with neurons rather than glia (Litwack et al.,
1994). However, glial expression of glypican cannot be ruled out, and
there is one report that Schwann cells express glypican in vitro (Carey
et al., 1993).
The observation that many of the glypican-positive brain
structures contain projection neurons is in good agreement with
glypican immunostaining which has revealed glypican protein in axon
tracts of the developing and adult nervous system (Karthikeyan et al.,
1994; Litwack, 1995). Several neuronal GPI-anchored proteins have
been found to be localized preferentially (or polarized) to axons,
suggesting one possible function for GPI attachment [examples include
TAG-1, Thy-1, and F3/F11 (Dodd et al., 1988; Dotti et al., 1991;
Faivre-Sarrailh et al., 1992)]. Glypican immunostaining in the
pyramidal layer of the hippocampus and in dorsal root ganglia is
consistent with axonal polarization, but the data are not conclusive
(Litwack, 1995). In vitro cultured hippocampal neurons express
glypican uniformly over the entire cell surface (Asli Kumbasar,
unpublished data), and there has been one report of glypican
expression on dendrites in vivo (Karthikeyan et al., 1994), so the
question of glypican localization in neurons at the cellular level
remains open.
Non-neuronal glypican staining in the mouse embryo
demonstrates widespread, but restricted patterns of expression (David
Litwack, unpublished data). For example, glypican staining is observed
in striated and smooth muscle, but not in cardiac muscle, and in
epidermal but not endothelial cells. Expression was also detected in
the periosteum of bones -- one region where osteoblasts are found --
consistent with in situ hybridization experiments that indicated
osteoblasts express the glypican mRNA.
In contrast to glypican, cerebroglycan mRNA and protein are
found in a simple, striking, regional and developmental pattern.
Cerebroglycan (CBG) mRNA is completely restricted to the nervous
system throughout development (See Figure 1, Chapter 3). Within the
rat nervous system, the CBG message is globally expressed in early
embryos, but by embryonic day 19 begins to disappear from structures,
such as the spinal cord, where neuronal development is advanced. By
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postnatal day 7, only late developing structures such as the
cerebellum, the dentate gyrus, and the olfactory bulb still retain CBG
mrRNA expression (Figure 2, Chapter 3). No CBG mRNA is detected in
the adult rat brain.
Closer examination of CBG mRNA expression at several stages has
shown that CBG expression is associated with immature neurons in
early, post-mitotic stages. Such neurons are, as a group, undergoing
processes such as cell body migration and axon outgrowth. Little or no
expression is detected in regions containing proliferative
neuroepithelium. For example, in the postnatal day 7 cerebellum, CBG
expression is associated with the deep half of the external granule
layer (the so called premigratory zone), a region containing neurons
that have ceased to divide and have begun axon outgrowth and cell
body migration (Figure 3, Chapter 3). The internal granule layer,
containing neurons that have completed migration and axon
outgrowth, is negative. These data are consistent with the view that
CBG expression is tightly correlated with the motile phases of
neuronal life.
As with glypican, immunolocalization of cerebroglycan is
consistent with the pattern of CBG mRNA expression. CBG protein is
found only in the developing nervous system, and, in particular is
expressed by post-mitotic neurons and not proliferating
neuroepithelium (Litwack, 1995). The CBG protein is also found in
axon tracts in the developing nervous system, consistent with the
observation that CBG mRNA is expressed by populations of neurons
undergoing axon outgrowth (Figure 4, Chapter 3). In addition,
immunolocalization of CBG in the developing dentate gyrus strongly
suggests that, at least in that structure, CBG protein is polarized to
axons (Litwack, 1995).
Recently, the first data for neuronal expression of the other
glypican family members have become available. K-glypican mRNA is
highly expressed in the ventricular zones of the embryonic day 13
mouse nervous system (Watanabe et al., 1995). In this regard, the
expression pattern of K-glypican appears to be similar to that of
glypican at a similar stage of development. Currently, no
immunolocalization data for K-glypican are available. Although, as
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mentioned above, OCI-5 mRNA has been detected in the rat brain, in
the absence of in situ hybrization data, it is not possible to determine
whether OCI-5 is expressed by neurons, glia, or non-parenchymal cells
(e.g. vascular tissue, meningeal tissue, blood cells, or choroid plexus).
The dally gene product in Drosophila is also expressed in the
nervous system (Nakato et al., 1995). Studies with enhancer trap lines
in which a -3-galactosidase (1-gal) reporter is inserted into the dally
locus have revealed that dally mRNA is expressed in the lamina
precursor cells (LPCs) adjacent to the anterior outer proliferative
center of the fly brain. The LPCs differentiate into lamina neurons that
receive input from axons of the photoreceptors in the eye, and, in turn
project to other targets in the Drosophila nervous system. The LPCs
are situated along the lamina furrow, which marks the progress of
differentiation in the lamina, and LPCs at distinct stages of their final
two rounds of cell division are positioned at distinct locations along
the lamina furrow (Selleck et al., 1992). LPC's complete the first of
these final two divisions and then remain in G1 phase of the second
round until they receive a signal from innervating photoreceptor axons
that stimulates them to complete their final division and differentiate
into lamina neurons (Selleck et al., 1992).
Expression of the dally enhancer trap S-gal reporter RNA is
restricted to LPCs in G2/M phase of their first round of division.
Colocalization of 13-gal protein and cyclin-B (a marker for late G2/early
M phase) demonstrated that the dally enhancer trap insertion is
expressed in a cell cycle-dependent fashion at several locations in the
developing fly nervous system, although 13-gal positive cells that did
not overlap with regions of cyclin-B expression were also observed
(Nakato et al., 1995).
Possible Functions
Although it is unclear whether they are true nulls or merely
hypomorphs, the phenotypes of dally mutant flies provide the first
direct evidence for in vivo function of a member of the glypican family
of HSPGs. In flies homozygous for the most severe alleles of dally
analyzed thus far, the epithelium containing the anterior outer
proliferative center and the LPCs is disordered, as is the eye disc, and
280
the flies show a severe defecit in phototaxis (Nakato et al., 1995).
Several other, nonneural structures such as antennae and genitalia also
show abnormal morphology. To further characterize the dally
phenotype, dally flies were stained with propidium iodide to visualize
mitotic figures, and with antibodies to cyclin-B to mark cells in G2, or
pulsed with bromodeoxyuridine to mark cells in S phase. These
experiments demonstrated that in the LPCs of dally flies, there is a
complete absence of cells in their second S, G2, or M phases. In
addition, the region containing cells in their first G2 phase is
enlarged, and the M phase cells of the first division are displaced.
Taken together, these observations suggest the loss of functional dally
protein causes a delayed entry into the first M phase in the lamina
furrow. This phenotype is the source of the name dally which stands
for division abnormally delayed. In the developing eye disc, where the
morphogenetic furrow is an analogous structure to the lamina furrow,
a similar phenotype is seen in dally flies. The second round of division
in the morphogenetic furrow does occur, but, as with the lamina
furrow, the zone of cells in their first G2 phase is enlarged, and cells
in their first M phase are displaced from their normal location relative
to the furrow (Nakato et al., 1995).
The apparent involvement of the dally protein in regulating the
transition of proliferating precursors to differentiating neurons is
especially intriguing in light of the expression patterns of glypican and
cerebroglycan in the early rat nervous system. As discussed above, in
early embryos glypican is highly expressed by cells in proliferative
neuroepithelia whereas cerebroglycan expression is seen in the newly
post-mitotic neurons that overlie these proliferative zones. Close
comparison of adjacent sections has shown that the expression
patterns of glypican and cerebroglycan are mutually exclusive, or
nearly so, in these early neural structures (Litwack, 1995). Thus the
expression of glypican family members appears to be tightly regulated
around the transition from proliferative neuronal precursor to
immature neuron, suggesting that individual members may play
distinct roles in facilitating this transition. In the future it will be
important to determine which if any of the mammalian glypican family
members is able to complement the dally phenotype. As Nakato et al
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have pointed out (Nakato et al., 1995), the dally protein, as a putative
integral membrane HSPG, is an excellent candidate receptor for any of
several extracellular HeS-binding factors that may influence neuronal
differentiation.
The expression of glypican and cerebroglycan on axons, and the
presence of K-glypican, glypican, and OCI-5 in the adult nervous
system suggest that whatever role, if any, glypican family HSPGs may
have in regulating precursor proliferation, they may also be adapted for
additional functions in the developing and adult nervous system.
Potential clues concerning these functions come from studies of PG
function and GPI-anchored molecules in other systems. A survey of
the literature suggests the following possibilities.
Glypican family members may act as coreceptors for HeS binding
growth factors.
Several HeS-binding growth factors are found in the developing
nervous system (Gonzalez et al., 1990; Merenmies and Rauvala, 1990;
Fu et al., 1991; Hutchins and Jefferson, 1992; Reddy and Pleasure,
1992; Chang et al., 1994; Ho et al., 1995). Perhaps the best
characterized of these is bFGF or FGF-2. Studies with fibroblasts and
Chinese hamster ovary cells deficient in HeS synthesis have
demonstrated that, at least under certain conditions, cell surface HeS
appears to be required for FGF-2 binding to its high affinity receptor
(Yayon et al., 1991; Ornitz et al., 1992), as well as for an FGF-2
induced mitogenic response (Rapraeger et al., 1991; Ornitz et al.,
1992). Studies such as these have led to the concept of PGs as
coreceptors. In the coreceptor hypothesis, cell surface HSPGs
function to facilitate the binding of an extracellular ligand to its
classical, high affinity receptor (Bernfield et al., 1992). Some authors
have reported that a biologically active FGF-2/HSPG complex is
released from cell surfaces by the bacterial enzyme phosphoinositol-
specific phospholipase C (PIPLC), which cleaves GPI anchors. These
studies point to the possibility that glypican family HSPGs in particular
serve as coreceptors for members of the FGF family (Bashkin et al.,
1989; Brunner et al., 1991).
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Glypican family members may act as receptors for extracellular matrix
molecules.
Besides soluble factors, other potential ligands for glypican family
members include extracellular matrix molecules such as laminins
(LNs), fibronectin (FN), thrombospondins (TSPs), and vitronectin
(VN). Both LNs and FN have been shown to promote neurite
outgrowth of various neuronal cell types, and LN-1 can actually guide
neurites in vitro (Gundersen, 1987; Rogers et al., 1989; Sanes, 1989;
Reichardt and Tomaselli, 1991). Both have the ability to bind to
HSPGs, and both are present in the developing nervous system. FN,
LN-1 and LN-3 are found transiently in the subplate (SP) of the
developing rat cortex at developmental time points that coincide with
the outgrowth through the SP of CBG positive axons [Chapter 3, this
thesis; (Sheppard et al., 1991; Hunter et al., 1992)]. Similarly, axons
of developing retinal neurons, neurons of the dorsal root ganglia, and
spinal cord motoneurons all navigate through regions that contain LN-
1 (Rogers et al., 1986; Cohen et al., 1987; McLoon et al., 1988).
Immunolocalization of glypican and CBG has revealed that many of
these axons may be expressing CBG and/or glypican [(Karthikeyan et
al., 1994; Litwack, 1995), Chapter 3, this thesis]. The observation that
both CBG and glypican bind to LN-1 with affinities in the nanomolar to
subnanomolar range further supports the idea that they could serve as
LN-1 receptors in vivo (see Chapter 4).
A recent study has demonstrated that neuronal cells can utilize a
cell surface HSPG to attach and spread on FN fragments that contain a
heparin-binding domain (Haugen et al., 1992). The adhesion and
spreading can be inhibited by heparitinase, or by antibodies raised to a
GPI-anchored HSPG in melanoma cells. These same antibodies
recognize a core protein of Mr 51 kDa, that shifts upward dramatically
upon reduction on western blots of neuronal PG preparations. Taken
together, the biochemical data suggest that the cell surface PG in
these studies is a member of the glypican family, and that it plays a
role in the interactions of neuronal cells with FN.
The heparin binding molecules TSP-1 and VN are both present in
the developing retina (Neugebauer et al., 1991), a structure where
high levels of CBG mRNA were found to be expressed. Both TSP-1 and
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VN promote attachment and neurite outgrowth by retinal neurons in
vitro, and attachment to TSP-1 is inhibited by the addition of soluble
heparin (Neugebauer et al., 1991), indicating a possible role for cell
surface HSPGs in the interaction of retinal neurons with this molecule.
TSP-1 is also expressed widely throughout other areas of the
developing nervous system, including the cerebellum, where it is
found associated with granule cell neurons in the premigratory zone of
external granule layer and in the molecular layer (O'Shea et al., 1990).
Interestingly, an antibody to TSP-1 was found to block granule cell
migration from the external granule layer to the molecular layer,
suggesting TSP-1 may directly participate in this process (O'Shea et
al., 1990). As described in Chapter 3 above, CBG mRNA in the
developing rat cerebellum is also specifically associated with neurons
of the premigratory zone raising the possibility that CBG and TSP-1
interact on the cell surfaces of these neurons.
Glypican family HSPGs as signalling molecules?
Antibody crosslinking of GPI-anchored proteins on the surfaces of
T cells results in proliferation and interleukin-2 secretion, suggesting
that GPI-anchored molecules may be involved in signalling (Presky et
al., 1990). Several reports have been published in which GPI-
anchored proteins are found to be associated with src family tyrosine
kinases (Stefanova et al., 1991; Thomas and Samelson, 1992;
Draberova and Draber, 1993; Stefanova et al., 1993), suggesting one
way signalling through a GPI-anchored receptor could occur. Others
have suggested that the GPI moiety itself could be involved. Although
inherently controversial because of the localization of the GPI anchor
to the outer leaflet of the cell membrane, this idea is not without some
experimental support: PIPLC treatment alone can cause cellular
"activation" (Depper et al., 1984; Ransom and Cambier, 1986), and
exogenously added GPI or phosphoinositol stimulates cytokine
secretion by monocytes, and simulates the effects of insulin on
adipocytes (Saltiel and Sorbara-Cazan, 1987; Schofield and Hackett,
1] )93).
Biochemical evidence that seems to support the notion that GPI
anchored molecules can associate somehow with intracellular src
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family kinases comes from studies of caveolae. Caveolae are caveolin-
rich membrane microdomains that are thought to be involved in the
uptake of small extracellular molecules by a process distinct from
coated-pit endocytosis (Anderson et al., 1992). Biochemical
characterization of caveolae-like subcellular particles has revealed that
they are enriched for GPI-anchored proteins and contain signal
transducing molecules, including GTP-binding proteins and src family
protein tyrosine kinases (Sargiacomo et al., 1993; Lisanti et al., 1994).
Although caveolin mRNA has not been detected in the brain, it is
possible that similar domains, in which GPI-anchored molecules are
clustered together with signal transducing proteins, exist on the
surfaces of neural cells.
Future Directions
Cerebroglycan-null transgenic mice.
The genomic clones obtained in Chapter 1 lay the groundwork for a
project to generate cerebroglycan null transgenic mice. The tissue
specific and developmental stage specific expression of cerebroglycan
makes it an attractive candidate for targeted disruption: no
cerebroglycan expression has been detected outside of the nervous
system, and within the nervous system, cerebroglycan is expressed by
post-mitotic, immature neurons. Neurogenesis occurs largely during
the second half of embryogenesis. For example, in the developing rat
cortex, the earliest neurons are born beginning around embryonic day
11-12. In addition, embryos with severe neurological defects are often
brought to term. Unless cerebroglycan expression is different in the
very early embryo than at later stages (a possibility that cannot be
dismissed), the phenotype of a cerebroglycan homozygous null animal
(if there is an obvious one) should be relatively easy to score. The fact
that the loss or reduction of function phenotype of the Drosophila
homologue, dally, is readily detected would seem to favor the chances
that targeted disruption of cerebroglycan would be informative.
Identification of cerebroglycan transcriptional control elements.
As indicated in Chapter 2, a considerable portion of the mouse
genomic locus upstream of the start site of transcription has been
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obtained. In addition, some of the intron/exon boundaries have been
identified. This information should facilitate the identification of the
transcriptional control elements that confer on cerebroglyan its
striking pattern of tissue specific, temporally restricted expression.
The necessary cis-acting elements may all be contained in the
promoter, or additional elements within the introns may be required.
One approach would be to generate expression vectors containing a
reporter gene such as ~-galactosidase downstream from various
fragments of the cerebroglycan genomic sequence from the region 5'
to the transcriptional start site. If necessary, intronic sequence could
also be incorporated. These constructs could then be injected into
the male pronuclei of in vitro fertilized oocytes to generate chimeric
embryos in which the expression of the reporter gene would be
analyzed. Because the extent of incorporation of the transgene will
vary from embryo to embryo, a number of embryos for each construct
will have to be analyzed to score expression patterns with confidence.
Using this approach, a 4 kb fragment upstream from the
cerebroglycan transcriptional start site has been tentatively identified
as containing the cis-acting elements required for the cerebroglycan
expression pattern (John Fesenko, unpublished data). Once
identified, these elements might prove useful for further experiments.
For example, a line of transgenic mice could be generated in which all
the immature, motile neurons of the central nervous system were
labelled by the expression of an easily assayble reporter gene. These
mice would be useful for identifying extrinsic factors that influence the
processes of neuronal differentiation (see below for one example).
Identification of extrinsic factors controlling cerebroglycan expression
Studies of cerebroglycan expression in olfactory epithelial (OE)
explant cultures suggested that extrinsic factors may influence
cerebroglycan expression. In vivo, cerebroglycan begins to be
expressed in neurons around the time of the last mitosis, and
continues to be expressed during the period encompassing axon
outgrowth and cell body migration (See Figure 4, Chapter 3). In OE
explant cultures, however, this was not seen to be the case. A large
number of neuronal precursors migrate away from the explants in this
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system before dividing to give rise to NCAM-positive immature
neurons. These immature neurons should also be cerebroglycan-
positive based on expectations from expression patterns in vivo, but no
cerebroglycan expression was seen among these cells. Instead,
cerebroglycan expression was only detected in cells that had remained
associated with the explants, suggesting that extrinsic factors supplied
either by the explant, or by the neuronal precursors clustered around
the explant, were responsible either for initiating cerebroglycan
expression, or for maintaining cerebroglycan expression.
One potential strategy for identifying these putative extrinsic
factors would involve a biochemical approach. Homogenates of
olfactory epithelium could be tested for the ability to restore
cerebroglycan expression to dispersed OE neuronal cells in vitro.
Such an approach would be facilitated by the availability of the
cerebroglycan-reporter gene line of transgenic mice described above.
After preliminary tests to show that the reporter construct gave an
expression pattern in OE cultures identical to that described in
Chapter 3, OE cells isolated from these transgenic mice could be used
in assays to search for extrinsic factors affecting cerebroglycan
expresson. A parallel approach of screening already identified factors
for the ability to restore CBG expression in these cells would also be a
part of this strategy. This parallel approach might yield results first,
especially if the factors being searched for are present at very low
concentrations in the OE. The use of whole brain homogenates rather
than OE homogenates would also simplify this approach although this
runs the risk of isolating a different factor than the one in the OE
(which might be interesting, nontheless).
Analysis of glycosaminoglycan attachment to cerebroglycan
The molecular weight data in Chapter 5 suggest raise the possibility
that at least a fraction of cerebroglycan core proteins may be
substituted with only one HeS chain. This model could be tested by
construction of cerebroglycan isoforms in which the five potential
glycanation sites are systematically eliminated. Such an approach has
already been successfully utilized to determine that glycosaminoglycan
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chains are attached to all three acceptor sites of ryudocan (syndecan-
4) (Shworak et al., 1994a).
This approach would also yield cerebroglycan for which it is known
for certain that only one HeS chain is attached. This isoform could
then be used to confirm that the high affinity binding of cerebroglycan
to LN-1 observed in Chapter 4 is not the result of multivalent HeS
chains on a single cerebroglycan core protein binding to multiple HeS
binding sites on LN-1.
Overexpression of unglycanated cerebroglycan core protein in this
same system could also provide material for an attempt at measuring a
potentially rather weak interaction between the cerebroglycan core
protein and LN-1. The results of Chapters 4 and 5 point to the
possibility that such an interaction occurs in the binding of intact
cerebroglycan with LN-1. The affinity of this interaction could be
impossible to measure by affinity coelectrophoresis since the LN-1
concentrations required might be impossible to attain. The availability
of large amounts of unglycanated cerebroglycan core protein could
provide one way to circumvent this problem. For example, limiting
amounts of labelled LN-1 could be used in binding reactions with
excess cerebroglycan core, and LN-1/cerebroglycan core protein
complexes could be collected using an anti- cerebroglycan affinity
matrix. The observation that cerebroglycan synthesized in 3T3 cells
binds to LN-1 with the same high affinity observed for cerebroglycan
derived from brain suggests that high affinity binding to LN-1 is not
the result of some sort of special brain-specific modification to the
cerebroglycan core or chains, and supports use of a cell line approach
in further elucidating the mechanism of cerebroglycan-LN-1 binding.
Glypican family members have, without exception, been found to be
homoglycans, attaching HeS chains only. In contrast, syndecan-1 and
ryudocan are heteroglycans, attaching both HeS and CS. A recent
study has shown that all three glycosaminoglycan attachment sites in
the ryudocan core protein can attach either HeS or CS. The factors
controlling whether a site will be an HeS attachment site, a CS
attachment site, or both have not been determined. One way to
approach this problem might be to make limited chimeras of ryudocan
and cerebroglycan or glypican. As a first step, glycosaminoglycan
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attachment sites from the two molecules could be substituted for each
other. A result in which a homoglycanated cerebroglycan site becomes
a heteroglycanated site in the context of the ryudocan core protein, or
vice versa would argue for a model where structural elements outside
of the attachment site regulate the type of chain attached. The
converse result (e.g. a homoglycanated cerebroglycan site remains
homoglycanated in ryudocan) would argue that structural elements
within the attachment site control glycanation.
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Conclusion
The identification and characterization of cerebroglycan have (1)
contributed to the realization that a whole family of glypican-related
FHSPGs exists; (2) demonstrated that PG core proteins can be
expressed in a tissue-specific fashion; (3) provided additional evidence
that cell surface HSPGs may be involved in neuronal cell migration and
axon outgrowth; (4) demonstrated that intact PGs can bind to their
ligands with much higher affinity than that of free heparin or heparan
sulfate; and (5) provided evidence suggesting that interactions of
HSPG core proteins with HSPG ligands may be more widespread than
previously appreciated. Future studies promise to reveal more, not
only about the cell biology of cerebroglycan, but also about the
processes underlying the development of the nervous system.
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